Peptide conjugates and their usage
By introducing peptide conjugates with extended half-lives into the peptide conjugates, the problem of short half-lives of therapeutic agents is solved, and the compliance and efficacy of therapeutic agents are improved.
Patent Information
- Application Number
- CN202080095675.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-03-25
- Filing Date
- 2020-12-03
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2040-12-03
AI Technical Summary
The short half-life of therapeutic agents necessitates frequent administration of high doses, reducing compliance, increasing costs, and raising the risk of side effects.
Develop peptide conjugates that extend half-life by linking peptides of formula (I) to thiol-containing amino acids, including conjugation of peptides to thiol-containing receptors such as PYY receptors, GLP-1 receptors, and GCG receptors, to form pharmaceutical compositions using pharmaceutically acceptable excipients.
It prolongs the half-life of the therapeutic agent, improves compliance, reduces the risk of side effects, and enhances therapeutic efficacy.
Smart Images

Figure CN115052615B_ABST
Abstract
Description
[0001] Cross-references
[0002] This application claims the benefits of U.S. Provisional Application Serial No. 62 / 943,667, filed December 4, 2019, and U.S. Provisional Application Serial No. 62 / 994,791, filed March 25, 2020, which are incorporated herein by reference in their entirety. Background Technology
[0003] The development of therapeutic agents is often hampered by short half-lives. The biological half-life of a drug is the time required for it to lose half of its pharmacological, physiological, or radiological activity. Consequently, patients often require more frequent administration of higher doses of therapeutic agents, which can lead to decreased compliance, increased costs, and an increased risk of side effects. Therefore, there is a need to develop therapeutic agents with extended half-lives. Summary of the Invention
[0004] This article discloses a peptide conjugate comprising:
[0005] a) Peptides selected from the following: peptides regulating the PYY receptor, peptides regulating the GLP-1 and GCG receptors, peptides regulating the GLP-1 and GIP receptors, and peptides regulating the GLP-1 receptor; and
[0006] b) Staples that link peptides at the first and second thiol-containing amino acids;
[0007] The stapled compound is a compound of formula (I):
[0008]
[0009] in:
[0010] A is -N-;
[0011] X 1 and X 2 For bond, -C(=O)-, -alkylene-C(=O)-, -C(=O)-alkylene-, -alkylene-C(=O)NR 3 -,-alkylene-NR 3 C(=O)-、-C(=O)NR 3 -alkylene-, -NR 3 C(=O)-alkylene-,-alkylene-C(=O)NR 3 -alkylene- or -alkylene-NR 3 C(=O)-alkylene-;
[0012] Where X 1 Linked to the thiol-containing amino acid of the peptide, X 2Linked to the thiol-containing amino acid of the peptide, and X 1 and X 2 same;
[0013] R represents hydrogen or -(L) s -Y;
[0014] Each L is independently -(CR) 1 R 2 ) v -、-alkylene-O-、-O-alkylene-、-C(=O)-alkylene-、-alkylene-C(=O-、-NR 3 -alkylene-, -alkylene-NR 3 -、-S-alkylene-、-alkylene-S-、-S(=O)-alkylene-、-alkylene-S(=O-、-S(=O)2-alkylene、-alkylene-S(=O)2-、-C(=O-、-C(=O)NR 3 -、-NR 3 C(=O)-、-NR 3 C(=O)NR 3 -、-NR 3 C(=O)NR 3 -alkylene-, -NR 3 C(=O)-alkylene-NR 3 -,-alkylene-C(=O)NR 3 -、-C(=O)NR 3 -alkylene-, -alkylene-NR 3 C(=O)-or-NR 3 C(=O)-alkylene-;
[0015] v is 2-20;
[0016] R 1 Or R 2 Each is independently hydrogen, halogen, -CN, -OR a -SR a -S(=O)R b -NO2, -NR c R d -S(=O)2R d -NR a S(=O)2R d -S(=O)2NR c R d -C(=O)R b -OC(=O)R b -CO2R a -OCO2R a -C(=O)NR cR d -OC(=O)NR c R d -NR a C(=O)NR c R d -NR a C(=O)R b -NR a C(=O)OR a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 ynyl, C1-C6 heteroalkyl, C3-C8 cycloalkyl, C2-C8 heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, ynyl and heteroalkyl are optionally converted by halogen, -OR a or -NR c R d One, two, or three of the alkyl, heterocyclic, aryl, and heteroaryl groups may be substituted with halogens, C1-C6 alkyl groups, C1-C6 haloalkyl groups, or -OR groups. a or -NR c R d One, two, or three can be substituted;
[0017] Or R 1 and R 2 Together they form C1-C6 cycloalkyl or C1-C6 heterocycloalkyl;
[0018] Each R 3 Independently hydrogen, -S(=O)R b -S(=O)2R a -S(=O)2NR c R d -C(=O)R b -CO2R a -C(=O)NR c R d C1-C6 alkyl, C2-C6 alkenyl, C2-C6 ynyl, C1-C6 heteroalkyl, C3-C8 cycloalkyl, C2-C8 heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, ynyl and heteroalkyl are optionally converted by halogen, -OR a or -NR c R d One, two, or three of the alkyl, heterocyclic, aryl, and heteroaryl groups may be substituted with halogens, C1-C6 alkyl groups, C1-C6 haloalkyl groups, or -OR groups. a or -NR c R d One, two, or three can be substituted;
[0019] Y is hydrogen, C1-C6 alkyl, -CO2H, -CO2(C1-C6 alkyl), -CO2NH2, -CO2N(alkyl)2 or -CO2NH(alkyl);
[0020] s is 0-20;
[0021] R a It is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C3-C8 cycloalkyl, C2-C8 heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, alkynyl and heteroalkyl are optionally substituted by one, two or three of a halogen, -OH, -OMe or -NH2; and the cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted by one, two or three of a halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OH, -OMe or -NH2;
[0022] R b It is a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 ynyl, C1-C6 heteroalkyl, C3-C8 cycloalkyl, C2-C8 heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, ynyl, and heteroalkyl are optionally substituted by one, two, or three of a halogen, -OH, -OMe, or -NH2; and the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted by one, two, or three of a halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OH, -OMe, or -NH2; and
[0023] R c and R d Each of the following is independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C3-C8 cycloalkyl, C2-C8 heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, and heteroalkyl are optionally substituted by one, two, or three of a halogen, -OH, -OMe, or -NH2; and the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted by one, two, or three of a halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OH, -OMe, or -NH2;
[0024] Or R c and R d Together with the nitrogen atoms to which they are attached, they form heterocyclic alkyl or heteroaryl groups; wherein the heterocyclic alkyl and heteroaryl groups are optionally substituted by one, two or three of a halogen, a C1-C6 alkyl, a C1-C6 haloalkyl, -OH, -OMe or -NH2.
[0025] This article also provides a peptide conjugate comprising:
[0026] a) A peptide that regulates the PYY receptor, comprising a peptide sequence having at least about 95% identity with any one of SEQ ID NO: 3, 5, 6, 8, 14-30, 36 or 37; and
[0027] b) Pinned peptides linked to the first and second amino acids.
[0028] This article also provides a peptide conjugate comprising:
[0029] a) A peptide that regulates the GLP-1 receptor and the GCGR receptor, comprising a peptide sequence having at least about 95% identity with any one of SEQ ID NO:50-59; and
[0030] b) A stapled peptide linked to the first and second amino acids.
[0031] This article also provides a peptide conjugate comprising:
[0032] a) A peptide that regulates the GLP-1 receptor and the GIP receptor, comprising a peptide sequence having at least about 95% identity with any one of SEQ ID NO:62-71; and
[0033] b) Pinned peptides linked to the first and second amino acids.
[0034] This article also provides a peptide conjugate comprising:
[0035] a) A peptide that regulates the GLP-1 receptor, comprising a peptide sequence having at least about 95% identity with any one of SEQ ID NO: 74 and 79; and
[0036] b) A stapled peptide linked to the first and second amino acids.
[0037] This article also provides a pharmaceutical composition comprising the peptide conjugate described herein and a pharmaceutically acceptable excipient.
[0038] This article also provides a method for treating a disease or condition in a subject in need, the method comprising administering to the subject a composition containing a therapeutically effective amount of the peptide conjugate described herein. Attached Figure Description
[0039] Figure 1A The dose-response curves of symmetrically pinned PYY analogues in the absence of fetal bovine serum are shown.
[0040] Figure 1B The dose-response curves of symmetrically pinned PYY analogs in the presence of fetal bovine serum (10%) are shown.
[0041] Figure 2 The pharmacokinetics of PYY2, conjugate 40, and conjugate 62 in rats are illustrated.
[0042] Figure 3A The figure illustrates the changes in food intake over 24 hours in mice treated with single doses of conjugate 187, conjugate 40, combinations of conjugates 187 and 40, or individual mediators.
[0043] Figure 3B The figure illustrates the changes in body weight of mice over 24 hours after treatment with a single dose of conjugate 187, conjugate 40, a combination of conjugates 187 and 40, or the mediator alone.
[0044] Figure 4A The figure illustrates the changes in food consumption on day 1 in diet-induced obese mice treated with conjugate 187, conjugate 40, combinations of conjugates 187 and 40, or alone.
[0045] Figure 4B The figure illustrates the changes in food consumption on day 5 in diet-induced obese mice treated with conjugate 187, conjugate 40, combinations of conjugate 187 and 40, or alone.
[0046] Figure 4C The figure illustrates the weight changes over 2 weeks in diet-induced obese mice treated with conjugate 187, conjugate 40, or combinations of conjugates 187 and 40, or individually.
[0047] Figure 4D The figure illustrates glucose levels in diet-induced obese mice after 14 days of treatment with conjugate 187, conjugate 40, or a combination or individual of conjugate 187 and 40 in an oral glucose tolerance test.
[0048] Figure 4E The figure shows the area under the curve (AUC) after 14 days of treatment in diet-induced obese mice treated with conjugates 187, 40, or combinations of 187 and 40, or alone, in an oral glucose tolerance test.
[0049] Figure 4F The figure shows fasting blood glucose levels in diet-induced obese mice after 14 days of treatment with conjugate 187, conjugate 40, or a combination of conjugates 187 and 40, or alone.
[0050] Figure 5A The dose-response curves of glucagon, semaglutide, conjugate 122 and conjugate 135 to GLP-1R are shown.
[0051] Figure 5BThe dose-response curves of glucagon, conjugate 122, and conjugate 135 to GCGR are shown.
[0052] Figure 5C The stability of conjugates 122 and 135 in 2% plasma over 50 h was described.
[0053] Figure 6A The pharmacokinetics of conjugate 135 during intravenous and subcutaneous delivery were described.
[0054] Figure 6B The pharmacokinetics of conjugate 122 during intravenous and subcutaneous delivery were described.
[0055] Figure 6C The pharmacokinetics of mice treated intravenously and subcutaneously with peptide 142 were described.
[0056] Figure 6D The pharmacokinetics of mice treated intravenously and subcutaneously with peptide 183 were described.
[0057] Figure 7A The effects of compounds on blood glucose levels over time (6 hours after administration) are described in an oral glucose tolerance test. A: 122, B: 135, C: 138, D: Cotadutide, E: Semaglutide.
[0058] Figure 7B The effects of compounds on blood glucose levels over time at 48 hours post-administration are described in an oral glucose tolerance test. A: 122, B: 135, C: 138, D: Cotadutide, E: Semaglutide.
[0059] Figure 7C The effects of compounds on blood glucose levels over time at 96 h post-administration were described in an oral glucose tolerance test. A: 122 and E: semaglutide.
[0060] Figure 7D The effects of compound treatment on blood glucose levels in an oral glucose tolerance test are described, as measured by the area under the curve (AUC) at 6 hours post-dose. A: 122, B: 135, C: 138, D: Cotadutide, E: Semaglutide.
[0061] Figure 7E The effects of compound treatment on blood glucose levels in an oral glucose tolerance test are described, as measured by the area under the curve (AUC) at 48 h post-dose. A: 122, B: 135, C: 138, D: Cotadutide, E: Semaglutide.
[0062] Figure 7FThe effects of compound treatment on blood glucose levels in an oral glucose tolerance test are described, as measured by the area under the curve (AUC) at 96 h post-dose. A: 122, B: 135, C: 138, D: Cotadutide, E: Semaglutide.
[0063] Figure 7G The effects of compounds on fasting glucose levels 6 hours after administration are described in an oral glucose tolerance test. A: 122, B: 135, C: 138, D: Cotadutide, E: Semaglutide.
[0064] Figure 7H The effects of compounds on fasting glucose levels 48 h after administration are described in an oral glucose tolerance test. A: 122, B: 135, C: 138, D: Cotadutide, E: Semaglutide.
[0065] Figure 7I The effects of compounds on fasting glucose levels 96 hours after administration are described in an oral glucose tolerance test. A: 122, B: 135, C: 138, D: Cotadutide, E: Semaglutide.
[0066] Figure 8A Results of GLP1 receptor activation reporter molecule assays for tirzepatide, NNC0090-2746, conjugates 142, 141, and 171 are described.
[0067] Figure 8B Results of GIP receptor activation reporter molecule assays for tesipatide, NNC0090-2746, conjugates 142, 141, and 171 are described.
[0068] Figure 9A The effects of compound treatment on the mediator control at 2 h post-administration in an oral glucose tolerance test are described. A: 141, B: 171, C: 142, D: Semaglutide, E: Tesipatide.
[0069] Figure 9B The effects of compound treatment on the control at 72 h post-dose in an oral glucose tolerance test are described. A: 141, B: 171, C: 142, D: Semaglutide, E: Tesipatide.
[0070] Figure 9C The effects of compound treatments on the control at 96 h post-dose in an oral glucose tolerance test are described. A: 141, B: 171, C: 142, D: Semaglutide, E: Tesipatide.
[0071] Figure 9D The effects of compound treatment on the control at 144 h post-administration in an oral glucose tolerance test are described. A: 141, B: 171, C: 142, D: Semaglutide, E: Tesipatide.
[0072] Figure 9E The effects of compound treatment on blood glucose levels in an oral glucose tolerance test are described, as measured by the area under the curve (AUC) at 2 h post-administration compared to the mediator control. A: 141, B: 171, C: 142, D: Semaglutide, E: Tesipatide.
[0073] Figure 9F The effects of compound treatment on blood glucose levels in an oral glucose tolerance test are described, as measured by the area under the curve (AUC) at 72 h post-dose compared to the mediator control. For all figures, A: 141, B: 171, C: 142, D: semaglutide, E: tesipatide.
[0074] Figure 9G The effects of compound treatment on blood glucose levels in an oral glucose tolerance test are described, as measured by the area under the curve (AUC) at 96 h post-dose compared to the mediator control. A: 141, B: 171, C: 142, D: Semaglutide, E: Tesipatide.
[0075] Figure 9H The effects of compound treatment on blood glucose levels in an oral glucose tolerance test are described, as measured by the area under the curve (AUC) at 144 h post-administration compared to the mediator control. A: 141, B: 171, C: 142, D: semaglutide, E: tesipatide.
[0076] Figure 9I The effects of treatment with the compounds on fasting glucose are described, as measured by the area under the curve (AUC) at 2 h post-administration compared to the median control. A: 141, B: 171, C: 142, D: semaglutide, E: tesipatide.
[0077] Figure 9J The effects of treatment with the compounds on fasting glucose are described, as measured by the area under the curve (AUC) at 72 h post-administration compared to the median control. A: 141, B: 171, C: 142, D: semaglutide, E: tesipatide.
[0078] Figure 9K The effects of treatment with the compounds on fasting glucose are described, as measured by the area under the curve (AUC) at 96 h post-administration compared to the median control. A: 141, B: 171, C: 142, D: semaglutide, E: tesipatide.
[0079] Figure 9L The effects of treatment with the compounds on fasting glucose are described, as measured by the area under the curve (AUC) at 144 h post-administration compared to the median control. A: 141, B: 171, C: 142, D: semaglutide, E: tesipatide.
[0080] Figure 10A The changes in body weight in mice treated subcutaneously with either the peptide or the carrier as a control, either once daily or twice daily, are shown. Gray arrows indicate once-daily compound administration, and black arrows indicate the number of days with twice-weekly compound administration. A: 142 (7x / wk), B: 142 (2x / wk), C: tesipatide (2x / wk), D: semaglutide (2x / wk).
[0081] Figure 10B The percentage change in body weight is shown for mice that received subcutaneous administration of the peptide or its carrier once daily or twice daily. Gray arrows indicate once-daily compound administration, and black arrows indicate the number of days with twice-weekly compound administration. A: 142 (7x / wk), B: 142 (2x / wk), C: tesipatide (2x / wk), D: semaglutide (2x / wk).
[0082] Figure 10C The cumulative food intake of mice over 7 days following subcutaneous administration of the peptide or mediator control is shown. Gray arrows indicate once-daily compound administration, and black arrows indicate days of twice-weekly compound administration. A: 142 (7x / wk), B: 142 (2x / wk), C: tesipatide (2x / wk), D: semaglutide (2x / wk).
[0083] Figure 10D The results show the effects of compounds on blood glucose levels over time in an oral glucose tolerance test (OGTT). A: 142 (7x / wk), B: 142 (2x / wk), C: tesipatide (2x / wk), D: semaglutide (2x / wk).
[0084] Figure 10E The results of the compounds on blood glucose levels in the oral glucose tolerance test (OGTT) are shown by area under the curve (AUC). A: 142 (7x / wk), B: 142 (2x / wk), C: tesipatide (2x / wk), D: semaglutide (2x / wk).
[0085] Figure 10FThe results of the compounds on fasting glucose on day 8 in the oral glucose tolerance test (OGTT) are shown. A: 142 (7x / wk), B: 142 (2x / wk), C: tesipatide (2x / wk), D: semaglutide (2x / wk).
[0086] Figure 11A The cumulative food intake of mice treated daily with the peptide or the medium is shown. A: 122, B: 142, C: Semaglutide, D: Cotadutide.
[0087] Figure 11B The changes in body weight of mice treated with either the peptide or the mediator control over 21 days are shown. A: 122, B: 142, C: Semaglutide, D: Cotadutide.
[0088] Figure 11C The percentage change in body weight of mice treated with either the peptide or the mediator control over 21 days is shown. A: 122, B: 142, C: Semaglutide, D: Cotadutide.
[0089] Figure 11D The effects of the compounds on plasma glucose fluctuations in the fed state on day 20, compared to a mediator control, are described. A: 122, B: 142, C: Semaglutide, D: Cotadutide.
[0090] Figure 11E The effects of the compounds on fasting plasma glucose fluctuations on day 20, compared to a mediator control, are described. A: 122, B: 142, C: Semaglutide, D: Cotadutide.
[0091] Figure 11F The effects of treatment with the compounds on day 21 of the oral glucose tolerance test (OGTT) are described compared to the mediator control. A: 122, B: 142, C: Semaglutide, D: Cotadutide.
[0092] Figure 11G The glucose levels determined by measuring the area under the curve (AUC) are described. A: 122, B: 142, C: Semaglutide, D: Cotadutide.
[0093] Figure 11H The effects of treatment with the compounds on plasma levels of aspartate aminotransferase (AST) are described. A: 122, B: 142, C: semaglutide, D: cotadutide.
[0094] Figure 11IThe effects of treatment with the compounds on plasma alanine aminotransferase (ALT) levels are described. A: 122, B: 142, C: semaglutide, D: cotadutide.
[0095] Figure 11J The effects of treatment with the compounds on plasma alkaline phosphatase (ALP) levels are described. A: 122, B: 142, C: Semaglutide, D: Cotadutide.
[0096] Figure 11K The effects of treatment with the compounds on plasma cholesterol levels are described. A: 122, B: 142, C: Semaglutide, D: Cotadutide.
[0097] Figure 11L The effects of treatment with the compounds on plasma triglyceride levels are described below. A: 122, B: 142, C: semaglutide, D: cotadutide.
[0098] Figure 11M The effects of treatments with compounds and mediators on the liver-to-body weight ratio are described. A: 122, B: 142, C: Semaglutide, D: Cotadutide.
[0099] Figure 11N The effects of treatments with compounds and mediators on fat weight are described. A: 122, B: 142, C: Semaglutide, D: Cotadutide.
[0100] Figure 11O The effects of treatment with compounds and control mediators on liver weight are described. A: 122, B: 142, C: Semaglutide, D: Cotadutide.
[0101] Figure 11P The effects of treatments with compounds and control mediators on liver triglyceride levels are described. A: 122, B: 142, C: semaglutide, D: cotadutide.
[0102] Figure 11Q The effects of treatments with compounds and mediators on the grade of fatty degeneration are described. A: 122, B: 142, C: semaglutide, D: cotadutide.
[0103] Figure 12 The in vitro plasma stability of PrRP31, conjugate 255 (97-L3), and conjugate 263 (97-L5) was demonstrated.
[0104] Figure 13 The plasma concentration of conjugate 263(97-L5) after a single subcutaneous injection of 1 mg / kg was shown in mice.
[0105] Figure 14 The plasma concentrations of conjugate 263 (97-L5) after a single subcutaneous injection of 5 mg / kg were shown in CD-1 female mice (n=4).
[0106] Figure 15 This study shows a 12-day weight gain study in a diet-induced obese (DIO) mouse model (n=8 per group) of daily subcutaneous administration of conjugate 263 (97-L5).
[0107] Figure 16 The study showed that DIO model mice (n=8 per group) administered daily subcutaneously (0.5 and 5 mg / kg) of conjugate 263 (97-L5) experienced weight loss over a 12-day period.
[0108] Figure 17 The study shows glucose levels on day 14 of an in vivo weight study in a fasting-induced obesity (DIO) model mouse after oral administration of PrRP31 and conjugate 263 (97-L5).
[0109] Figure 18 The AUC is shown on day 14 of the in vivo weight study in fasting-induced obesity (DIO) model mice after oral administration of PrRP31 and conjugate 263 (97-L5). Detailed Implementation
[0110] Peptide YY (PYY) and glucagon-like peptide (GLP)-1 are peptides secreted by intestinal L cells in response to diet. Elevated plasma levels of each peptide have been shown to reduce appetite and inhibit food intake. In rodents administered PYY and GLP-1 compounds, an additive effect of appetite inhibition was observed at individual doses of either compound. This additive inhibition of appetite was also observed in genetically obese models (ob / ob and db / db mice). Other studies in healthy human volunteers have also shown an additive effect of PYY and GLP-1 compounds on energy intake reduction (27%) during assisted meals. Individuals receiving this combination therapy experienced a greater reduction in energy intake compared to administration of either PYY or GLP-1 compounds alone. Therefore, PYY, optionally in combination with GLP-1 or similar compounds, is a promising therapeutic agent for treating conditions associated with weight loss.
[0111] The neuropeptide Y family regulates signal transduction between the brain and gut via neuropeptide Y receptors, including peptides PYY, NPY (neuropeptide Y), and PP (pancreatic polypeptide). PYY is a naturally secreted 36-amino acid peptide, PYY(1-36), which is cleaved into PYY(3-36). However, PYY(3-36) is rapidly eliminated, with a reported half-life of less than 30 minutes in pigs. Therefore, the pharmacokinetic properties of naturally occurring PYY compounds are suboptimal for therapeutic applications.
[0112] G protein-coupled receptors (GPCRs) are membrane-bound proteins with seven transmembrane domains linked by three intracellular loops and three extracellular loops. Their ligand-binding sites are highly specialized, allowing each receptor to respond only to a limited number of chemicals that bind with high affinity. Examples of GPCR ligands include peptides, proteins, lipid-derived molecules, small organic compounds, and ions. GPCRs have been of interest as drug targets because they are involved in a variety of pathophysiological processes, including the regulation of neuronal excitability, metabolism, reproduction, hormonal homeostasis, and behavior. It is estimated that approximately 34% of all FDA-approved drugs target the 108 members of the GPCR family. GPCRs are generally classified into several superfamilies. GPCR family B, or the so-called secretin receptor family, is a small but structurally and functionally distinct group of receptors. These proteins are essential for many physiological functions and serve as key drug targets for several human diseases such as type 2 diabetes mellitus (T2DM), migraine, osteoporosis, depression, and anxiety. This family includes receptors for polypeptide hormones ranging from 27 to 141 residues in length. Nine of these receptors are targeted by structurally related ligands, examples of which include glucagon-like peptides (GLP-1 and GLP-2), glucagon, glucose-dependent insulinotropic peptide (GIP), vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating peptide (PACAP), and growth hormone-releasing hormone (GHRH).
[0113] Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin hormone released into the circulation by intestinal L cells in response to ingested nutrients. By binding to its homologous receptor (GLP-1R), GLP-1 promotes insulin secretion while inhibiting glucagon secretion (but only when glucose levels are elevated), thus offering the potential to lower plasma glucose levels and reduce the risk of hypoglycemia. Furthermore, GLP-1 reduces gastric emptying rate and decreases appetite, leading to weight loss.
[0114] GLP-1 receptor agonists (GLP-1RAs) represent a unique approach to treating diabetes, offering benefits beyond glucose control, including positive effects on weight, blood pressure, cholesterol levels, and beta-cell function. Currently, the United States has approved two short-acting (exenatide and liraglutide; administered once or twice daily) and three long-acting (albiglutide, dulaglutide, and exenatide LAR; administered weekly) GLP-1RAs. In particular, exenatide, a GLP-1 analog originally isolated from the saliva of the Gila monster, has a 30-minute half-life after intravenous administration and a 2-3 hour half-life after subcutaneous administration. These drugs mimic the action of the naturally occurring incretin hormone GLP-1 by activating GLP-1 receptors in the pancreas, resulting in enhanced insulin release and reduced glucagon release in a glucose-dependent manner, thereby reducing the risk of hypoglycemia. These GLP-1RAs also cause decreased appetite and delayed glucose absorption, accompanied by weight loss, due to their effects on GLP-1 receptors in the CNS and gastrointestinal tract. Given their limited oral bioavailability, these GLP-1RAs are currently administered subcutaneously. In some respects, this article presents GLP-1RAs linked to fatty acid-derived side-chain stabilizers to increase their half-life.
[0115] Incretin-based peptides are effective therapeutic agents for type 2 diabetes mellitus (T2DM). Gastrin-secreting factor (OXM), a dual agonist of GLP-1R and GCGR, has shown superior weight loss and glucose-lowering effects compared to single GLP-1R agonists. To overcome the short half-life and rapid renal clearance that limit the therapeutic potential of OXM, lipid- and PEG-modified OXM analogs have been reported. However, these approaches often lead to reduced potency or PEG-related toxicities. In some embodiments, this paper provides a dual agonist of GLP-1R and GCGR with increased plasma stability and higher potency in activating GLP-1R and GCGR.
[0116] GIP is also characterized by its incretin-like properties that stimulate insulin secretion in a glucose-dependent manner. Dual agonists of GIP and GLP-1 receptors have been shown to reduce fasting blood glucose and decrease weight compared to placebo. This dual agonist, LY3298176, is administered subcutaneously once weekly. In some embodiments, this document also provides dual agonists of GIPR and GLP-1R that incorporate pinning features to increase serum stability and half-life.
[0117] Prolactin-releasing peptide (PrRP) is a novel peptide initially discovered in the hypothalamus that stimulates prolactin secretion in anterior pituitary cells by activating the orphan G protein-coupled receptor human gustatory receptor 3 (Gr3) and its rat orthotopic unknown hypothalamic receptor-1 (UHR-1). However, later reports showed that PrRP does not stimulate the secretion of prolactin or other pituitary hormones, but it can act as a neuromodulator and play a key role in regulating energy homeostasis by activating the prolactin-releasing peptide receptor (also known as G protein-coupled receptor 10 (GPR10, the same as hGr3)). PrRP can reduce body weight and food intake, and alter body temperature upon central administration, suggesting its role in energy homeostasis. The appetite-suppressing effect of PrRP is mediated by the corticotropin-releasing hormone (CRH) receptor, and it also interacts with leptin to reduce food intake and body weight. PrRP-deficient mice exhibit late-onset obesity and obesity, indicating that PrRP transmits satiety signals in the brain. Disorders of PrRP receptor signaling can lead to obesity and metabolic disorders. Therefore, PrP could potentially serve as a therapeutic agent for diabetes and obesity by utilizing its appetite-suppressing properties for food intake and weight loss.
[0118] However, central administration of PrRP resulted in a significant increase in myocardial contractility, heart rate, and blood pressure. PrRP belongs to the RFamide peptide family and, in addition to activating GPR10, exhibits a high affinity for NPFF2R (neuropeptide FF receptor 2 or GPR74). While NPFF2R signaling may contribute to amplifying GPR10-mediated anorexia, NPFF2R is associated with elevated arterial blood pressure and may be responsible for PrRP-induced cardiovascular effects. PrRP causes increases in arterial blood pressure and heart rate, which can be eliminated by co-administration of RF9 (a specific NPFF2R antagonist) rather than neuropeptide Y (a putative GPR10 antagonist). Direct conjugation of palmitic acid to the N-terminus of PrRP via the Lys side chain at position 11 results in a significant prolongation of half-life and in vivo anorexia, accompanied by reduced food intake, body weight, and glucose intolerance in rat and mouse obesity models. While its central nervous system effects are beneficial after peripheral administration, palmitoylated PrRP analogs appear to demonstrate increased activity against NPFF2R. Therefore, there is a need to develop GPR10-selective PrRP analogs that retain their appetite-suppressing and antidiabetic effects while reducing their NPFF2R agonist activity and associated cardiovascular risks.
[0119] This article provides peptide conjugates containing therapeutic peptides that are pinned to molecules such as half-life-extending molecules.
[0120] In some embodiments, the stapled peptide comprises an incretin peptide or an incretin peptide mimic. Incretin peptides typically bind to their homologous receptors in an α-helical conformation; therefore, some embodiments herein provide modifications to stabilize the α-helix, which in some cases increases binding affinity to their receptors. Furthermore, proteolytic stability can also be enhanced with a helical rather than an elongated conformation. In some respects, this document provides such stapled peptides that exhibit increased circulating half-life and potency to their homologous receptors.
[0121] In some respects, this paper describes peptide engineering strategies for producing stapled long-acting peptide analogs with potency comparable to that of natural peptides and significantly enhanced pharmacokinetic properties.
[0122] Peptides that regulate PYY receptors
[0123] In one aspect, this document provides peptide conjugates comprising peptides specific to derivatives of neuropeptide Y family receptors (NPY family of bioactive peptides, NPY, peptide YY (PYY), and pancreatic polypeptide (PP)). In another aspect, this document provides peptide conjugates comprising peptides that regulate PYY receptors. In some embodiments, the peptide regulating PYY receptors is a PYY receptor agonist.
[0124] The binding affinity of the peptide conjugates described herein is within approximately 5% of the binding affinity of the unmodified peptide. The binding affinity of the peptide conjugates described herein is within approximately 10% of the binding affinity of the unmodified peptide. The binding affinity of the peptide conjugates described herein is within approximately 15% of the binding affinity of the unmodified peptide. The binding affinity of the peptide conjugates described herein is within approximately 20% of the binding affinity of the unmodified peptide.
[0125] In some cases, NPY derivatives refer to PYY derivatives. In other cases, NPY derivatives refer to PYY derivatives having an amino acid sequence that differs from PYY having SEQ ID NO:1 or 2 by less than 9, 8, 7, 6, 5, 4, 3, 2, or 10 amino acids.
[0126] NPY derivatives, such as PYY derivatives, may contain one or more thiol-containing amino acid residues. One or more thiol-containing amino acid residues may be used to link a stapler to PYY. One or more thiol-containing amino acid residues may be used to link HEM to an NPY derivative. One or more thiol-containing amino acid residues may be naturally present in an NPY derivative. One or more thiol-containing amino acid residues may be inserted into a PYY derivative. One or more thiol-containing amino acid residues may replace one or more amino acid residues in a PYY derivative. Methods of amino acid substitution and / or insertion are known in the art.
[0127] NPY derivatives, such as PYY derivatives, may contain one or more amine residues. Non-limiting examples of amine residues include lysine, ornithine, diaminobutyric acid, diaminopropionic acid, and homolysine. One or more amine residues may be used to attach a stapler to a PYY derivative. One or more amine residues may be used to attach a HEM to a PYY derivative. One or more amine residues may be naturally present in a PYY derivative. One or more amine residues may be inserted into a PYY derivative. One or more amine residues may replace one or more amino acid residues in a PYY derivative.
[0128] NPY derivatives, such as PYY derivatives, may comprise at least a portion of a wild-type peptide containing one or more amino acid mutations. One or more amino acid mutations may include deletion, substitution, addition, or a combination thereof. One or more amino acid mutations may include the addition of one or more amino acid residues to a wild-type peptide. One or more amino acid mutations may include the deletion of one or more amino acid residues of a wild-type peptide. One or more amino acid mutations may include the substitution of one or more amino acid residues of a wild-type peptide with one or more cysteine, lysine, or other thiol- or amine-containing residues. One or more amino acid mutations may include the substitution of one or more amino acid residues of a wild-type peptide with one or more D-amino acid residues. One or more amino acid residues of a wild-type peptide may comprise one or more alanine, methionine, arginine, serine, threonine, and tyrosine.
[0129] NPY derivatives (e.g., PYY derivatives) can be modified by, for example, acetylation, phosphorylation, and methylation. Peptide modification can include chemical modification. Peptide modification can occur at the N-terminus of the peptide. Peptide modification can include acetylation of an amino group at the N-terminus of the peptide. Alternatively, peptide modification can occur at the C-terminus of the peptide. Peptide modification can occur at one or more internal amino acids of the peptide. Peptide modification can include substitution of the carboxyl group at the C-terminus of the peptide. Peptide modification can include modification of the carboxyl group at the C-terminus of the peptide. The carboxyl group at the C-terminus of the peptide can be modified to produce an amide group. The carboxyl group at the C-terminus of the peptide can be modified to produce an amino group.
[0130] In some embodiments, the peptide derivative may be a PYY modified by replacing L-serine with D-serine. In some embodiments, the peptide derivative may be a PYY modified by replacing L-serine with aminoisobutyric acid [Aib]. In some embodiments, the peptide derivative may be a PYY modified by replacing leucine (Leu) with neuroleucine [Nle].
[0131] In some embodiments, the peptide regulating the PYY receptor comprises a truncated wild-type 36-amino acid PYY peptide. In some embodiments, the N-terminus is truncated by 1, 2, 3, or 4 residues. In some embodiments, the N-terminus is truncated by 2 residues. In some cases, the PYY derivative comprises a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with SEQ ID NO:1 or 2. In some cases, the peptide derivative has an amino acid sequence having at least about 80% identity with any one of SEQ ID NO:1 or 2. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 90% identity with SEQ ID NO:1 or 2. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 91% identity with SEQ ID NO:1 or 2. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 92% identity with SEQ ID NO:1 or 2. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 93% identity with SEQ ID NO:1 or 2. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 94% identity with SEQ ID NO:1 or 2. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 95% identity with SEQ ID NO:1 or 2. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 96% identity with SEQ ID NO:1 or 2. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 97% identity with SEQ ID NO:1 or 2. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 98% identity with SEQ ID NO:1 or 2. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 99% identity with SEQ ID NO:1 or 2.
[0132] In some embodiments, the peptide regulating the PYY receptor comprises the peptide sequence of any one of SEQ ID NO:3-45. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with any one of SEQ ID NO:3-45. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 90% identity with any one of SEQ ID NO:3-45. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 95% identity with any one of SEQ ID NO:3-45. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 99% identity with any one of SEQ ID NO:3-45. In some cases, the peptide regulating the PYY receptor comprises an amino acid sequence having at most about 1, 2, 3, 4, or 5 amino acid insertions, deletions, modifications, or substitutions compared to any one of SEQ ID NO:3-45.
[0133] In some embodiments, the peptide regulating the PYY receptor comprises the peptide sequence of SEQ ID NO:6. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with SEQ ID NO:6. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 90% identity with SEQ ID NO:6. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 95% identity with SEQ ID NO:6. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 99% identity with SEQ ID NO:6. In some cases, the peptides that regulate the PYY receptor contain amino acid sequences with up to about 1, 2, 3, 4 or 5 amino acid insertions, deletions, modifications or substitutions compared to SEQ ID NO:6.
[0134] In some embodiments, the peptide regulating the PYY receptor comprises the peptide sequence of SEQ ID NO:10. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with SEQ ID NO:10. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 90% identity with SEQ ID NO:10. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 95% identity with SEQ ID NO:10. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 99% identity with SEQ ID NO:10. In some cases, the peptides that regulate the PYY receptor contain amino acid sequences with up to about 1, 2, 3, 4 or 5 amino acid insertions, deletions, modifications or substitutions compared to SEQ ID NO:10.
[0135] In some embodiments, the peptide regulating the PYY receptor comprises the peptide sequence of SEQ ID NO:20. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with SEQ ID NO:20. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 90% identity with SEQ ID NO:20. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 95% identity with SEQ ID NO:20. In some cases, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 99% identity with SEQ ID NO:20. In some cases, the peptides that regulate the PYY receptor contain amino acid sequences with up to about 1, 2, 3, 4 or 5 amino acid insertions, deletions, modifications or substitutions compared to SEQ ID NO:20.
[0136] In some cases, PYY derivatives are numbered with the last amino acid in the sequence as position 36.
[0137] Non-limiting examples of peptide derivatives are shown in Table 1.
[0138] Table 1: PYY SEQ ID Table
[0139]
[0140]
[0141]
[0142] (*) indicates a C-terminal -OH group. All others have a C-terminal -NH2 group.
[0143] Peptides that regulate GLP-1 and GCG receptors
[0144] In one aspect, this document provides peptide conjugates comprising peptides that regulate the GLP-1 receptor and / or the GCG receptor. In some embodiments, the peptide regulates both the GLP-1 receptor and the GCG receptor. In some embodiments, the peptide regulating the GLP-1 receptor is a GLP-1 receptor agonist. In some embodiments, the peptide regulating the GCG receptor is a GCG receptor agonist.
[0145] The binding affinity of the peptide conjugates described herein is within approximately 5% of the binding affinity of the unmodified peptide. The binding affinity of the peptide conjugates described herein is within approximately 10% of the binding affinity of the unmodified peptide. The binding affinity of the peptide conjugates described herein is within approximately 15% of the binding affinity of the unmodified peptide. The binding affinity of the peptide conjugates described herein is within approximately 20% of the binding affinity of the unmodified peptide.
[0146] Peptides regulating GLP-1 and GCG receptors may contain one or more thiol-containing amino acid residues. One or more thiol-containing amino acid residues may be used to link stapling agents. One or more thiol-containing amino acid residues may be used to link HEMs. One or more thiol-containing amino acid residues may be naturally present in peptides regulating GLP-1 and GCG receptors. One or more thiol-containing amino acid residues may be inserted into peptides regulating GLP-1 and GCG receptors. One or more thiol-containing amino acid residues may replace one or more amino acid residues in peptides regulating GLP-1 and GCG receptors. Methods of amino acid substitution and / or insertion are known in the art.
[0147] Peptides regulating GLP-1 and GCG receptors may contain one or more amine-containing residues. Non-limiting examples of amine-containing residues include lysine, ornithine, diaminobutyric acid, diaminopropionic acid, and homolysine. One or more amine-containing residues may be used to link stapling agents. One or more amine-containing residues may be used to link HEMs. One or more amine-containing residues may be naturally present in peptides regulating GLP-1 and GCG receptors. One or more amine-containing residues may be inserted into peptides regulating GLP-1 and GCG receptors. One or more amine-containing residues may replace one or more amino acid residues in peptides regulating GLP-1 and GCG receptors.
[0148] Peptides that regulate GLP-1 and GCG receptors may comprise at least a portion of a wild-type peptide containing one or more amino acid mutations. One or more amino acid mutations may include deletions, substitutions, additions, or combinations thereof. One or more amino acid mutations may include the addition of one or more amino acid residues to a wild-type peptide. One or more amino acid mutations may include the deletion of one or more amino acid residues of a wild-type peptide. One or more amino acid mutations may include the substitution of one or more amino acid residues of a wild-type peptide with one or more cysteine, lysine, or other thiol- or amine-containing residues. One or more amino acid mutations may include the substitution of one or more amino acid residues of a wild-type peptide with one or more D-amino acid residues. One or more amino acid residues of a wild-type peptide may comprise one or more alanine, methionine, arginine, serine, threonine, and tyrosine.
[0149] Peptides that regulate GLP-1 and GCG receptors can be modified, for example, by acetylation, phosphorylation, and methylation. Peptide modification can include chemical modification. Peptide modification can occur at the N-terminus of the peptide. Peptide modification can include acetylation of an amino group at the N-terminus of the peptide. Alternatively, peptide modification can occur at the C-terminus of the peptide. Peptide modification can occur at one or more internal amino acids of the peptide. Peptide modification can include substitution of the carboxyl group at the C-terminus of the peptide. Peptide modification can include modification of the carboxyl group at the C-terminus of the peptide. The carboxyl group at the C-terminus of the peptide can be modified to produce an amide group. The carboxyl group at the C-terminus of the peptide can be modified to produce an amino group.
[0150] In some embodiments, the peptides regulating the GLP-1 receptor and GCG receptor may be peptides modified by replacing L-serine with D-serine. In some embodiments, the peptides regulating the GLP-1 receptor and GCG receptor may be peptides modified by replacing L-serine with aminoisobutyric acid [Aib]. In some embodiments, the peptides regulating the GLP-1 receptor and GCG receptor may be peptides modified by replacing leucine (Leu) with neuroleucine [Nle].
[0151] In some embodiments, the peptides regulating the GLP-1 receptor and the GCG receptor comprise the peptide sequence of any one of SEQ ID NO:48-61 or 80-82. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor comprise a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with any one of SEQ ID NO:48-61 or 80-82. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor comprise a peptide sequence having at least about 90% identity with any one of SEQ ID NO:48-61 or 80-82. In some cases, the peptides regulating the GLP-1 receptor and GCG receptor comprise a peptide sequence having at least about 95% identity with any one of SEQ ID NO:48-61 or 80-82. In some cases, the peptides regulating the GLP-1 receptor and GCG receptor comprise a peptide sequence having at least about 99% identity with any one of SEQ ID NO:48-61 or 80-82. In some cases, the peptides regulating the GLP-1 receptor and GCG receptor comprise an amino acid sequence having at most about 1, 2, 3, 4, or 5 amino acid insertions, deletions, modifications, or substitutions compared to any one of SEQ ID NO:48-61 or 80-82.
[0152] In some embodiments, the peptides regulating the GLP-1 receptor and the GCG receptor comprise the peptide sequence of any one of SEQ ID NO:108-114. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor comprise a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with any one of SEQ ID NO:108-114. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor comprise a peptide sequence having at least about 90% identity with any one of SEQ ID NO:108-114. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor contain a peptide sequence having at least about 95% identity with any one of SEQ ID NO:108-114. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor contain a peptide sequence having at least about 99% identity with any one of SEQ ID NO:108-114. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor contain an amino acid sequence having at most about 1, 2, 3, 4, or 5 amino acid insertions, deletions, modifications, or substitutions compared to any one of SEQ ID NO:108-114.
[0153] In some embodiments, the peptides regulating the GLP-1 receptor and the GCG receptor comprise the peptide sequence of any one of SEQ ID NO:80-82. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor comprise a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with any one of SEQ ID NO:80-82. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor comprise a peptide sequence having at least about 90% identity with any one of SEQ ID NO:80-82. In some cases, the peptides regulating the GLP-1 receptor and GCG receptor comprise a peptide sequence having at least about 95% identity with any one of SEQ ID NO:80-82. In some cases, the peptides regulating the GLP-1 receptor and GCG receptor comprise a peptide sequence having at least about 99% identity with any one of SEQ ID NO:80-82. In some cases, the peptides regulating the GLP-1 receptor and GCG receptor comprise an amino acid sequence having at most about 1, 2, 3, 4, or 5 amino acid insertions, deletions, modifications, or substitutions compared to any one of SEQ ID NO:80-82.
[0154] In some embodiments, the peptides regulating the GLP-1 receptor and the GCG receptor comprise the peptide sequence of any one of SEQ ID NO:48-59. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor comprise a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with any one of SEQ ID NO:48-59. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor comprise a peptide sequence having at least about 90% identity with any one of SEQ ID NO:48-59. In some cases, the peptides regulating the GLP-1 receptor and GCG receptor comprise a peptide sequence having at least about 95% identity with any one of SEQ ID NO:48-59. In some cases, the peptides regulating the GLP-1 receptor and GCG receptor comprise a peptide sequence having at least about 99% identity with any one of SEQ ID NO:48-59. In some cases, the peptides regulating the GLP-1 receptor and GCG receptor comprise an amino acid sequence having at most about 1, 2, 3, 4, or 5 amino acid insertions, deletions, modifications, or substitutions compared to any one of SEQ ID NO:48-59.
[0155] In some embodiments, the peptides regulating the GLP-1 receptor and the GCG receptor comprise the peptide sequence of any one of SEQ ID NO:108-110. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor comprise a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with any one of SEQ ID NO:108-110. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor comprise a peptide sequence having at least about 90% identity with any one of SEQ ID NO:108-110. In some cases, the peptides regulating the GLP-1 receptor and GCG receptor contain a peptide sequence having at least about 95% identity with any one of SEQ ID NO:108-110. In some cases, the peptides regulating the GLP-1 receptor and GCG receptor contain a peptide sequence having at least about 99% identity with any one of SEQ ID NO:108-110. In some cases, the peptides regulating the GLP-1 receptor and GCG receptor contain an amino acid sequence having at most about 1, 2, 3, 4, or 5 amino acid insertions, deletions, modifications, or substitutions compared to any one of SEQ ID NO:108-110.
[0156] In some embodiments, the peptides regulating the GLP-1 receptor and the GCG receptor comprise the peptide sequence of any one of SEQ ID NO: 60-61 or 80-82. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor comprise a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with any one of SEQ ID NO: 60-61 or 80-82. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor comprise a peptide sequence having at least about 90% identity with any one of SEQ ID NO: 60-61 or 80-82. In some cases, the peptides regulating the GLP-1 receptor and GCG receptor comprise a peptide sequence having at least about 95% identity with any one of SEQ ID NO:60-61 or 80-82. In some cases, the peptides regulating the GLP-1 receptor and GCG receptor comprise a peptide sequence having at least about 99% identity with any one of SEQ ID NO:60-61 or 80-82. In some cases, the peptides regulating the GLP-1 receptor and GCG receptor comprise an amino acid sequence having at most about 1, 2, 3, 4, or 5 amino acid insertions, deletions, modifications, or substitutions compared to any one of SEQ ID NO:60-61 or 80-82.
[0157] In some embodiments, the peptides regulating the GLP-1 receptor and the GCG receptor comprise the peptide sequence of SEQ ID NO:111. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor comprise a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with SEQ ID NO:111. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor comprise a peptide sequence having at least about 90% identity with SEQ ID NO:111. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor comprise a peptide sequence having at least about 95% identity with SEQ ID NO:111. In some cases, the peptides regulating the GLP-1 receptor and GCG receptor contain a peptide sequence that is at least about 99% identical to SEQ ID NO:111. In some cases, the peptides regulating the GLP-1 receptor and GCG receptor contain an amino acid sequence with up to about 1, 2, 3, 4, or 5 amino acid insertions, deletions, modifications, or substitutions compared to SEQ ID NO:111.
[0158] In some embodiments, the peptides regulating the GLP-1 receptor and the GCG receptor comprise a peptide sequence of any one of SEQ ID NO:48-52, 55-61, or 80-82. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor comprise a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with any one of SEQ ID NO:48-52, 55-61, or 80-82. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor comprise a peptide sequence having at least about 90% identity with any one of SEQ ID NO:48-52, 55-61, or 80-82. In some cases, the peptides regulating the GLP-1 receptor and GCG receptor comprise a peptide sequence having at least about 95% identity with any one of SEQ ID NO:48-52, 55-61, or 80-82. In some cases, the peptides regulating the GLP-1 receptor and GCG receptor comprise a peptide sequence having at least about 99% identity with any one of SEQ ID NO:48-52, 55-61, or 80-82. In some cases, the peptides regulating the GLP-1 receptor and GCG receptor comprise an amino acid sequence having at most about 1, 2, 3, 4, or 5 amino acid insertions, deletions, modifications, or substitutions compared to any one of SEQ ID NO:48-52, 55-61, or 80-82.
[0159] In some embodiments, the peptides regulating the GLP-1 receptor and the GCG receptor comprise the peptide sequence of SEQ ID NO:48. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor comprise a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with SEQ ID NO:48. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor comprise a peptide sequence having at least about 90% identity with SEQ ID NO:48. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor comprise a peptide sequence having at least about 95% identity with SEQ ID NO:48. In some cases, the peptides regulating the GLP-1 receptor and GCG receptor contain a peptide sequence that is at least about 99% identical to SEQ ID NO:48. In some cases, the peptides regulating the GLP-1 receptor and GCG receptor contain an amino acid sequence with up to about 1, 2, 3, 4, or 5 amino acid insertions, deletions, modifications, or substitutions compared to SEQ ID NO:48.
[0160] In some embodiments, the peptides regulating the GLP-1 receptor and the GCG receptor comprise the peptide sequence of SEQ ID NO:60. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor comprise a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with SEQ ID NO:60. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor comprise a peptide sequence having at least about 90% identity with SEQ ID NO:60. In some cases, the peptides regulating the GLP-1 receptor and the GCG receptor comprise a peptide sequence having at least about 95% identity with SEQ ID NO:60. In some cases, the peptides regulating the GLP-1 receptor and GCG receptor contain a peptide sequence that is at least about 99% identical to SEQ ID NO:60. In some cases, the peptides regulating the GLP-1 receptor and GCG receptor contain an amino acid sequence with up to about 1, 2, 3, 4, or 5 amino acid insertions, deletions, modifications, or substitutions compared to SEQ ID NO:60.
[0161] Non-limiting examples of peptide derivatives are shown in Table 2.
[0162] Table 2: GLP-1R / GCGR Regulator SEQ ID Table
[0163]
[0164]
[0165] Peptides that regulate GLP-1 and GIP receptors
[0166] In one aspect, this document provides peptide conjugates comprising peptides that regulate the GLP-1 receptor and / or the GIP receptor. In some embodiments, the peptide regulates both the GLP-1 receptor and the GIP receptor. In some embodiments, the peptide regulating the GLP-1 receptor is a GLP-1 receptor agonist. In some embodiments, the peptide regulating the GIP receptor is a GIP receptor agonist.
[0167] The binding affinity of the peptide conjugates described herein is within approximately 5% of the binding affinity of the unmodified peptide. The binding affinity of the peptide conjugates described herein is within approximately 10% of the binding affinity of the unmodified peptide. The binding affinity of the peptide conjugates described herein is within approximately 15% of the binding affinity of the unmodified peptide. The binding affinity of the peptide conjugates described herein is within approximately 20% of the binding affinity of the unmodified peptide.
[0168] Peptides regulating GLP-1 and GIP receptors may contain one or more thiol-containing amino acid residues. One or more thiol-containing amino acid residues may be used to link stapling agents. One or more thiol-containing amino acid residues may be used to link HEMs. One or more thiol-containing amino acid residues may be naturally present in peptides regulating GLP-1 and GIP receptors. One or more thiol-containing amino acid residues may be inserted into peptides regulating GLP-1 and GIP receptors. One or more thiol-containing amino acid residues may replace one or more amino acid residues in peptides regulating GLP-1 and GIP receptors. Methods of amino acid substitution and / or insertion are known in the art.
[0169] Peptides that regulate GLP-1 and GIP receptors may contain one or more amine-containing residues. Non-limiting examples of amine-containing residues include lysine, ornithine, diaminobutyric acid, diaminopropionic acid, and homolysine. One or more amine-containing residues may be used to link stapling agents. One or more amine-containing residues may be used to link HEMs. One or more amine-containing residues may be naturally present in peptides that regulate GLP-1 and GIP receptors. One or more amine-containing residues may be inserted into peptides that regulate GLP-1 and GIP receptors. One or more amine-containing residues may replace one or more amino acid residues in peptides that regulate GLP-1 and GIP receptors.
[0170] Peptides that regulate GLP-1 and GIP receptors may comprise at least a portion of a wild-type peptide containing one or more amino acid mutations. One or more amino acid mutations may include deletions, substitutions, additions, or combinations thereof. One or more amino acid mutations may include the addition of one or more amino acid residues to the wild-type peptide. One or more amino acid mutations may include the deletion of one or more amino acid residues of the wild-type peptide. One or more amino acid mutations may include the substitution of one or more amino acid residues of the wild-type peptide. One or more amino acid mutations may include the substitution of one or more amino acid residues of the wild-type peptide with one or more cysteine, lysine, or other thiol- or amine-containing residues. One or more amino acid mutations may include the substitution of one or more amino acid residues of the wild-type peptide with one or more D-amino acid residues. One or more amino acid residues of the wild-type peptide may comprise one or more alanine, methionine, arginine, serine, threonine, and tyrosine.
[0171] Peptides that regulate GLP-1 and GIP receptors can be modified, for example, by acetylation, phosphorylation, and methylation. Peptide modification can include chemical modification. Peptide modification can occur at the N-terminus of the peptide. Peptide modification can include acetylation of an amino group at the N-terminus of the peptide. Alternatively, peptide modification can occur at the C-terminus of the peptide. Peptide modification can occur at one or more internal amino acids of the peptide. Peptide modification can include substitution of the carboxyl group at the C-terminus of the peptide. Peptide modification can include modification of the carboxyl group at the C-terminus of the peptide. The carboxyl group at the C-terminus of the peptide can be modified to produce an amide group. The carboxyl group at the C-terminus of the peptide can be modified to produce an amino group.
[0172] In some embodiments, the peptides regulating the GLP-1 receptor and GIP receptor may be peptides modified by replacing L-serine with D-serine. In some embodiments, the peptides regulating the GLP-1 receptor and GIP receptor may be peptides modified by replacing L-serine with aminoisobutyric acid [Aib]. In some embodiments, the peptides regulating the GLP-1 receptor and GIP receptor may be peptides modified by replacing leucine (Leu) with neuroleucine [Nle].
[0173] In some embodiments, the peptides regulating the GLP-1 receptor and the GIP receptor comprise the peptide sequence of any one of SEQ ID NO:62-71. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with any one of SEQ ID NO:62-71. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise a peptide sequence having at least about 90% identity with any one of SEQ ID NO:62-71. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise a peptide sequence having at least about 95% identity with any one of SEQ ID NO:62-71. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise a peptide sequence having at least about 99% identity with any one of SEQ ID NO:62-71. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise an amino acid sequence having at most about 1, 2, 3, 4, or 5 amino acid insertions, deletions, modifications, or substitutions compared to any one of SEQ ID NO:62-71.
[0174] In some embodiments, the peptides regulating the GLP-1 receptor and the GIP receptor comprise the peptide sequence of any one of SEQ ID NO: 62 or 65. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with any one of SEQ ID NO: 62 or 65. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise a peptide sequence having at least about 90% identity with any one of SEQ ID NO: 62 or 65. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise a peptide sequence having at least about 95% identity with any one of SEQ ID NO: 62 or 65. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise a peptide sequence having at least about 99% identity with any one of SEQ ID NO: 62 or 65. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise an amino acid sequence having at most about 1, 2, 3, 4, or 5 amino acid insertions, deletions, modifications, or substitutions compared to any one of SEQ ID NO: 62 or 65.
[0175] In some embodiments, the peptides regulating the GLP-1 receptor and the GIP receptor comprise the peptide sequence of any one of SEQ ID NO:114-120. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with any one of SEQ ID NO:114-120. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise a peptide sequence having at least about 90% identity with any one of SEQ ID NO:114-120. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise a peptide sequence having at least about 95% identity with any one of SEQ ID NO:114-120. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise a peptide sequence having at least about 99% identity with any one of SEQ ID NO:114-120. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise an amino acid sequence having at most about 1, 2, 3, 4, or 5 amino acid insertions, deletions, modifications, or substitutions compared to any one of SEQ ID NO:114-120.
[0176] In some embodiments, the peptides regulating the GLP-1 receptor and the GIP receptor comprise the peptide sequence of any one of SEQ ID NO:62-68. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with any one of SEQ ID NO:62-68. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise a peptide sequence having at least about 90% identity with any one of SEQ ID NO:62-68. In some embodiments, the peptides regulating the GLP-1 receptor and GIP receptor comprise a peptide sequence having at least about 95% identity with any one of SEQ ID NO:62-68. In some embodiments, the peptides regulating the GLP-1 receptor and GIP receptor comprise a peptide sequence having at least about 99% identity with any one of SEQ ID NO:62-68. In some embodiments, the peptides regulating the GLP-1 receptor and GIP receptor comprise an amino acid sequence having at most about 1, 2, 3, 4, or 5 amino acid insertions, deletions, modifications, or substitutions compared to any one of SEQ ID NO:62-68. In some embodiments, the peptides regulating the GLP-1 receptor and GIP receptor comprise a peptide sequence of any one of SEQ ID NO:69-71. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with any of SEQ ID NO:69-71. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise a peptide sequence having at least about 90% identity with any of SEQ ID NO:69-71. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise a peptide sequence having at least about 95% identity with any of SEQ ID NO:69-71. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise a peptide sequence having at least about 99% identity with any one of SEQ ID NO:69-71. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise an amino acid sequence having at most about 1, 2, 3, 4, or 5 amino acid insertions, deletions, modifications, or substitutions compared to any one of SEQ ID NO:69-71.In some embodiments, the peptides regulating the GLP-1 receptor and the GIP receptor comprise the peptide sequence of SEQ ID NO:63. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with SEQ ID NO:63. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise a peptide sequence having at least about 90% identity with SEQ ID NO:63. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor comprise a peptide sequence having at least about 95% identity with SEQ ID NO:63. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor contain a peptide sequence that is at least about 99% identical to SEQ ID NO:63. In some cases, the peptides regulating the GLP-1 receptor and the GIP receptor contain an amino acid sequence with up to about 1, 2, 3, 4, or 5 amino acid insertions, deletions, modifications, or substitutions compared to SEQ ID NO:63.
[0177] Non-limiting examples of peptide derivatives are shown in Table 3.
[0178] Table 3: GLP-1R / GIPR Modifier SEQ ID Table
[0179]
[0180] Peptides that regulate GLP-1 receptor
[0181] In one aspect, this document provides peptide conjugates comprising a peptide that regulates the GLP-1 receptor. In some embodiments, the peptide that regulates the GLP-1 receptor is a GLP-1 receptor agonist.
[0182] The binding affinity of the peptide conjugates described herein is within approximately 5% of the binding affinity of the unmodified peptide. The binding affinity of the peptide conjugates described herein is within approximately 10% of the binding affinity of the unmodified peptide. The binding affinity of the peptide conjugates described herein is within approximately 15% of the binding affinity of the unmodified peptide. The binding affinity of the peptide conjugates described herein is within approximately 20% of the binding affinity of the unmodified peptide.
[0183] The peptide regulating the GLP-1 receptor may contain one or more thiol-containing amino acid residues. One or more thiol-containing amino acid residues may be used to link a stapling. One or more thiol-containing amino acid residues may be used to link a HEM. One or more thiol-containing amino acid residues may be naturally present in the peptide regulating the GLP-1 receptor. One or more thiol-containing amino acid residues may be inserted into the peptide regulating the GLP-1 receptor. One or more thiol-containing amino acid residues may replace one or more amino acid residues in the peptide regulating the GLP-1 receptor. Methods of amino acid substitution and / or insertion are known in the art.
[0184] Peptides that regulate the GLP-1 receptor may contain one or more amine-containing residues. Non-limiting examples of amine-containing residues include lysine, ornithine, diaminobutyric acid (GABA), diaminopropionic acid (DPA), and homolysine. One or more amine-containing residues may be used to link stapling agents. One or more amine-containing residues may be used to link HEMs. One or more amine-containing residues may be naturally present in the peptide regulating the GLP-1 receptor. One or more amine-containing residues may be inserted into the peptide regulating the GLP-1 receptor. One or more amine-containing residues may replace one or more amino acid residues in the peptide regulating the GLP-1 receptor.
[0185] The peptide regulating the GLP-1 receptor may comprise at least a portion of a wild-type peptide containing one or more amino acid mutations. One or more amino acid mutations may include deletion, substitution, addition, or a combination thereof. One or more amino acid mutations may include the addition of one or more amino acid residues to the wild-type peptide. One or more amino acid mutations may include the deletion of one or more amino acid residues of the wild-type peptide. One or more amino acid mutations may include the substitution of one or more amino acid residues of the wild-type peptide with one or more cysteine, lysine, or other thiol- or amine-containing residues. One or more amino acid mutations may include the substitution of one or more amino acid residues of the wild-type peptide with one or more D-amino acid residues. The one or more amino acid residues of the wild-type peptide may comprise one or more alanine, methionine, arginine, serine, threonine, and tyrosine.
[0186] Peptides that regulate the GLP-1 receptor can be modified, for example, by acetylation, phosphorylation, and methylation. Peptide modification can include chemical modification. Peptide modification can occur at the N-terminus of the peptide. Peptide modification can include acetylation of an amino group at the N-terminus of the peptide. Alternatively, peptide modification can occur at the C-terminus of the peptide. Peptide modification can occur at one or more internal amino acids of the peptide. Peptide modification can include substitution of the carboxyl group at the C-terminus of the peptide. Peptide modification can include modification of the carboxyl group at the C-terminus of the peptide. The carboxyl group at the C-terminus of the peptide can be modified to produce an amide group. The carboxyl group at the C-terminus of the peptide can be modified to produce an amino group.
[0187] In some embodiments, the peptide regulating the GLP-1 receptor may be a peptide modified by replacing L-serine with D-serine. In some embodiments, the peptide regulating the GLP-1 receptor may be a peptide modified by replacing L-serine with aminoisobutyric acid [Aib]. In some embodiments, the peptide regulating the GLP-1 receptor may be a peptide modified by replacing leucine (Leu) with neuroleucine [Nle].
[0188] In some embodiments, the peptide regulating the GLP-1 receptor comprises a peptide sequence of any one of SEQ ID NO:48-82 or 108-120. In some cases, the peptide regulating the GLP-1 receptor comprises a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with any one of SEQ ID NO:48-82 or 108-120. In some cases, the peptide regulating the GLP-1 receptor comprises a peptide sequence having at least about 90% identity with any one of SEQ ID NO:48-82 or 108-120. In some embodiments, the peptide regulating the GLP-1 receptor comprises a peptide sequence having at least about 95% identity with any one of SEQ ID NO:48-82 or 108-120. In some embodiments, the peptide regulating the GLP-1 receptor comprises a peptide sequence having at least about 99% identity with any one of SEQ ID NO:48-82 or 108-120. In some embodiments, the peptide regulating the GLP-1 receptor comprises an amino acid sequence having at most about 1, 2, 3, 4, or 5 amino acid insertions, deletions, modifications, or substitutions compared to any one of SEQ ID NO:48-82 or 108-120.
[0189] In some embodiments, the peptide regulating the GLP-1 receptor comprises the peptide sequence of any one of SEQ ID NO:72-79. In some cases, the peptide regulating the GLP-1 receptor comprises a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with any one of SEQ ID NO:72-79. In some cases, the peptide regulating the GLP-1 receptor comprises a peptide sequence having at least about 90% identity with any one of SEQ ID NO:72-79. In some cases, the peptide regulating the GLP-1 receptor comprises a peptide sequence having at least about 95% identity with any one of SEQ ID NO:72-79. In some cases, the peptide regulating the GLP-1 receptor comprises a peptide sequence having at least about 99% identity with any of SEQ ID NO:72-79. In some cases, the peptide regulating the GLP-1 receptor comprises an amino acid sequence having at most about 1, 2, 3, 4, or 5 amino acid insertions, deletions, modifications, or substitutions compared to any of SEQ ID NO:72-79.
[0190] In some embodiments, the peptide regulating the GLP-1 receptor comprises the peptide sequence of any one of SEQ ID NO:72-75. In some cases, the peptide regulating the GLP-1 receptor comprises a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with any one of SEQ ID NO:72-75. In some cases, the peptide regulating the GLP-1 receptor comprises a peptide sequence having at least about 90% identity with any one of SEQ ID NO:72-75. In some cases, the peptide regulating the GLP-1 receptor comprises a peptide sequence having at least about 95% identity with any one of SEQ ID NO:72-75. In some cases, the peptide regulating the GLP-1 receptor comprises a peptide sequence having at least about 99% identity with any of SEQ ID NO:72-75. In some cases, the peptide regulating the GLP-1 receptor comprises an amino acid sequence having at most about 1, 2, 3, 4, or 5 amino acid insertions, deletions, modifications, or substitutions compared to any of SEQ ID NO:72-75.
[0191] In some embodiments, the peptide regulating the GLP-1 receptor comprises the peptide sequence of any one of SEQ ID NO:76-79. In some cases, the peptide regulating the GLP-1 receptor comprises a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with any one of SEQ ID NO:76-79. In some cases, the peptide regulating the GLP-1 receptor comprises a peptide sequence having at least about 90% identity with any one of SEQ ID NO:76-79. In some cases, the peptide regulating the GLP-1 receptor comprises a peptide sequence having at least about 95% identity with any one of SEQ ID NO:76-79. In some cases, the peptide regulating the GLP-1 receptor comprises a peptide sequence having at least about 99% identity with any of SEQ ID NO:76-79. In some cases, the peptide regulating the GLP-1 receptor comprises an amino acid sequence having at most about 1, 2, 3, 4, or 5 amino acid insertions, deletions, modifications, or substitutions compared to any of SEQ ID NO:76-79.
[0192] In some embodiments, the peptide regulating the GLP-1 receptor comprises the peptide sequence of SEQ ID NO:76. In some cases, the peptide regulating the GLP-1 receptor comprises a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with SEQ ID NO:76. In some cases, the peptide regulating the GLP-1 receptor comprises a peptide sequence having at least about 90% identity with SEQ ID NO:76. In some cases, the peptide regulating the GLP-1 receptor comprises a peptide sequence having at least about 95% identity with SEQ ID NO:76. In some cases, the peptide regulating the GLP-1 receptor comprises a peptide sequence having at least about 99% identity with SEQ ID NO:76. In some cases, the peptides that regulate the GLP-1 receptor contain amino acid sequences with up to about 1, 2, 3, 4 or 5 amino acid insertions, deletions, modifications or substitutions compared to SEQ ID NO:76.
[0193] In some embodiments, the peptide regulating the GLP-1 receptor comprises the peptide sequence of SEQ ID NO:77. In some cases, the peptide regulating the GLP-1 receptor comprises a peptide sequence having at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identity with SEQ ID NO:77. In some cases, the peptide regulating the GLP-1 receptor comprises a peptide sequence having at least about 90% identity with SEQ ID NO:77. In some cases, the peptide regulating the GLP-1 receptor comprises a peptide sequence having at least about 95% identity with SEQ ID NO:77. In some cases, the peptide regulating the GLP-1 receptor comprises a peptide sequence having at least about 99% identity with SEQ ID NO:77. In some cases, the peptides that regulate the GLP-1 receptor contain amino acid sequences with up to about 1, 2, 3, 4 or 5 amino acid insertions, deletions, modifications or substitutions compared to SEQ ID NO:77.
[0194] Non-limiting examples of peptide derivatives are shown in Table 4.
[0195] Table 4: GLP-1R Modifier SEQ ID Table
[0196]
[0197] (*) indicates a C-terminal -OH group. All others have a C-terminal -NH2 group.
[0198] Prolactin-releasing peptide (PrRP)
[0199] In one respect, this article provides peptide conjugates containing prolactin-releasing peptide (PrRP).
[0200] The binding affinity of the peptide conjugates described herein is within approximately 5% of the binding affinity of the unmodified peptide. The binding affinity of the peptide conjugates described herein is within approximately 10% of the binding affinity of the unmodified peptide. The binding affinity of the peptide conjugates described herein is within approximately 15% of the binding affinity of the unmodified peptide. The binding affinity of the peptide conjugates described herein is within approximately 20% of the binding affinity of the unmodified peptide.
[0201] Prolactin-releasing peptide (PrRP) may contain one or more thiol-containing amino acid residues. One or more thiol-containing amino acid residues may be used to attach a staple to prolactin-releasing peptide (PrRP). One or more thiol-containing amino acid residues may be naturally present in prolactin-releasing peptide (PrRP). One or more thiol-containing amino acid residues may be inserted into prolactin-releasing peptide (PrRP). One or more thiol-containing amino acid residues may replace one or more amino acid residues in prolactin-releasing peptide (PrRP). Methods of amino acid substitution and / or insertion are known in the art.
[0202] Prolactin-releasing peptide (PrRP) may comprise at least a portion of a wild-type peptide containing one or more amino acid mutations. One or more amino acid mutations may include deletion, substitution, addition, or a combination thereof. One or more amino acid mutations may include the addition of one or more amino acid residues to the wild-type peptide. One or more amino acid mutations may include the deletion of one or more amino acid residues of the wild-type peptide. One or more amino acid mutations may include the substitution of one or more amino acid residues of the wild-type peptide with one or more cysteine, lysine, or other thiol- or amine-containing residues. One or more amino acid mutations may include the substitution of one or more amino acid residues of the wild-type peptide with one or more D-amino acid residues. The one or more amino acid residues of the wild-type peptide may comprise one or more alanine, methionine, arginine, serine, threonine, and tyrosine.
[0203] Prolactin-releasing peptide (PrRP) can be modified, for example, by acetylation, phosphorylation, and methylation. Peptide modification can include chemical modification. Peptide modification can occur at the N-terminus of the peptide. Peptide modification can include acetylation of an amino group at the N-terminus of the peptide. Alternatively, peptide modification can occur at the C-terminus of the peptide. Peptide modification can occur at one or more internal amino acids of the peptide. Peptide modification can include substitution of the carboxyl group at the C-terminus of the peptide. Peptide modification can include modification of the carboxyl group at the C-terminus of the peptide. The carboxyl group at the C-terminus of the peptide can be modified to produce an amide group. The carboxyl group at the C-terminus of the peptide can be modified to produce an amino group.
[0204] In some embodiments, the peptide derivative may be a prolactin-releasing peptide (PrRP) modified by replacing Arg with hArg. In some embodiments, the peptide derivative may be a prolactin-releasing peptide (PrRP) modified by replacing Arg with β-hArg. In some embodiments, the peptide derivative may be a prolactin-releasing peptide (PrRP) modified by replacing Arg with NMe-Arg. In some embodiments, the peptide derivative may be a prolactin-releasing peptide (PrRP) modified by replacing Met with Nle.
[0205] Non-limiting examples of prolactin-releasing peptide (PrRP) are shown in Table 5.
[0206] In some cases, prolactin-releasing peptide (PrRP) has an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to any one of SEQ ID NO:83-105. In some cases, prolactin-releasing peptide (PrRP) has an amino acid sequence that is at least about 80% identical to any one of SEQ ID NO:83-105. In some cases, prolactin-releasing peptide (PrRP) has an amino acid sequence that is at least about 80% identical to any one of SEQ ID NO:83-105. In some cases, prolactin-releasing peptide (PrRP) has an amino acid sequence that is at least about 85% identical to any one of SEQ ID NO:83-105. In some cases, prolactin-releasing peptide (PrRP) has an amino acid sequence that is at least about 90% identical to any one of SEQ ID NO:83-105. In some cases, prolactin-releasing peptide (PrRP) has an amino acid sequence that is at least about 95% identical to any one of SEQ ID NO:83-105. In some cases, prolactin-releasing peptide (PrRP) has an amino acid sequence that is at least about 99% identical to any one of SEQ ID NO:83-105. In some cases, PrRP contains an amino acid sequence with at most about 1, 2, 3, 4, or 5 amino acid insertions, deletions, modifications, or substitutions compared to any one of SEQ ID NO:83-105.
[0207] Table 5: PrRP SEQ ID Table
[0208]
[0209]
[0210]
[0211] stapled
[0212] This article discloses peptide conjugates containing staples.
[0213] In some embodiments, the stapler linked to the peptide is a compound of formula (I):
[0214]
[0215] in:
[0216] A is an optionally substituted alkylene, optionally substituted arylene, optionally substituted heteroarylene, or optionally substituted -NR. 3 -alkylene-NR 3 -or -N-;
[0217] X 1 and X 2 Independently, it is a bond, -C(=O)-, -alkylene-C(=O)-, -C(=O)-alkylene-, -alkylene-C(=O)NR 3 -,-alkylene-NR 3 C(=O)-、-C(=O)NR 3 -alkylene-, -NR 3 C(=O)-alkylene-,-alkylene-C(=O)NR 3 -alkylene- or -alkylene-NR 3 C(=O)-alkylene-;
[0218] Where X 1 Linked to the first amino acid of the peptide, and X 2 Linked to the second amino acid of the peptide;
[0219] R represents hydrogen or -(L) s -Y;
[0220] Each L is independently -(CR) 1 R 2 ) v -、-alkylene-O-、-O-alkylene-、-C(=O)-alkylene-、-alkylene-C(=O-、-NR 3 -alkylene-, -alkylene-NR 3 -、-S-alkylene-、-alkylene-S-、-S(=O)-alkylene-、-alkylene-S(=O-、-S(=O)2-alkylene、-alkylene-S(=O)2-、-C(=O-、-C(=O)NR 3 -、-NR 3 C(=O)-、-NR 3 C(=O)NR 3 -、-NR 3 C(=O)NR 3 -alkylene-, -NR 3 C(=O)-alkylene-NR 3 -,-alkylene-C(=O)NR 3 -、-C(=O)NR 3 -alkylene-, -alkylene-NR 3 C(=O)-or-NR 3 C(=O)-alkylene-;
[0221] v is 2-20;
[0222] R 1 Or R 2 Each is independently hydrogen, halogen, -CN, -OR a -SR a -S(=O)R b -NO2, -NR c R d -S(=O)2R d -NR a S(=O)2R d -S(=O)2NR c R d -C(=O)R b -OC(=O)R b -CO2R a -OCO2R a -C(=O)NR c R d -OC(=O)NR c R d -NR a C(=O)NR c R d -NR a C(=O)R b -NR a C(=O)OR a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 ynyl, C1-C6 heteroalkyl, C3-C8 cycloalkyl, C2-C8 heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, ynyl and heteroalkyl are optionally converted by halogen, -OR a or -NR c R d One, two, or three of the alkyl, heterocyclic, aryl, and heteroaryl groups may be substituted with halogens, C1-C6 alkyl groups, C1-C6 haloalkyl groups, or -OR groups. a -NR c R d One, two, or three can be substituted;
[0223] Or R 1 and R 2 Together they form C1-C6 cycloalkyl or C1-C6 heterocycloalkyl;
[0224] Each R 3 Independently hydrogen, -S(=O)R b -S(=O)2R a -S(=O)2NR c R d-C(=O)R b -CO2R a -C(=O)NR c R d C1-C6 alkyl, C2-C6 alkenyl, C2-C6 ynyl, C1-C6 heteroalkyl, C3-C8 cycloalkyl, C2-C8 heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, ynyl and heteroalkyl are optionally converted by halogen, -OR a or -NR c R d One, two, or three of the alkyl, heterocyclic, aryl, and heteroaryl groups may be substituted with halogens, C1-C6 alkyl groups, C1-C6 haloalkyl groups, or -OR groups. a or -NR c R d One, two, or three can be substituted;
[0225] Y is hydrogen, C1-C6 alkyl, -CO2H, -CO2(C1-C6 alkyl), -CO2NH2, -CO2N(alkyl)2, or -CO2NH(alkyl); and
[0226] s is 0-20;
[0227] R a It is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C3-C8 cycloalkyl, C2-C8 heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, alkynyl and heteroalkyl are optionally substituted by one, two or three of a halogen, -OH, -OMe or -NH2; and the cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted by one, two or three of a halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OH, -OMe or -NH2;
[0228] R b It is a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C3-C8 cycloalkyl, C2-C8 heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, and heteroalkyl are optionally substituted by one, two, or three of a halogen, -OH, -OMe, or -NH2; and the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted by one, two, or three of a halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OH, -OMe, or -NH2;
[0229] R c and R dEach of the following is independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C3-C8 cycloalkyl, C2-C8 heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, and heteroalkyl are optionally substituted by one, two, or three of a halogen, -OH, -OMe, or -NH2; and the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted by one, two, or three of a halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OH, -OMe, or -NH2;
[0230] Or R c and R d Together with the nitrogen atoms to which they are attached, they form heterocyclic alkyl or heteroaryl groups; wherein the heterocyclic alkyl and heteroaryl groups are optionally substituted by one, two or three of a halogen, a C1-C6 alkyl, a C1-C6 haloalkyl, -OH, -OMe or -NH2.
[0231] In some embodiments, the stapler linked to the peptide is a compound of formula (I):
[0232]
[0233] in:
[0234] A is -N-;
[0235] X 1 and X 2 For bond, -C(=O)-, -alkylene-C(=O)-, -C(=O)-alkylene-, -alkylene-C(=O)NR 3 -,-alkylene-NR 3 C(=O)-、-C(=O)NR 3 -alkylene-, -NR 3 C(=O)-alkylene-,-alkylene-C(=O)NR 3 -alkylene- or -alkylene-NR 3 C(=O)-alkylene-;
[0236] Where X 1 Linked to the first amino acid of the peptide, X 2 Linked to the second amino acid of the peptide, and X 1 and X 2 same;
[0237] R represents hydrogen or -(L) s -Y;
[0238] Each L is independently -(CR) 1 R 2 ) v-、-alkylene-O-、-O-alkylene-、-C(=O)-alkylene-、-alkylene-C(=O-、-NR 3 -alkylene-, -alkylene-NR 3 -、-S-alkylene-、-alkylene-S-、-S(=O)-alkylene-、-alkylene-S(=O-、-S(=O)2-alkylene、-alkylene-S(=O)2-、-C(=O-、-C(=O)NR 3 -、-NR 3 C(=O)-、-NR 3 C(=O)NR 3 -、-NR 3 C(=O)NR 3 -alkylene-, -NR 3 C(=O)-alkylene-NR 3 -,-alkylene-C(=O)NR 3 -、-C(=O)NR 3 -alkylene-, -alkylene-NR 3 C(=O)-or-NR 3 C(=O)-alkylene-;
[0239] v is 2-20;
[0240] R 1 Or R 2 Each is independently hydrogen, halogen, -CN, -OR a -SR a -S(=O)R b -NO2, -NR c R d -S(=O)2R d -NR a S(=O)2R d -S(=O)2NR c R d -C(=O)R b -OC(=O)R b -CO2R a -OCO2R a -C(=O)NR c R d -OC(=O)NR c R d -NR a C(=O)NR c R d -NR a C(=O)R b -NR a C(=O)ORa C1-C6 alkyl, C2-C6 alkenyl, C2-C6 ynyl, C1-C6 heteroalkyl, C3-C8 cycloalkyl, C2-C8 heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, ynyl and heteroalkyl are optionally converted by halogen, -OR a or -NR c R d One, two, or three of the alkyl, heterocyclic, aryl, and heteroaryl groups may be substituted with halogens, C1-C6 alkyl groups, C1-C6 haloalkyl groups, or -OR groups. a or -NR c R d One, two, or three can be substituted;
[0241] Or R 1 and R 2 Together they form C1-C6 cycloalkyl or C1-C6 heterocycloalkyl;
[0242] Each R 3 Independently hydrogen, -S(=O)R b -S(=O)2R a -S(=O)2NR c R d -C(=O)R b -CO2R a -C(=O)NR c R d C1-C6 alkyl, C2-C6 alkenyl, C2-C6 ynyl, C1-C6 heteroalkyl, C3-C8 cycloalkyl, C2-C8 heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, ynyl and heteroalkyl are optionally converted by halogen, -OR a or -NR c R d One, two, or three of the alkyl, heterocyclic, aryl, and heteroaryl groups may be substituted with halogens, C1-C6 alkyl groups, C1-C6 haloalkyl groups, or -OR groups. a or -NR c R d One, two, or three can be substituted;
[0243] Y is hydrogen, C1-C6 alkyl, -CO2H, -CO2(C1-C6 alkyl), -CO2NH2, -CO2N(alkyl)2 or -CO2NH(alkyl);
[0244] s is 0-20;
[0245] R aIt is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C3-C8 cycloalkyl, C2-C8 heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, alkynyl and heteroalkyl are optionally substituted by one, two or three of a halogen, -OH, -OMe or -NH2; and the cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted by one, two or three of a halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OH, -OMe or -NH2;
[0246] R b It is a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 ynyl, C1-C6 heteroalkyl, C3-C8 cycloalkyl, C2-C8 heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, ynyl, and heteroalkyl are optionally substituted by one, two, or three of a halogen, -OH, -OMe, or -NH2; and the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted by one, two, or three of a halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OH, -OMe, or -NH2; and
[0247] R c and R d Each of the following is independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C3-C8 cycloalkyl, C2-C8 heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, and heteroalkyl are optionally substituted by one, two, or three of a halogen, -OH, -OMe, or -NH2; and the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted by one, two, or three of a halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OH, -OMe, or -NH2;
[0248] Or R c and R d Together with the nitrogen atoms to which they are attached, they form heterocyclic alkyl or heteroaryl groups; wherein the heterocyclic alkyl and heteroaryl groups are optionally substituted by one, two or three of a halogen, a C1-C6 alkyl, a C1-C6 haloalkyl, -OH, -OMe or -NH2.
[0249] In some embodiments, A is an optionally substituted alkylene group. In some embodiments, A is -(CH2). t - where t is 1-12. In some implementations, A is -(CH2). t - where t is 1-10. In some implementations, A is -(CH2). t - where t is 1-8. In some implementations, A is -(CH2). t - where t is 1-6. In some implementations, A is -(CH2).t -, where t is 1-4.
[0250] In some embodiments, A is an optionally substituted arylene. In some embodiments, A is an arylene optionally substituted with a halogen, alkyl, or haloalkyl group. In some embodiments, A is an unsubstituted arylene.
[0251] In some implementations, A is -NR 3 -alkylene-NR 3 - In some implementations, A is -N-.
[0252] In some implementation schemes, X 1 and X 2 Same. In some implementations, X 1 and X 2 different.
[0253] In some implementation schemes, X 1 and X 2 For -C(=O)-. In some implementations, X 1 and X 2 Independently, it is -alkylene-C(=O)- or -C(=O)alkylene-. In some embodiments, X 1 and X 2 Independently, it is -CH2-C(=O)- or -C(=O)-CH2-. In some implementations, X 1 and X 2 Independently -alkylene-C(=O)NR 3 or -C(=O)NR 3 -alkylene-. In some embodiments, X 1 and X 2 Independently -CH2-C(=O)NR 3 -or-C(=O)NR 3 -CH2-. In some implementations, X 1 and X 2 Independently -alkylene-C(=O)NR 3 -alkylene- or -alkylene-NR 3 C(=O)-alkylene-. In some embodiments, X 1 and X 2 Independently CH2-C(=O)NR 3 -CH2CH2- or -CH2-NR 3 C(=O)-CH2CH2-. In some implementations, X 1 and X 2It can be independently -CH2-C(=O)NH-CH2CH2- or -CH2-NHC(=O)-CH2CH2-.
[0254] In some implementations, each R 3 Independently hydrogen or C1-C6 alkyl. In some embodiments, R 3 Each is hydrogen.
[0255] In some implementations, >AR has the following structure:
[0256] r1 and r2 are each independently 0-4.
[0257] In some implementations, r1 and r2 are each independently 0-2. In some implementations, r1 and r2 are each 0. In some implementations, r1 and r2 are each 1. In some implementations, r1 and r2 are each 3. In some implementations, r1 and r2 are each 2.
[0258] In some implementations, >AR has the following structure:
[0259]
[0260] In some implementations, >AR has the following structure:
[0261] Where p1 is 1-5.
[0262] In some implementations, p1 is 1-3. In some implementations, p1 is 1-2. In some implementations, p1 is 1. In some implementations, p1 is 2. In some implementations, p1 is 3. In some implementations, p1 is 4. In some implementations, p1 is 5.
[0263] In some implementations, >AR has the following structure:
[0264]
[0265] In some implementations, >AR has the following structure:
[0266]
[0267] In some implementations, s is 1-15. In some implementations, s is 1-10. In some implementations, s is 5-15. In some implementations, s is 5-10. In some implementations, s is 5-20.
[0268] In some embodiments, Y is hydrogen or -CO2H. In some embodiments, Y is hydrogen. In some embodiments, Y is -CO2H.
[0269] In some implementations, each L is independently -(CR) 1 R 2 ) v -, -alkylene-O-, -C(=O)-, -C(=O)NR 3 -、-NR 3 C(=O)-, -alkylene-C(=O)NR 3 -or -alkylene-NR 3 C(=O)-; and v is 2-20.
[0270] In some implementations, each L is independently -(CR) 1 R 2 ) v -, -alkylene-O-, -C(=O)-, -C(=O)NR 3 -、-NR 3 C(=O)-, -alkylene-C(=O)NR 3 -or -alkylene-NR 3 C(=O)-; and v is 2-16.
[0271] In some implementations, v is 2-16. In some implementations, v is 2-5. In some implementations, v is 5-16. In some implementations, v is 5 or 16. In some implementations, v is 2 or 16.
[0272] In some implementation schemes, R 1 Or R 2 Each is independently hydrogen, halogen, -CN, -OR a -NR c R d -C(=O)R b -CO2R a -C(=O)NR c R d Or C1-C6 alkyl.
[0273] In some implementation schemes, R 1 Or R 2 Each is independently hydrogen, halogen, -CO2R a -C(=O)NR c R d Or C1-C6 alkyl. In some embodiments, R 1 Or R 2 Each independently is hydrogen, -CO2R a、or -C(=O)NR c R d In some implementation schemes, R 1 Or R 2 Each is independently hydrogen or -CO2R a .
[0274] In some implementations, the stapler is
[0275] In some implementations, the stapler linked to the peptide is Each L 1 Independently for -(CR) 1 R 2 ) v -、-alkylene-O-、-O-alkylene-、-C(=O)NR 3 -、-NR 3 C(=O)-, -alkylene-C(=O)NR 3 -or -alkylene-NR 3 C(=O)-;v is 2-20;and s1 is 1-15.
[0276] In some implementations, the stapler linked to the peptide is Each L 2 Independently for -(CR) 1 R 2 ) v -、-alkylene-O-、-O-alkylene-、-C(=O)NR 3 -、-NR 3 C(=O)-, -alkylene-C(=O)NR 3 -or -alkylene-NR 3 C(=O)-;v is 2-20;and s2 is 1-15.
[0277] In some implementations, the stapler linked to the peptide is Each L 3 Independently for -(CR) 1 R 2 ) v -、-alkylene-O-、-O-alkylene-、-C(=O)NR 3 -、-NR 3 C(=O)-, -alkylene-C(=O)NR 3 -or -alkylene-NR 3 C(=O)-;v is 2-20;and s3 is 1-15.
[0278] In some implementations, the stapler linked to the peptide is Each L4 Independently for -(CR) 1 R 2 ) v -、-alkylene-O-、-O-alkylene-、-C(=O)NR 3 -、-NR 3 C(=O)-, -alkylene-C(=O)NR 3 -or -alkylene-NR 3 C(=O)-;v is 2-20;and s4 is 1-15.
[0279] In some implementations, the stapler linked to the peptide is Each L 5 Independently for -(CR) 1 R 2 ) v -、-C(=O)NR 3 -、-NR 3 C(=O)-, -alkylene-C(=O)NR 3 -or -alkylene-NR 3 C(=O)-;v is 2-20;and s5 is 1-10.
[0280] In some implementations, the stapler linked to the peptide is Each L 6 Independently for -(CR) 1 R 2 ) v -、-C(=O)NR 3 -、-NR 3 C(=O)-, -alkylene-C(=O)NR 3 -or -alkylene-NR 3 C(=O)-;v is 2-20;and s6 is 1-5.
[0281] In some implementations, the stapler linked to the peptide is Each L 7 Independently for -(CR) 1 R 2 ) v -、-C(=O)NR 3 -or-NR 3 C(=O)-; v is 2-20; and s7 is 1-5.
[0282] In some implementations, the stapler linked to the peptide is Where L 8 -(CR) 1 R 2 ) v - And v is 10-20.
[0283] In some implementations, the stapler linked to the peptide is Each L 9 Independently for -(CR) 1 R 2 ) v -、-C(=O)NR 3 -、-NR 3 C(=O)-, -alkylene-C(=O)NR 3 -or -alkylene-NR 3 C(=O)-;v is 2-20;and s9 is 1-5.
[0284] In some implementations, the stapler linked to the peptide is
[0285] Where L 10 -(CR) 1 R 2 ) v - And v is 10-20.
[0286] In some implementations, the stapler linked to the peptide is
[0287] In some implementations, the stapler linked to the peptide is Each L 11 Independently for -(CR) 1 R 2 ) v -、-alkylene-O-、-O-alkylene-、-C(=O)NR 3 -、-NR 3 C(=O)-, -alkylene-C(=O)NR 3 -or -alkylene-NR 3 C(=O)-;v is 2-20;and s11 is 1-15.
[0288] In some implementations, the stapler linked to the peptide is Each L 12 Independently for -(CR) 1 R 2 ) v -、-alkylene-O-、-O-alkylene-、-C(=O)NR 3 -、-NR 3 C(=O)-, -alkylene-C(=O)NR 3 -or -alkylene-NR 3 C(=O)-;v is 2-20;and s12 is 1-15.
[0289] In some implementations, the stapler linked to the peptide is Each L 13 Independently for -(CR) 1 R 2 ) v -、-alkylene-O-、-O-alkylene-、-C(=O)NR 3 -、-NR 3 C(=O)-, -alkylene-C(=O)NR 3 -or -alkylene-NR 3 C(=O)-;v is 2-20;and s13 is 1-15.
[0290] In some implementations, the stapler linked to the peptide is Each L 14 Independently for -(CR) 1 R 2 ) v -、-alkylene-O-、-O-alkylene-、-C(=O)NR 3 -、-NR 3 C(=O)-, -alkylene-C(=O)NR 3 -or -alkylene-NR 3 C(=O)-;v is 2-20;and s14 is 1-15.
[0291] In some implementations, the stapler linked to the peptide is Each L 15 Independently for -(CR) 1 R 2 ) v -、-C(=O)NR 3 -、-NR 3 C(=O)-, -alkylene-C(=O)NR 3 -or -alkylene-NR 3 C(=O)-;v is 2-20;and s15 is 1-10.
[0292] In some implementations, the stapler linked to the peptide is Each L 16 Independently for -(CR) 1 R 2 ) v -、-C(=O)NR 3 -or-NR 3 C(=O)-;v is 2-20;and s16 is 1-5.
[0293] In some implementations, the stapler linked to the peptide is
[0294] Each L 17 Independently for -(CR) 1 R 2 ) v -、-C(=O)NR 3 -or-NR 3 C(=O)-;v is 2-20;and s17 is 1-5.
[0295] In some implementations, the stapler linked to the peptide is
[0296] Where L 18 -(CR) 1 R 2 ) v - And v is 10-20.
[0297] In some implementations, the stapler linked to the peptide is
[0298] Each L1 9 Independently for -(CR) 1 R 2 ) v -、-C(=O)NR 3 -、-NR 3 C(=O)-, -alkylene-C(=O)NR 3 -or -alkylene-NR 3 C(=O)-;v is 2-20;and s19 is 1-5.
[0299] In some implementations, the stapler linked to the peptide is Where L 20 -(CR) 1 R 2 ) v - And v is 10-20.
[0300] In some implementations, the stapler linked to the peptide is:
[0301]
[0302]
[0303]
[0304]
[0305]
[0306] It is part of a cysteine, homocysteine, 2-amino-5-mercaptovalerate, or 2-amino-6-mercaptohexanoate residue, and It is part of lysine, ornithine, diaminobutyric acid, diaminopropionic acid, or high-lysine residues.
[0307] In some implementations, the stapler linked to the peptide is:
[0308] Where n is 1-4 and m is 6-20; It is part of a cysteine, homocysteine, 2-amino-5-mercaptovalerate, or 2-amino-6-mercaptohexanoate residue, and It is part of lysine, ornithine, diaminobutyric acid, diaminopropionic acid, or high-lysine residues.
[0309] In some implementations, the stapler linked to the peptide is:
[0310] It is part of a cysteine, homocysteine, 2-amino-5-mercaptovalerate, or 2-amino-6-mercaptohexanoate residue, and It is part of lysine, ornithine, diaminobutyric acid, diaminopropionic acid, or high-lysine residues.
[0311] In some implementations, the stapler linked to the peptide is:
[0312] It is part of a cysteine, homocysteine, 2-amino-5-mercaptovalerate, or 2-amino-6-mercaptohexanoate residue.
[0313] In some implementations, the stapler linked to the peptide is:
[0314] It is part of lysine, ornithine, diaminobutyric acid, diaminopropionic acid, or high-lysine residues.
[0315] In some implementations, the stapler linked to the peptide is:
[0316] It is part of lysine, ornithine, diaminobutyric acid, diaminopropionic acid, or high-lysine residues.
[0317] In some implementations, the stapler linked to the peptide is:
[0318] It is part of a cysteine, homocysteine, 2-amino-5-mercaptovalerate, or 2-amino-6-mercaptohexanoate residue.
[0319] In some implementations, the stapler linked to the peptide is:
[0320] It is part of a cysteine, homocysteine, 2-amino-5-mercaptovalerate, or 2-amino-6-mercaptohexanoate residue.
[0321] In some implementations, the stapler linked to the peptide is:
[0322] It is part of a cysteine, homocysteine, 2-amino-5-mercaptovalerate, or 2-amino-6-mercaptohexanoate residue.
[0323] In some implementations, the stapler linked to the peptide is:
[0324] It is part of lysine, ornithine, diaminobutyric acid, diaminopropionic acid, or high-lysine residues.
[0325] In some implementations, the stapler linked to the peptide is:
[0326] It is part of lysine, ornithine, diaminobutyric acid, diaminopropionic acid, or high-lysine residues.
[0327] In some implementations, the stapler linked to the peptide is:
[0328] It is part of lysine, ornithine, diaminobutyric acid, diaminopropionic acid, or high-lysine residues.
[0329] Extended half-life portion (HEM)
[0330] This article discloses peptide conjugates containing HEM.
[0331] In some embodiments, the HEM linked to the peptide is a compound of formula (II):
[0332] -X 3 -(L) s -Y formula (II)
[0333] in:
[0334] X 3 For bond, -C(=O)-, -alkylene-C(=O)-, -C(=O)-alkylene-, -alkylene-C(=O)NR 3 -,-alkylene-NR3 C(=O)-、-C(=O)NR 3 -alkylene-, -NR 3 C(=O)-alkylene-,-alkylene-C(=O)NR 3 -alkylene- or -alkylene-NR 3 C(=O)-alkylene-;
[0335] Where X 3 Linked to the first amino acid of the peptide;
[0336] Each L is independently -(CR) 1 R 2 ) v -、-alkylene-O-、-O-alkylene-、-C(=O)-alkylene-、-alkylene-C(=O-、-NR 3 -alkylene-, -alkylene-NR 3 -、-S-alkylene-、-alkylene-S-、-S(=O)-alkylene-、-alkylene-S(=O-、-S(=O)2-alkylene、-alkylene-S(=O)2-、-C(=O-、-C(=O)NR 3 -、-NR 3 C(=O)-、-NR 3 C(=O)NR 3 -、-NR 3 C(=O)NR 3 -alkylene-, -NR 3 C(=O)-alkylene-NR 3 -,-alkylene-C(=O)NR 3 -、-C(=O)NR 3 -alkylene-, -alkylene-NR 3 C(=O)-or-NR 3 C(=O)-alkylene-;
[0337] v is 2-20;
[0338] R 1 Or R 2 Each is independently hydrogen, halogen, -CN, -OR a -SR a -S(=O)R b -NO2, -NR c R d -S(=O)2R d -NR a S(=O)2R d -S(=O)2NR c R d -C(=O)Rb -OC(=O)R b -CO2R a -OCO2R a -C(=O)NR c R d -OC(=O)NR c R d -NR a C(=O)NR c R d -NR a C(=O)R b -NR a C(=O)OR a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 ynyl, C1-C6 heteroalkyl, C3-C8 cycloalkyl, C2-C8 heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, ynyl and heteroalkyl are optionally converted by halogen, -OR a or -NR c R d One, two, or three of the alkyl, heterocyclic, aryl, and heteroaryl groups may be substituted with halogens, C1-C6 alkyl groups, C1-C6 haloalkyl groups, or -OR groups. a -NR c R d One, two, or three can be substituted;
[0339] Or R 1 and R 2 Together they form C1-C6 cycloalkyl or C1-C6 heterocycloalkyl;
[0340] Each R 3 Independently hydrogen, -S(=O)R b -S(=O)2R a -S(=O)2NR c R d -C(=O)R b -CO2R a -C(=O)NR c R d C1-C6 alkyl, C2-C6 alkenyl, C2-C6 ynyl, C1-C6 heteroalkyl, C3-C8 cycloalkyl, C2-C8 heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, ynyl and heteroalkyl are optionally converted by halogen, -OR a or -NR c R d One, two, or three of the alkyl, heterocyclic, aryl, and heteroaryl groups may be substituted with halogens, C1-C6 alkyl groups, C1-C6 haloalkyl groups, or -OR groups. a or -NRc R d One, two, or three can be substituted;
[0341] Y is hydrogen, C1-C6 alkyl, -CO2H, -CO2(C1-C6 alkyl), -CO2NH2, -CO2N(alkyl)2, or -CO2NH(alkyl); and
[0342] s is 0-20;
[0343] R a It is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C3-C8 cycloalkyl, C2-C8 heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, alkynyl and heteroalkyl are optionally substituted by one, two or three of a halogen, -OH, -OMe or -NH2; and the cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted by one, two or three of a halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OH, -OMe or -NH2;
[0344] R b It is a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C3-C8 cycloalkyl, C2-C8 heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, and heteroalkyl are optionally substituted by one, two, or three of a halogen, -OH, -OMe, or -NH2; and the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted by one, two, or three of a halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OH, -OMe, or -NH2;
[0345] R c and R d Each of the following is independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C3-C8 cycloalkyl, C2-C8 heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, and heteroalkyl are optionally substituted by one, two, or three of a halogen, -OH, -OMe, or -NH2; and the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted by one, two, or three of a halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OH, -OMe, or -NH2;
[0346] Or R c and R d Together with the nitrogen atoms to which they are attached, they form heterocyclic alkyl or heteroaryl groups; wherein the heterocyclic alkyl and heteroaryl groups are optionally substituted by one, two or three of a halogen, a C1-C6 alkyl, a C1-C6 haloalkyl, -OH, -OMe or -NH2.
[0347] In some implementation schemes, X 3 For key.
[0348] In some implementation schemes, X 3 It is -alkylene-C(=O)- or -C(=O)alkylene-. In some embodiments, X 3 It is -CH2-C(=O)- or -C(=O)-CH2-. In some implementations, X 3 -alkylene-C(=O)NR 3 or -C(=O)NR 3 -alkylene-. In some embodiments, X 3 -CH2-C(=O)NR 3 -or-C(=O)NR 3 -CH2-. In some implementations, X 3 -alkylene-C(=O)NR 3 -alkylene- or -alkylene-NR 3 C(=O)-alkylene-. In some embodiments, X 3 -CH2-C(=O)NR 3 -CH2CH2- or -CH2-NR 3 C(=O)-CH2CH2-. In some implementations, X 3 It is -CH2-C(=O)NH-CH2CH2- or -CH2-NHC(=O)-CH2CH2-.
[0349] In some implementations, each R 3 Independently hydrogen or C1-C6 alkyl. In some embodiments, R 3 Each is hydrogen.
[0350] In some implementations, s is 1-15. In other implementations, s is 1-10.
[0351] In some implementations, s is 5-15. In some implementations, s is 5-10. In some implementations, s is 5-20.
[0352] In some embodiments, Y is hydrogen or -CO2H. In some embodiments, Y is hydrogen. In some embodiments, Y is -CO2H.
[0353] In some implementations, each L is independently -(CR) 1 R 2 ) v -, -alkylene-O-, -C(=O)-, -C(=O)NR 3 -、-NR 3C(=O)-, -alkylene-C(=O)NR 3 -or -alkylene-NR 3 C(=O)-; and v is 2-20.
[0354] In some implementations, each L is independently -(CR) 1 R 2 ) v -, -alkylene-O-, -C(=O)-, -C(=O)NR 3 -、-NR 3 C(=O)-, -alkylene-C(=O)NR 3 -or -alkylene-NR 3 C(=O)-; and v is 2-16.
[0355] In some implementations, v is 2-16. In some implementations, v is 2-5. In some implementations, v is 5-16. In some implementations, v is 5 or 16. In some implementations, v is 2 or 16.
[0356] In some implementation schemes, R 1 Or R 2 Each is independently hydrogen, halogen, -CN, -OR a -NR c R d -C(=O)R b -CO2R a -C(=O)NR c R d Or C1-C6 alkyl.
[0357] In some implementation schemes, R 1 Or R 2 Each is independently hydrogen, halogen, -CO2R a -C(=O)NR c R d Or C1-C6 alkyl. In some embodiments, R 1 Or R 2 Each independently is hydrogen, -CO2R a or -C(=O)NR c R d In some implementations, R 1 Or R 2 Each is independently hydrogen or -CO2R a .
[0358] In some implementations, the HEM linked to the peptide is:
[0359] It is part of a cysteine, homocysteine, 2-amino-5-mercaptovalerate, or 2-amino-6-mercaptohexanoate residue.
[0360] In some implementations, the HEM linked to the peptide is:
[0361] Where n is 1-4 and m is 6-20; It is part of a cysteine, homocysteine, 2-amino-5-mercaptovalerate, or 2-amino-6-mercaptohexanoate residue.
[0362] peptide conjugates with pinning structures
[0363] In one aspect, this document discloses peptide conjugates comprising (a) a peptide selected from the group consisting of a peptide that regulates a PYY receptor, a peptide that regulates a GLP-1 receptor and a GCG receptor, a peptide that regulates a GLP-1 receptor and a GIP receptor, and a peptide that regulates a GLP-1 receptor; and (b) a conjugate linked to a peptide at a first amino acid and a second amino acid.
[0364] In some embodiments, the peptide conjugate comprises (a) a peptide that regulates the PYY receptor; and (b) a stapled conjugate linked to the peptide at the first and second amino acids.
[0365] In some embodiments, the peptide conjugate comprises (a) a peptide that regulates the GLP-1 receptor and the GCG receptor; and (b) a stapling attached to the peptide at the first and second amino acids.
[0366] In some embodiments, the peptide conjugate comprises (a) a peptide that regulates the GLP-1 receptor and the GIP receptor; and (b) a stapled peptide linked to the first and second amino acids.
[0367] In some embodiments, the peptide conjugate comprises (a) a peptide that regulates the GLP-1 receptor; and (b) a stapled conjugate linked to the peptide at the first and second amino acids.
[0368] Non-limiting examples of amino acids used for conjugation include cysteine, homocysteine, 2-amino-5-mercaptovalerate, 2-amino-6-mercaptohexanoate, lysine, ornithine, diaminobutyric acid, diaminopropionic acid, homolysine, other thiol-containing amino acids, or other amine-containing amino acids. In some embodiments, the two amino acids linked by the conjugate are separated by about or at least about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or more amino acids. For example, the first amino acid is at position i, and the second amino acid is at position i+7, i+11, i+13, i+15, or i+16. For example, the first amino acid is at position i in the peptide, and the second amino acid is at position i+n in the peptide, where n is 4-16. In some embodiments, the first amino acid is at position 14 of the peptide, and the second amino acid is at position 21 of the peptide. In some embodiments, the first amino acid is at position 17 of the peptide, and the second amino acid is at position 24 of the peptide.
[0369] For example, the first amino acid is at position i in the peptide, and the second amino acid is at position i+4. For example, the first amino acid is at position i in the peptide, and the second amino acid is at position i+5. For example, the first amino acid is at position i in the peptide, and the second amino acid is at position i+6. For example, the first amino acid is at position i in the peptide, and the second amino acid is at position i+7. For example, the first amino acid is at position i in the peptide, and the second amino acid is at position i+8. For example, the first amino acid is at position i in the peptide, and the second amino acid is at position i+9. For example, the first amino acid is at position i in the peptide, and the second amino acid is at position i+10. For example, the first amino acid is at position i in the peptide, and the second amino acid is at position i+11. For example, the first amino acid is at position i in the peptide, and the second amino acid is at position i+12. For example, the first amino acid is at position i in the peptide, and the second amino acid is at position i+13. For example, the first amino acid is at position i in the peptide, and the second amino acid is at position i+14. For example, the first amino acid is at position i in the peptide, and the second amino acid is at position i+15. For example, the first amino acid is at position i in the peptide, and the second amino acid is at position i+16.
[0370] In some implementations, the first and second amino acids are independently selected from amine-containing amino acids and thiol-containing amino acids.
[0371] In some embodiments, the first and second amino acids are independently selected from cysteine, homocysteine, 2-amino-5-mercaptovalerate, and 2-amino-6-mercaptohexanoate. In some embodiments, the first and second amino acids are cysteine.
[0372] In some implementations, the first and second amino acids are independently selected from lysine, ornithine, diaminobutyric acid, diaminopropionic acid, and homolysine.
[0373] In some implementations, the first and second amino acids are lysine.
[0374] In some implementations, the first and second amino acids are ornithine.
[0375] In some embodiments, the peptide conjugate further comprises a half-life extension molecule linked to a thiol-containing or amine-containing amino acid residue in the peptide.
[0376] In some implementations, the amine-containing amino acid is selected from lysine, ornithine, diaminobutyric acid, diaminopropionic acid, and homolysine.
[0377] In some implementations, the amine-containing amino acid is lysine.
[0378] In some embodiments, the thiol-containing amino acid is selected from cysteine, homocysteine, 2-amino-5-mercaptovalerate, and 2-amino-6-mercaptohexanoate.
[0379] In some implementations, the thiol-containing amino acid is cysteine.
[0380] Peptide conjugates with extended half-life
[0381] In one aspect, this document discloses peptide conjugates comprising (a) a peptide selected from: a peptide that regulates the PYY receptor, a peptide that regulates the GLP-1 receptor and the GCG receptor, a peptide that regulates the GLP-1 receptor and the GIP receptor, and a peptide that regulates the GLP-1 receptor; and (b) a half-life extension moiety (HEM) attached to the peptide at the first amino acid.
[0382] In some embodiments, the peptide conjugate comprises (a) a peptide that regulates the PYY receptor; and (b) a half-life extension moiety (HEM) linked to the peptide at the first amino acid.
[0383] In some embodiments, the peptide conjugate comprises (a) a peptide that regulates the GLP-1 receptor and the GCG receptor; and (b) a half-life extension moiety (HEM) attached to the peptide at the first amino acid.
[0384] In some embodiments, the peptide conjugate comprises (a) a peptide that regulates the GLP-1 receptor and the GIP receptor; and (b) a half-life extension moiety (HEM) attached to the peptide at the first amino acid.
[0385] In some embodiments, the peptide conjugate comprises (a) a peptide that regulates the GLP-1 receptor; and (b) a half-life extension moiety (HEM) linked to the peptide at the first amino acid.
[0386] Non-limiting examples of amino acids used for conjugation include cysteine, homocysteine, 2-amino-5-mercaptovalerate, 2-amino-6-mercaptohexanoate, lysine, ornithine, diaminobutyric acid, diaminopropionic acid, homolysine, other thiol-containing amino acids, or other amine-containing amino acids. In some embodiments, the first amino acid is selected from amine-containing amino acids and thiol-containing amino acids. In some embodiments, the first amino acid is selected from cysteine, homocysteine, 2-amino-5-mercaptovalerate, and 2-amino-6-mercaptohexanoate. In some embodiments, the first amino acid is cysteine. In some embodiments, the first amino acid is selected from lysine, ornithine, diaminobutyric acid, diaminopropionic acid, and homolysine. In some embodiments, the first amino acid is lysine. In some embodiments, the first amino acid is ornithine. In some embodiments, the peptide conjugate further comprises a second half-life extension portion linked to a thiol-containing or amine-containing amino acid residue in the peptide. In some embodiments, the amine-containing amino acid is selected from lysine, ornithine, diaminobutyric acid, diaminopropionic acid, and homolysine. In some embodiments, the amine-containing amino acid is lysine. In some embodiments, the thiol-containing amino acid is selected from cysteine, homocysteine, 2-amino-5-mercaptovalerate, and 2-amino-6-mercaptohexanoate. In some embodiments, the thiol-containing amino acid is cysteine.
[0387] In some embodiments, the peptide conjugate comprises:
[0388] a) A peptide that regulates the PYY receptor, comprising a peptide sequence having at least about 95% identity with any one of SEQ ID NO: 3, 5, 6, 8, 14-30, 36 or 37; and
[0389] b) A stapled peptide linked to the first and second amino acids.
[0390] In some embodiments, the peptide regulating the PYY receptor comprises a peptide sequence having at least about 99% identity with any one of SEQ ID NO:3, 5, 6, 8, 14-30, 36 or 37;
[0391] In some implementations, the peptide that regulates the PYY receptor comprises the peptide sequence of SEQ ID NO:3, 5, 6, 8, 14-30, 36 or 37.
[0392] In some embodiments, the peptide that regulates the PYY receptor comprises a sequence that has at least about 99% identity with SEQ ID NO:6.
[0393] In some implementations, the peptide that regulates the PYY receptor contains the sequence of SEQ ID NO:6.
[0394] In some embodiments, the peptide conjugate comprises:
[0395] a) A peptide that regulates the GLP-1 receptor and the GCGR receptor, comprising a peptide sequence having at least about 95% identity with any one of SEQ ID NO:50-59; and
[0396] b) A stapled peptide linked to the first and second amino acids.
[0397] In some embodiments, the peptides that regulate the GLP-1 receptor and the GCG receptor comprise peptide sequences that are at least about 99% identical to any one of SEQ ID NO:50-59.
[0398] In some embodiments, the peptides that regulate the GLP-1 receptor and the GCG receptor comprise peptide sequences selected from SEQ ID NO:50-59.
[0399] In some embodiments, the peptide conjugate comprises:
[0400] a) A peptide that regulates the GLP-1 receptor and the GIP receptor, comprising a peptide sequence having at least about 95% identity with any one of SEQ ID NO:62-71; and
[0401] b) A stapled peptide linked to the first and second amino acids.
[0402] In some embodiments, the peptides that regulate the GLP-1 receptor and the GIP receptor comprise peptide sequences that are at least about 99% identical to any one of SEQ ID NO:62-71.
[0403] In some embodiments, the peptides that regulate the GLP-1 receptor and the GIP receptor comprise peptide sequences selected from SEQ ID NO:62-71.
[0404] In some embodiments, the peptides that regulate the GLP-1 receptor and the GIP receptor contain a sequence that has at least about 99% identity with SEQ ID NO:63.
[0405] In some implementations, the peptides that regulate the GLP-1 receptor and the GIP receptor contain the sequence of SEQ ID NO:63.
[0406] In some embodiments, the peptide conjugate comprises:
[0407] a) A peptide that regulates the GLP-1 receptor, comprising a peptide sequence having at least about 95% identity with any one of SEQ ID NO: 74 or 79; and
[0408] b) A stapled peptide linked to the first and second amino acids.
[0409] In some embodiments, the peptide that regulates the GLP-1 receptor comprises a peptide sequence that is at least about 99% identical to any one of SEQ ID NO:74 or 79.
[0410] In some embodiments, the peptide that regulates the GLP-1 receptor comprises a peptide sequence selected from SEQ ID NO:74 or 79.
[0411] In some embodiments, the peptide conjugate comprises:
[0412] a) A peptide that regulates the PYY receptor, comprising the peptide sequence of SEQ ID NO:6; and
[0413] b) A stapled peptide with the following structure linked to the first and second cysteine residues ( (part of a cysteine residue):
[0414]
[0415] In some embodiments, the peptide conjugate comprises:
[0416] a) A peptide that regulates the PYY receptor, comprising the peptide sequence of SEQ ID NO:10; and
[0417] b) HEMs with the following structure linked to the peptide at the first cysteine residue (b) (part of a cysteine residue):
[0418]
[0419] In some embodiments, the peptide conjugate comprises:
[0420] a) A peptide that regulates the GLP-1 receptor and the GCG receptor, comprising the peptide sequence of SEQ ID NO:48; and
[0421] b) A stapled peptide with the following structure linked to the first and second lysine residues ( (Part of a lysine residue):
[0422]
[0423] In some embodiments, the peptide conjugate comprises:
[0424] a) A peptide that regulates the GLP-1 receptor and the GCG receptor, comprising the peptide sequence of SEQ ID NO:60; and
[0425] b) A stapled peptide with the following structure linked to the first and second cysteine residues ( (part of a cysteine residue):
[0426]
[0427] In some embodiments, the peptide conjugate comprises:
[0428] a) A peptide that regulates the GLP-1 receptor and the GIP receptor, comprising the peptide sequence of SEQ ID NO:63; and
[0429] b) A stapled peptide with the following structure linked to the first and second lysine residues ( (Part of a lysine residue):
[0430]
[0431] In some embodiments, the peptide conjugate comprises:
[0432] a) A peptide that regulates the GLP-1 receptor, comprising the peptide sequence of SEQ ID NO:76; and
[0433] b) A stapled peptide with the following structure linked to the first and second cysteine residues ( (part of a cysteine residue):
[0434]
[0435] In some embodiments, the peptide conjugate comprises:
[0436] a) A peptide that regulates the GLP-1 receptor, comprising the peptide sequence of SEQ ID NO:77; and
[0437] b) A stapled peptide with the following structure linked to the first and second cysteine residues ( (part of a cysteine residue):
[0438]
[0439] Prolactin-releasing peptide (PrRP) peptide conjugate
[0440] In one aspect, this document discloses peptide conjugates comprising prolactin-releasing peptide (PrRP). In an exemplary embodiment, the prolactin-releasing peptide (PrRP) comprises two amino acids linked by a pin. Non-limiting examples of amino acids used for the conjugation include cysteine, homocysteine, 2-amino-5-mercaptovalerate, 2-amino-6-mercaptohexanoate, or other thiol-containing amino acids. For a prolactin-releasing peptide (PrRP) comprising two amino acids linked by a pin, the two amino acids are separated by about or at least about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or more amino acids. For example, the first amino acid is at position i, and the second amino acid is at position i+7, i+11, i+13, i+15, or i+16. For example, the first amino acid is at position i in the peptide, and the second amino acid is at position i+n in the peptide, where n is 4-16. For example, the first amino acid is at position i in the peptide, and the second amino acid is at position i+7 in the peptide. For example, the first amino acid is at position i in the peptide, and the second amino acid is at position i+11. For example, the first amino acid is at position i in the peptide, and the second amino acid is at position i+15. For example, the first amino acid is at position i in the peptide, and the second amino acid is at position i+16.
[0441] This article discloses peptide conjugates containing:
[0442] a) Prolactin-releasing peptide (PrRP); and
[0443] b) A half-life-extending molecule linked to the stapled peptide, wherein the stapled peptide is linked to the first and second amino acids.
[0444] In some implementations, the first and second amino acids are independently selected from thiol-containing amino acids.
[0445] In some embodiments, the first and second amino acids are independently selected from cysteine, homocysteine, 2-amino-5-mercaptovalerate, and 2-amino-6-mercaptohexanoate. In some embodiments, the first and second amino acids are cysteine.
[0446] In some embodiments of prolactin-releasing peptide (PrRP) and half-life-extending molecules linked to the conjugate, the peptide conjugate comprises:
[0447] a) Prolactin-releasing peptide (PrRP), comprising peptide sequences selected from SEQ ID NO:83-105; and
[0448] b) A half-life-extending molecule linked to a stapler, wherein the stapler is linked to the peptide at the first and second cysteine residues;
[0449] This half-life-extending molecule is linked to a peg having the following structure ( (part of a cysteine residue):
[0450]
[0451]
[0452] In some embodiments of prolactin-releasing peptide (PrRP) and half-life-extending molecules linked to the conjugate, the peptide conjugate comprises:
[0453] a) Prolactin-releasing peptide (PrRP), comprising peptide sequences selected from SEQ ID NO:83-105; and
[0454] b) A half-life-extending molecule linked to a stapler, wherein the stapler is linked to the peptide at the first and second cysteine residues;
[0455] This half-life-extending molecule is linked to a pinned molecule with the following structure (“S” is part of a cysteine residue):
[0456]
[0457]
[0458] In some embodiments of prolactin-releasing peptide (PrRP) and half-life-extending molecules linked to the conjugate, the peptide conjugate comprises:
[0459] a) Prolactin-releasing peptide (PrRP), comprising peptide sequences selected from SEQ ID NO:83-105; and
[0460] b) A half-life-extending molecule linked to a stapler, wherein the stapler is linked to the peptide at the first and second cysteine residues;
[0461] This half-life-extending molecule is linked to a pinned molecule with the following structure (“S” is part of a cysteine residue):
[0462]
[0463]
[0464] In some embodiments of prolactin-releasing peptide (PrRP) and half-life-extending molecules linked to the conjugate, the peptide conjugate comprises:
[0465] a) Prolactin-releasing peptide (PrRP), comprising peptide sequences selected from SEQ ID NO:83-105; and
[0466] b) A half-life-extending molecule linked to a stapler, wherein the stapler is linked to the peptide at the first and second cysteine residues;
[0467] This half-life-extending molecule is linked to a pinned molecule with the following structure (“S” is part of a cysteine residue):
[0468]
[0469] In some embodiments of prolactin-releasing peptide (PrRP) and half-life-extending molecules linked to the conjugate, the peptide conjugate comprises:
[0470] a) Prolactin-releasing peptide (PrRP), comprising peptide sequences selected from SEQ ID NO:83-105; and
[0471] b) A half-life-extending molecule linked to a stapler, wherein the stapler is linked to the peptide at the first and second cysteine residues;
[0472] This half-life-extending molecule is linked to a pinned molecule with the following structure (“S” is part of a cysteine residue):
[0473]
[0474] In some embodiments of prolactin-releasing peptide (PrRP) and half-life-extending molecules linked to the conjugate, the peptide conjugate comprises:
[0475] a) Prolactin-releasing peptide (PrRP), comprising peptide sequences selected from SEQ ID NO:83-105; and
[0476] b) A half-life-extending molecule linked to a stapler, wherein the stapler is linked to the peptide at the first and second cysteine residues;
[0477] This half-life-extending molecule is linked to a pinned molecule with the following structure (“S” is part of a cysteine residue):
[0478]
[0479] In some embodiments of prolactin-releasing peptide (PrRP), the peptide conjugate comprises:
[0480] a) Prolactin-releasing peptide (PrRP), comprising peptide sequences selected from SEQ ID NO:83-105; and
[0481] b) Peptides linked to the first and second cysteine residues;
[0482] This half-life-extending molecule is linked to a pinned molecule with the following structure (“S” is part of a cysteine residue):
[0483]
[0484] Pharmacokinetics
[0485] The mechanisms by which peptide conjugates positively affect pharmacokinetic or pharmacodynamic behavior include, but are not limited to, (i) preventing or mitigating in vivo proteolytic degradation or other activities of the therapeutic agent by reducing chemical modifications; (ii) improving half-life or other pharmacokinetic properties by reducing renal filtration, reducing receptor-mediated clearance, or increasing bioavailability; (iii) reducing toxicity; (iv) increasing solubility; and / or (v) increasing the bioactivity and / or target selectivity of the unconjugated therapeutic agent. Therapeutic agents may comprise PYY receptor modulators, GLP-1 receptor modulators, GCG receptor modulators, GIP receptor modulators, or agents (e.g., peptides) that modulate combinations thereof.
[0486] Peptide conjugates can enhance one or more pharmacokinetic properties of a therapeutic agent when conjugated with the therapeutic agent. Compared to a single therapeutic agent or an unmodified therapeutic peptide, the peptide conjugates disclosed herein can enhance one or more pharmacokinetic properties of a therapeutic agent by at least about 200%, as measured by pharmacodynamics. Compared to a single therapeutic agent or an unmodified therapeutic peptide, the peptide conjugates disclosed herein can enhance one or more pharmacokinetic properties of a therapeutic agent by at least about 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000%, as measured by pharmacodynamics.
[0487] Pharmacokinetic properties may include half-life. The half-life of a peptide conjugate may be at least about 2 times the half-life of a single unmodified peptide. The half-life of the peptide conjugates disclosed herein may be at least about 3, 4, 5, or 10 times the half-life of a single therapeutic agent or an unmodified therapeutic peptide. The half-life of the peptide conjugates disclosed herein may be at least about 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 times the half-life of a single unmodified peptide.
[0488] In some embodiments, the half-life of the peptide conjugate is at least about twice that of the unmodified peptide. In some embodiments, the half-life of the peptide conjugate is at least about five times that of the unmodified peptide. In some embodiments, the half-life of the peptide conjugate is at least about ten times that of the unmodified peptide.
[0489] Furthermore, compared to unmodified therapeutic peptides in their unconjugated form, the peptide conjugates described herein can have a positive effect on increasing peptide manufacturability and / or reducing peptide immunogenicity.
[0490] Therapeutic uses
[0491] In one respect, the peptide conjugates disclosed herein can be used to treat, alleviate, inhibit, and / or prevent one or more diseases and / or conditions. The disease and / or condition may be chronic. Alternatively, the disease and / or condition may be acute. The disease or condition may be relapsing, refractory, accelerating, or remission-related. The disease or condition may affect one or more cell types. The one or more diseases and / or conditions may be autoimmune diseases, inflammatory diseases, or metabolic diseases.
[0492] This document discloses a method for treating a disease or condition in a subject in need, the method comprising administering the peptide conjugate described herein to the subject. The disease or condition may be diabetes or obesity, or a medical condition associated with diabetes or obesity. The disease or condition may be non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), or cardiovascular disease. The disease or condition may be an autoimmune disease. The disease or condition may be Crohn's disease or ulcerative colitis. The disease or condition may be short bowel syndrome (SBS). The disease or condition may be inflammatory bowel disease (IBD), inflammatory bowel syndrome (IBS), or psoriasis. The disease or condition may be Alzheimer's disease, Parkinson's disease, or Huntington's disease. The PLC may be administered in combination with one or more other therapeutic agents. This document discloses a method for treating a disease or condition in a subject in need, the method comprising administering the composition disclosed herein containing one or more peptide conjugates to the subject.
[0493] This article provides a method for preventing or treating metabolic diseases or conditions in subjects who require it, the method comprising administering the peptide conjugates described herein to the subject. Metabolic diseases or conditions may include diabetes. Metabolic diseases or conditions may include obesity. Metabolic diseases or conditions can include glycogen storage disease, phenylketonuria, maple syrup urine disease, glutaricacidemia type 1, carbamoyl phosphate synthetase I deficiency, alcaptonuria, medium-chain acyl-coenzyme A dehydrogenase deficiency (MCADD), acute intermittent porphyria, Lesch-Nyhan syndrome, lipoid congenital adrenal hyperplasia, congenital adrenal hyperplasia, POMPC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. This includes syndromes such as Alstrome syndrome, Prader-Willi syndrome, Kearns-Sayre syndrome, Zellweger syndrome, Gaucher's disease, and Niemann Pick disease.
[0494] This article provides a method for preventing or treating NAFLD, NASH, or cardiovascular disease in subjects who require it, the method comprising administering the peptide conjugate described herein to the subject.
[0495] This article provides a method for the prevention or treatment of short bowel syndrome (SBS) in subjects in need, which involves administering the peptide conjugate described herein to the subject.
[0496] This article provides a method for the prevention or treatment of inflammatory bowel disease (IBD), inflammatory bowel syndrome (IBS), or psoriasis in subjects in need, the method comprising administering the peptide conjugate described herein to the subject.
[0497] This article provides a method for preventing or treating Crohn's disease or ulcerative colitis in subjects who require it, the method comprising administering the peptide conjugate described herein to the subject.
[0498] This article provides a method for preventing or treating sleep disorders.
[0499] This article provides a method for preventing or treating absence seizures.
[0500] This article provides a method for preventing or treating chronic kidney disease (such as complications of diabetes). This article provides a method for preventing or treating diabetic heart disease.
[0501] This article provides a method for preventing or treating cardiovascular events.
[0502] This article provides a method for preventing or treating Alzheimer's disease, Parkinson's disease, or Huntington's disease in subjects who require it, the method comprising administering the peptide conjugate described herein to the subject.
[0503] This article provides a method for preventing or treating gastrointestinal-related conditions, such as treating newborns with impaired bowel function, osteoporosis, and DPP-IV (dipeptidyl peptidase-IV) mediated conditions. Examples of stomach and intestinal-related conditions include ulcers, gastritis, digestion disorders, malabsorption syndrome, short-gut syndrome, cul-de-sac syndrome, inflammatory bowel disease, celiac sprue (e.g., caused by gluten-induced enteropathy or gluten intolerance), tropical sprue, hypogammaglobulinemia sprue, enteritis, regional enteritis (Crohn's disease), ulcerative colitis, irritable bowel syndrome associated with diarrhea, small intestinal damage, and short bowel syndrome.
[0504] This article provides a method for preventing or treating radiation enteritis, infectious or post-infectious enteritis, and small bowel damage caused by toxic or other chemotherapeutic agents. This may require the administration of peptide conjugates before, during, or after chemotherapy or radiotherapy procedures to reduce chemotherapy side effects such as diarrhea, abdominal cramps, and vomiting, and to reduce structural and functional damage to the intestinal epithelium caused by chemotherapy or radiotherapy.
[0505] This article provides a method for preventing or treating malnutrition, such as conditions like wasting syndrome cachexia and anorexia.
[0506] This article provides a method for preventing or treating diseases or conditions that benefit from PYY receptor modulators in subjects in need, comprising administering the peptide conjugate described herein to the subject.
[0507] This article provides a method for preventing or treating diseases or conditions that benefit from GLP-1 receptor modulators in subjects in need, comprising administering the peptide conjugate described herein to the subject.
[0508] This article provides a method for preventing or treating diseases or conditions that benefit from GLP-1 / GIP receptor modulators in subjects in need, comprising administering the peptide conjugate described herein to the subject.
[0509] This article provides a method for preventing or treating diseases or conditions that benefit from GLP-1 / GCG receptor modulators in subjects in need, comprising administering the peptide conjugate described herein to the subject.
[0510] This article provides a method for preventing or treating diseases or conditions in subjects who benefit from prolactin-releasing peptide (PrRP) receptor modulators, comprising administering the peptide conjugate described herein to the subject.
[0511] combination
[0512] This article discloses a pharmaceutical composition comprising the peptide conjugate described herein and one or more other therapeutic agents.
[0513] Other treatment agents may include one or more other diabetes drugs, DPP4 inhibitors, SGLT2 inhibitors, hypoglycemic drugs and biguanidine drugs, insulin secretagogues and sulfonyl ureas, TZD drugs, insulin and insulin analogs, FGF21 and analogs, leptin or leptin analogs, amylin and amylin analogs, anti-inflammatory drugs, cyclosporine A or FK506, 5-ASA or statins, or any combination thereof. Aspirin may also be an additional treatment agent.
[0514] Other therapeutic agents may include therapeutic incretins or derivatives thereof. Non-limiting examples of incretins or derivatives thereof include GLP-1, glucagon, gastrin, salicornin exopeptide-4, GLP-2, GIP, and combinations thereof.
[0515] In some implementations, combination therapy has shown superior glucose control, reduced food intake, and weight loss compared to the use of a single agent. In some implementations, combination therapy mimics the beneficial effects of bariatric surgery in obese patients.
[0516] In some implementations, the PYY receptor modulator is administered together with the GLP-1 receptor modulator.
[0517] In some implementations, the PYY receptor modulator is administered together with the GLP-1 / GIP receptor modulator.
[0518] In some implementations, the PYY receptor modulator is administered together with the GLP-1 / GCG receptor modulator.
[0519] In some implementations, the GLP-1 / GIP receptor modulator is administered together with the GLP-1 receptor modulator.
[0520] In some implementations, the GLP-1 / GIP receptor modulator is administered together with the GLP-1 / GCG receptor modulator.
[0521] In some implementations, the GLP-1 / GCG receptor modulator is administered together with the GLP-1 receptor modulator.
[0522] In some embodiments, the combination comprises multiple peptide conjugates described herein. In some embodiments, an additional therapeutic agent is conjugate 187.
[0523] Composition
[0524] This document discloses pharmaceutical compositions comprising the peptide conjugates described herein and pharmaceutically acceptable excipients or mediators. Pharmaceutically acceptable excipients or mediators may include carriers, excipients, diluents, antioxidants, preservatives, coloring agents, flavoring agents, diluting agents, emulsifying agents, suspending agents, solvents, fillers, bulking agents, buffers, delivery vehicles, tonicity agents, cosolvents, wetting agents, complexing agents, buffering agents, antimicrobial agents, and surfactants.
[0525] Neutral buffered saline or saline mixed with serum albumin is an exemplary suitable carrier. Pharmaceutical compositions may include antioxidants such as ascorbic acid; low molecular weight peptides; proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrin; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and / or nonionic surfactants such as Tween, pluronics, or polyethylene glycol (PEG). Suitable tensile enhancers also include, for example, alkali metal halides (preferably sodium chloride or potassium chloride), mannitol, sorbitol, etc. Suitable preservatives include benzalkonium chloride, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid, etc. Hydrogen peroxide may also be used as a preservative. Suitable solubilizers include glycerol, propylene glycol, and PEG. Suitable chelating agents include caffeine, polyvinylpyrrolidone, β-cyclodextrin, or hydroxypropyl-β-cyclodextrin. Suitable surfactants or wetting agents include sorbitan esters, polysorbates such as polysorbate 80, tromethorphan, lecithin, cholesterol, tyloxapal, etc. Buffers can be conventional buffers such as acetates, borates, citrates, phosphates, bicarbonates, or Tris-HCl. Acetate buffers can be at approximately pH 4–5.5, and Tris buffers can be at approximately pH 7–8.5. Other agents are described in Remington's Pharmaceutical Sciences, 18th Edition, edited by ARGennaro, Mack Publishing Company (1990).
[0526] The composition may be in liquid or lyophilized / freeze-dried form and may include one or more lyophilization protectants, excipients, surfactants, high molecular weight structural additives, and / or swelling agents. In one embodiment, a lyophilization protectant is included, which is a non-reducing sugar such as sucrose, lactose, or trehalose. The amount of lyophilization protectant typically included is such that the resulting formulation will be isotonic upon remodeling, although hypertonic or slightly hypotonic formulations may also be suitable. Furthermore, the amount of lyophilization protectant should be sufficient to prevent unacceptable degradation and / or aggregation of proteins during lyophilization. Exemplary lyophilization protectant concentrations for sugars (e.g., sucrose, lactose, trehalose) in pre-lyophilized formulations are from about 10 mM to about 400 mM. In another embodiment, surfactants are included, such as nonionic surfactants and ionic surfactants such as polysorbates (e.g., polysorbate 20, polysorbate 80); poloxamer (e.g., poloxamer 188); poly(ethylene glycol) phenyl ether (e.g., Triton); sodium dodecyl sulfate (SDS); sodium laurel sulfate; sodium octyl glycoside. glycoside); lauryl-sulfobetaine, myristyl-sulfobetaine, linoleyl-sulfobetaine, or stearyl-sulfobetaine; lauryl-sarcosine, myristyl-sarcosine, linoleyl-sarcosine, or stearyl-sarcosine; linoleyl-betaine, myristyl-betaine, or cetyl-betaine;Lauroamidopropyl-betaine, cocamidopropyl-betaine, linoleamidopropyl-betaine, myristamidopropyl-betaine, palmitopropyl-betaine, or isostearamidopropyl-betaine (e.g., lauroamidopropyl); myristamidopropyl-dimethylamine, palmitopropyl-dimethylamine, or isostearamidopropyl-dimethylamine; sodium methyl cocoyl-taurate or disodium methyl cocoyl-taurate. cocoyl-taurate); and MONAQUAT; TMThe surfactants include a series of compounds (Mona Industries, Inc., Paterson, NJ), polyethylene glycol, polypropyl glycol, and copolymers of ethylene and propylene glycol (e.g., Pluronics, PF68, etc.). An exemplary amount of surfactant that may be present in the pre-lyophilized formulation is about 0.001-0.5%.High molecular weight structural additives (e.g., fillers, binders) may include, for example, gum arabic, albumin, alginate, calcium phosphate (dibasic), cellulose, carboxymethyl cellulose, carboxymethyl cellulose sodium, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, microcrystalline cellulose, dextran, dextrin, dextran binder, sucrose, tylose, pregelatinized starch, calcium sulfate, amylose, glycine, bentonite, maltose, sorbitol, ethyl cellulose, disodium hydrogen phosphate, and disodium... The ingredients include phosphate, disodium pyrosulfite, polyvinyl alcohol, gelatin, glucose, guar gum, liquid glucose, compressible sugar, magnesium aluminum silicate, maltodextrin, polyethylene oxide, polymethacrylate, povidone, sodium alginate, tragacanth, microcrystalline cellulose, starch, and zein. Exemplary concentrations of high molecular weight structural additives are 0.1-10% by weight.In other embodiments, a swelling agent (e.g., mannitol, glycine) may be included.
[0527] The composition is suitable for parenteral administration. Exemplary compositions are suitable for injection or infusion into animals via any route available to a technician, such as intra-articular, subcutaneous, intravenous, intramuscular, intraperitoneal, intracranial (within brain parenchyma), intraventricular, intramuscular, intraocular, intra-arterial, or intralesional routes. Parenteral preparations are typically sterile, pyrogen-free, isotonic aqueous solutions, optionally containing pharmaceutically acceptable preservatives.
[0528] Examples of non-aqueous solvents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcohol / aqueous solutions, emulsions, or suspensions, including saline and buffer media. Parenteral carriers include sodium chloride solutions, Ringer's glucose, glucose and sodium chloride, lactated Ringer's solution, or non-volatile oils. Intravenous carriers include fluids and nutritional supplements, electrolyte supplements (e.g., those based on Ringer's glucose), etc. Preservatives and other additives may also be present, such as antimicrobial agents, antioxidants, chelating agents, and inert gases. See also Remington's Pharmaceutical Science, 16th Ed. (Mack Eds., 1980).
[0529] The pharmaceutical compositions described herein can be formulated for controlled or sustained delivery in a manner that provides local concentrations of the product (e.g., injection, reservoir effect) and / or increased stability or half-life in a specific local environment. The compositions may include formulations of peptide conjugates, polypeptides, nucleic acids, or carriers disclosed herein, particulate formulations of polymeric compounds such as polylactic acid, polyglycolic acid, etc., and reagents such as biodegradable matrices, injectable microspheres, microcapsules, microcapsules, bioerodible particulate beads, liposomes, and implantable delivery devices that provide controlled or sustained release of an active agent, which may then be delivered as a reservoir injection. Techniques for formulating such sustained or controlled delivery methods are known, and a variety of polymers have been developed for the controlled release and delivery of drugs. Such polymers are typically biodegradable and biocompatible. Polymer hydrogels, including those formed by complexation of enantiomeric polymers or polypeptide fragments, and hydrogels with temperature or pH-sensitive properties, may be desirable for providing a drug reservoir effect due to the mild and aqueous conditions involved in capturing bioactive protein reagents (e.g., peptide conjugates).
[0530] Based on the intended route of administration, delivery method, and required dosage, suitable and / or preferred pharmaceutical formulations can be determined in light of the content of this invention and general knowledge of formulation technology. Regardless of the route of administration, an effective dosage can be calculated based on the patient's weight, body surface area, or organ size. Further refinement of the calculations used to determine the appropriate dosage for treatment involving each formulation described herein is routinely performed in the art and is within the scope of tasks routinely performed in the art. Appropriate dosages can be determined by using appropriate dose-response data.
[0531] definition
[0532] As used herein and in the appended claims, unless the context clearly indicates otherwise, the singular forms “a / an” and “the” include plural indicators. Thus, for example, reference to “a reagent” includes multiple such reagents, reference to “the cell” includes reference to one or more cells (or multiple cells) and their equivalents known to those skilled in the art, and so on. When the scope is used herein for physical properties (e.g., molecular weight) or chemical properties (e.g., chemical formula), it is intended to include all combinations and sub-combinations of the scope and specific embodiments thereof. When referring to a number or numerical range, the term “about” means that the number or numerical range mentioned is an approximation within experimental variability (or within statistical experimental error), and therefore in some cases, the number or numerical range will vary between 1% and 15% of that number or numerical range. The term “comprising” (and related terms such as “comprise / comprises”, “having”, or “including”) is not intended to exclude embodiments in which, for example, any embodiment of a material composition, composition, method, or process described herein is “composed of” or “substantially composed of” the described features.
[0533] As used in the specification and appended claims, unless otherwise stated, the following terms have the meanings indicated below.
[0534] "alkyl" refers to a straight-chain or branched hydrocarbon monovalent group that can be fully saturated or unsaturated and has 1 to about 10 carbon atoms or 1 to 6 carbon atoms, wherein the sp3 hybridized carbon of the alkyl residue is connected to the rest of the molecule by a single bond. Examples of monovalent groups in saturated hydrocarbons include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl and hexyl, as well as longer alkyl groups, such as heptyl, octyl, etc. Whenever it appears herein, the numerical range such as "C1-C6 alkyl" means that the alkyl group consists of 1, 2, 3, 4, 5, or 6 carbon atoms, although this definition also covers the occurrence of the term "alkyl" where no numerical range is specified. In some embodiments, the alkyl group is C1-C6. 10 Alkyl, C1-C9 alkyl, C1-C8 alkyl, C1-C7 alkyl, C1-C6 alkyl, C1-C5 alkyl, C1-C4 alkyl, C1-C3 alkyl, C1-C2 alkyl, or C1 alkyl. When alkyl refers to a monovalent group of an unsaturated straight-chain or branched hydrocarbon, it is referred to as “alkenyl” or “alkynyl”. Alkenyl can be in cis or trans conformations with respect to the double bond and should be understood to include both isomers. Examples of alkenyl include, but are not limited to, vinyl (-CH=CH2), 1-propenyl (-CH2CH=CH2), isopropenyl [-C(CH3)=CH2], butenyl, 1,3-butadienyl, etc. Whenever it appears herein, numerical ranges such as “C2-C6 alkenyl” mean that the alkenyl can consist of 2, 3, 4, 5, or 6 carbon atoms, although this definition also covers the occurrence of the term “alkenyl” where no numerical range is specified. In some implementations, the alkenyl group is C2-C. 10 Alkenyl, C2-C9 alkenyl, C2-C8 alkenyl, C2-C7 alkenyl, C2-C6 alkenyl, C2-C5 alkenyl, C2-C4 alkenyl, C2-C3 alkenyl, or C2 alkenyl. Examples of ynyl groups include, but are not limited to, ethynyl, 2-propynyl, 2-, etc. Whenever it appears herein, a numerical range such as “C2-C6 ynyl” means that the ynyl group can consist of 2, 3, 4, 5, or 6 carbon atoms, although this definition also covers the occurrence of the term “ynyl” where no numerical range is specified. In some embodiments, the alkenyl group is C2-C... 10The alkyl group can be C2-C9, C2-C8, C2-C7, C2-C6, C2-C5, C2-C4, C2-C3, or C2. Unless otherwise specified in the specification, the alkyl group may optionally be substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc., as described below. In some embodiments, the alkyl group may optionally be substituted with oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkyl group may optionally be substituted with oxo, halogen, -CN, -CF3, -OH, or -OMe. In some embodiments, the alkyl group may optionally be substituted with halogen.
[0535] "alkylene" refers to a straight-chain or branched divalent hydrocarbon chain. Whenever it appears herein, a numerical range such as "C1-C6 alkylene" means that the alkylene consists of 1, 2, 3, 4, 5, or 6 carbon atoms, although this definition also covers instances where no numerical range is specified for the term "alkylene." In some embodiments, the alkylene is C1-C6. 10 Alkylene, C1-C9 alkylene, C1-C8 alkylene, C1-C7 alkylene, C1-C6 alkylene, C1-C5 alkylene, C1-C4 alkylene, C1-C3 alkylene, C1-C2 alkylene, or C1 alkylene. Unless otherwise specified in the specification, the alkylene may optionally be substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxy, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, the alkylene is optionally substituted with oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkylene is optionally substituted with oxo, halogen, -CN, -CF3, -OH, or -OMe. In some embodiments, the alkylene is optionally substituted with halogen.
[0536] "Alkoxy" refers to the formula -OR a The group, wherein R a Alkyl groups are defined as such. Unless otherwise specified in the specification, the alkoxy group may optionally be substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, the alkoxy group is optionally substituted with oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkoxy group is optionally substituted with oxo, halogen, -CN, -CF3, -OH, or -OMe. In some embodiments, the alkoxy group is optionally substituted with halogen.
[0537] "Aryl" refers to a group derived from a hydrocarbon ring system containing hydrogen, 6 to 30 carbon atoms, and at least one aromatic ring. Aryl groups can be monocyclic, bicyclic, tricyclic, or tetracyclic systems, and can include fused rings (where the aryl group is bonded by aromatic ring atoms when fused with a cycloalkyl or heterocyclic alkyl ring) or bridged ring systems. In some embodiments, the aryl group is a 6-10 membered aryl group. In some embodiments, the aryl group is a 6-membered aryl group. Aryl groups include, but are not limited to, aryl groups derived from hydrocarbon ring systems of anthracene, naphthylene, phenanthrene, anthracene, azulene, benzene, chrysoprase, fluorene, as-indacene, s-indacene, indene, indene, naphthalene, phenanthracene, pleiadene, pyrene, and benzo[a]phenanthrene. In some embodiments, the aryl group is a phenyl group. Unless otherwise specified in the specification, the aryl group may optionally be substituted with, for example, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, the aryl group is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the aryl group is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the aryl group is optionally substituted with halogen.
[0538] "Cycloalkyl" refers to a stable, partially or fully saturated monocyclic or polycyclic carbon ring, which may include fused rings (where the cycloalkyl group is bonded through non-aromatic ring atoms when fused with an aryl or heteroaryl ring) or bridged ring systems. Representative cycloalkyl groups include, but are not limited to, those having 3-15 carbon atoms (C3-C4). 15 cycloalkyl groups, 3-10 carbon atoms (C3-C4) 10Cycloalkyl groups are 3-8 carbon atoms (C3-C8 cycloalkyl), 3-6 carbon atoms (C3-C6 cycloalkyl), 3-5 carbon atoms (C3-C5 cycloalkyl), or 3-4 carbon atoms (C3-C4 cycloalkyl). In some embodiments, the cycloalkyl group is a 3-6 membered cycloalkyl group. In some embodiments, the cycloalkyl group is a 5-6 membered cycloalkyl group. Monocyclic cycloalkyl groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyl or carbocyclic compounds include, for example, adamantyl, norbornel, decahydronaphthyl, bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, cis-decahydronaphthyl, trans-decahydronaphthyl, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, and bicyclo[3.3.2]decane, as well as 7,7-dimethyl-bicyclo[2.2.1]heptyl. Partially saturated cycloalkyl compounds include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Unless otherwise specified in the specification, cycloalkyl compounds may optionally be substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocyclic alkyl, heteroaryl, etc. In some embodiments, the cycloalkyl group is optionally substituted with an oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the cycloalkyl group is optionally substituted with an oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the cycloalkyl group is optionally substituted with a halogen.
[0539] "Halogen" or "halogen" refers to bromine, chlorine, fluorine, or iodine. In some embodiments, the halogen is fluorine or chlorine.
[0540] "Halogenated alkyl" refers to an alkyl group as defined above that is substituted with one or more halogenated groups as defined above, such as trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, etc.
[0541] "Heterocyclic alkyl" refers to a stable 3-24 membered or fully saturated cyclic group containing 2-23 carbon atoms and 1-8 heteroatoms selected from nitrogen, oxygen, phosphorus, and sulfur. Representative heterocyclic alkyl groups include, but are not limited to, heterocyclic alkyl groups having 2-15 carbon atoms (C2-C4). 15 Heterocyclic alkyl groups, 2-10 carbon atoms (C2-C4) 10Heterocyclic alkyl groups are 2-8 carbon atoms (C2-C8 heterocyclic alkyl groups), 2-6 carbon atoms (C2-C6 heterocyclic alkyl groups), 2-5 carbon atoms (C2-C5 heterocyclic alkyl groups), or 2-4 carbon atoms (C2-C4 heterocyclic alkyl groups). In some embodiments, the heterocyclic alkyl group is a 3-6 membered heterocyclic alkyl group. In some embodiments, the heterocyclic alkyl group is a 5-6 membered heterocyclic alkyl group. Unless otherwise specified in the specification, the heterocyclic alkyl group can be a monocyclic, bicyclic, tricyclic, or tetracyclic system, which may include fused rings (where the heterocyclic alkyl group is bonded through non-aromatic ring atoms when fused with an aryl or heteroaryl ring) or bridged ring systems; and the nitrogen, carbon, or sulfur atom in the heterocyclic alkyl group may optionally be oxidized; the nitrogen atom may optionally be quaternized. Examples of such heterocyclic alkyl groups include, but are not limited to, aziridinyl, azetidinyl, dioxolanyl, thiophene[1,3]dithiaalkyl, decahydroisoquinolinyl, imidazolinyl, imidazoalkyl, isothiazolyl, isoxazolyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperidinyl, 2-oxopiperidinyl, 2-oxopiperidinyl, 2-oxopiperidyl, oxazolyl, piperidinyl, piperazinyl, 4-piperidonyl Heteroalkyl, pyrroloalkyl, quinoalkyl, thiazoalkyl, tetrahydrofuranyl, trithiaalkyl, tetrahydropyranyl, thiomorpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, 1,3-dihydroisobenzofuran-1-yl, 3-oxo-1,3-dihydroisobenzofuran-1-yl, methyl-2-oxo-1,3-dioxacyclopenten-4-yl, and 2-oxo-1,3-dioxacyclopenten-4-yl. The term heterocyclic alkyl also includes all cyclic forms of carbohydrates, including but not limited to monosaccharides, disaccharides, and oligosaccharides. Unless otherwise stated, heterocyclic alkyl groups have 2-10 carbons in the ring. It should be understood that when referring to the number of carbon atoms in a heterocyclic alkyl group, the number of carbon atoms in the heterocyclic alkyl group is different from the total number of atoms (including heteroatoms) constituting the heterocyclic alkyl group (i.e., the skeleton atoms of the heterocyclic alkyl ring). Partially saturated heterocyclic alkyl groups include, for example, dihydropyrrolyl or tetrahydropyridine. Unless otherwise specified in the specification, heterocyclic alkyl groups are optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocyclic alkyl, heteroaryl, etc. In some embodiments, the heterocyclic alkyl group is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the heterocyclic alkyl group is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heterocyclic alkyl group is optionally substituted with halogen.
[0542] "Heteroalkyl" refers to an alkyl group, wherein one or more skeletal atoms of the alkyl group are selected from atoms other than carbon, such as oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, or combinations thereof. The heteroalkyl group is attached to the remainder of the molecule at a carbon atom. In one aspect, the heteroalkyl group is a C1-C6 heteroalkyl group, wherein the heteroalkyl group comprises 1-6 carbon atoms and one or more atoms other than carbon, such as oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, or combinations thereof, wherein the heteroalkyl group is attached to the remainder of the molecule at a carbon atom. Unless otherwise specified in the specification, the heteroalkyl group is optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, the heteroalkyl group is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the heteroalkyl group is optionally substituted with an oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heteroalkyl group is optionally substituted with a halogen.
[0543] "Heteroaryl" refers to a 5-14 membered ring system group comprising a hydrogen atom, 1-13 carbon atoms, 1-6 heteroatoms selected from nitrogen, oxygen, phosphorus, and sulfur, and at least one aromatic ring. Heteroaryl groups can be monocyclic, bicyclic, tricyclic, or tetracyclic systems, and may include fused rings (where the heteroaryl group is bonded via aromatic ring atoms when fused with a cycloalkyl or heterocyclic alkyl ring) or bridged ring systems; and the nitrogen, carbon, or sulfur atoms in the heteroaryl group may optionally be oxidized; the nitrogen atom may optionally be quaternized. In some embodiments, the heteroaryl group is a 5-10 membered heteroaryl group. In some embodiments, the heteroaryl group is a 5-6 membered heteroaryl group. In some embodiments, the heteroaryl group is a 5-membered heteroaryl group. In some embodiments, the heteroaryl group is a 6-membered heteroaryl group. Examples include, but are not limited to, azepinyl, acridine, benzimidazolyl, benzothiazolyl, benzoindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxane-heptyl, 1,4-benzodioxanyl, and benzonaphthofuran. yl), benzoxazolyl, benzodioxazolyl, benzodioxinyl, benzopyranyl, benzopyranoneyl, benzofuranyl, benzofuranoneyl, benzothiopheneyl (benzobenzenethio), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridyl, carbazoleyl, cinnolinyl, dibenzofuranyl, dibenzobenzenethio, furanyl, furanoneyl, isothiazolyl, imidazoyl, indazoleyl, indole Indazole, isoindolyl, indololinyl, isoindololinyl, isoquinolinyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-pyridinyl oxide, 1-pyrimidinyl oxide, 1-pyrazinyl oxide, 1-pyridazinyl oxide, 1-phenyl-1H-pyrroleyl, phen Azinyl, phenothiazinyl, phenotoxazinyl, phthalazinyl, pteridinyl, purine, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrazolylquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and phenylthio (i.e., thiophene). Unless otherwise specified in the specification, heteroaryl groups may optionally be substituted with, for example, halogens, amino groups, nitriles, hydroxyl groups, alkyl groups, alkenyl groups, alkynyl groups, haloalkyl groups, alkoxy groups, aryl groups, cycloalkyl groups, heterocycloalkyl groups, and heteroaryl groups.In some embodiments, the heteroaryl group is optionally substituted with a halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the heteroaryl group is optionally substituted with a halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heteroaryl group is optionally substituted with a halogen.
[0544] The term "percentage of identity" refers to a comparison between two nucleic acid or amino acid sequences. This comparison is measured using any number of alignment methods known in the art, including but not limited to global (e.g., Needleman–Wunsch algorithm) or local alignments (e.g., Smith–Waterman, Sellers, or other algorithms). Percentage of identity typically refers to the percentage of matching positions between two sequences for a contiguous portion of the sequence, where the two sequences are arranged in a manner that maximizes matching positions and minimizes gaps at non-matching positions. In some cases, alignments are performed where there are no gaps between the two sequences. In some cases, alignments result in less than 5%, less than 3%, or less than 1% gaps. Other methods of sequence comparison or alignment are also consistent with this disclosure.
[0545] After aligning sequences and introducing gaps (if necessary) to obtain the maximum percentage of sequence identity, and without considering any conserved substitutions as part of the sequence identity, the percentage (%) of amino acid residues in the candidate sequence that are identical to those in the reference polypeptide sequence is the sequence identity. Alignments used to determine the percentage of amino acid sequence identity can be performed in various known ways, such as using publicly available computer software like BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Appropriate parameters for sequence alignment can be determined, including the algorithm required to achieve maximum alignment across the full length of the sequences being compared. However, for the purposes of this paper, the sequence alignment computer program ALIGN-2 is used to generate the amino acid sequence identity value (%). The ALIGN-2 sequence alignment computer program is licensed by Genentech, Inc., and the source code, along with a user manual, has been submitted to the U.S. Copyright Office in Washington, D.C. (20559), U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or can be compiled from the source code. The ALIGN-2 program should be compiled for use on UNIX operating systems (including digital UNIX V4.0D). All sequence comparison parameters are set by the ALIGN-2 program and remain unchanged. When performing amino acid sequence comparisons using ALIGN2, the percentage of amino acid sequence identity (which may also be expressed as the percentage of amino acid sequence identity of given amino acid sequence A with respect to given amino acid sequence B, with respect to given amino acid sequence B, or for given amino acid sequence B) is calculated as follows: 100 multiplied by the fraction X / Y, where X is the number of amino acid residues that are scored as identical matches by the sequence alignment program ALIGN-2 in the sequence alignment of A and B, and where Y is the total number of amino acid residues in B. It should be understood that when the length of amino acid sequence A is not equal to the length of amino acid sequence B, the percentage of amino acid sequence identity of A with B will not be equal to the percentage of amino acid sequence identity of B with A. Unless otherwise specifically stated, all amino acid sequence identity values (%) used herein are obtained using the ALIGN-2 computer program as described in the preceding paragraph.
[0546] "Pharmaceutical acceptable" means approved or recognized by a federal or state government regulatory agency, or listed in the United States Pharmacopeia or other recognized pharmacopoeia for use in animals, including humans.
[0547] "Pharmaceutical acceptable salt" refers to a salt of a compound that is pharmaceutically acceptable and has the desired pharmacological activity of the parent compound.
[0548] "Pharmaceutical acceptable excipients, carriers or adjuvants" means excipients, carriers or adjuvants that can be administered to the target together with at least one antibody of the present invention, and which, when administered in a dose sufficient to deliver a therapeutic amount of the compound, do not impair its pharmacological activity and are non-toxic.
[0549] "Pharmaceutically acceptable mediator" refers to a diluent, adjuvant, excipient, or carrier that is administered together with at least one antibody of the present invention.
[0550] Terms such as "treating / treatment / to treat" or "alleviating / to alleviate" can refer to: 1) therapeutic measures that cure, slow, or alleviate the symptoms of a diagnosed pathological condition or symptom and / or halt the progression of the diagnosed pathological condition or symptom; and / or 2) prophylactic or preventative measures that prevent and / or slow the development of a target pathological condition or symptom. "Treatment" refers to a clinical intervention that attempts to alter the natural processes of the treated individual or cells and can be performed for prevention or during a clinicopathological process. Ideal effects of treatment include preventing the onset or recurrence of disease, alleviating symptoms and reducing any direct or indirect pathological consequences of the disease, preventing metastasis, slowing the rate of disease progression, improving or mitigating the disease state, and alleviating or improving prognosis. Therefore, people who need treatment may include those who already have the condition; those who are susceptible to the condition; and those who want to prevent the condition.
[0551] "Amino acids" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimics that function similarly to naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, and those that are subsequently modified, such as hydroxyproline, γ-carboxyglutamic acid, and O-phosphoserine. Amino acid analogs are compounds that have the same basic chemical structure as naturally occurring amino acids, such as an α-carbon bound to hydrogen, a carboxyl group, an amino group, and an R group, such as homoserine, ortholeucine, methionine sulfoxide, and methionine methylsulfonium. These analogs may have modified R groups (e.g., ortholeucine) or modified peptide backbones, but retain the same basic chemical structure as naturally occurring amino acids. Amino acid mimics are chemical compounds that have a structure different from the general chemical structure of amino acids, but function similarly to naturally occurring amino acids.
[0552] "Symptom" or "disease" refers to a condition that would benefit from treatment with the substances / molecules disclosed herein (e.g., peptide conjugates disclosed herein) or methods. This includes both chronic and acute symptoms or diseases, including those pathological conditions that make mammals susceptible to said symptoms.
[0553] "Mammalian" for therapeutic purposes means any animal classified as a mammal, including humans, rodents (e.g., mice and rats) and monkeys; livestock and farm animals; and zoo animals, sporting animals, laboratory animals, or pets, such as dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, etc. In some embodiments, the mammal is selected from humans, rodents, or monkeys.
[0554] "Regulation" refers to the ability of a peptide to bind to a protein receptor. In some embodiments, the regulator is a ligand of the receptor. In some embodiments, the regulator is an agonist. In some embodiments, the regulator is an antagonist. For example, a peptide regulating the GLP-1 receptor binds to the GLP-1 receptor (GLP-1R). For example, a peptide regulating the GCG receptor binds to the GCG receptor (GCGR). For example, a peptide regulating the GIP receptor binds to the GIP receptor (GIPR). For example, a peptide regulating the PYY receptor binds to the PYY receptor (PYYR). As a non-limiting example, a peptide regulating the GLP-1 receptor is a GLP-1R agonist. As a non-limiting example, a peptide regulating both the GLP-1 and GCG receptors is a dual GLP-1R / GCGR agonist. As a non-limiting example, a peptide regulating both the GLP-1 and GIP receptors is a dual GLP-1R / GIPR agonist. As a non-limiting example, a peptide regulating the PYY receptor is a PYYR agonist.
[0555] "Unmodified peptide" refers to an unmodified sequence (wild-type peptide) or a modified sequence without a stapler.
[0556] Example
[0557] Peptides were synthesized using standard solid-phase peptide synthesis (SPPS) technology and purified by HPLC (as described).
[0558] Unless otherwise specified, all reagents were purchased from commercial suppliers (Sigma-Aldrich, Fisher, Oakwood) and used without further purification. All reactions involving air- or moisture-sensitive reagents or intermediates were carried out under an inert atmosphere of nitrogen or argon. All solvents used were HPLC grade. Reactions were monitored by LC-MS or by thin-layer chromatography (TLC) on Merck 50 × 100 mm silica gel 60 aluminum plates stained with an aqueous solution of KMnO4.
[0559] Rapid chromatographic purification on a pre-packed silica column (40 μm, from Teledyne Isco) On Rf) The procedure was performed on an Rf (Teledyne Isco) spectrometer. The purified final compound was eluted as a single and symmetrical peak (thus confirming a purity of ≥95%).
[0560] The Shimadzu HPLC was performed using a Phenomenex Luna column (C18, pore size...) Particle size 10 μm, 250 × 10.0 mm, flow rate: 4 mL / min) or on an Agilent 1200 HPLC using a Phenomenex Luna column (C18, pore size 10 μm, 250 × 10.0 mm, flow rate: 4 mL / min) or on an Agilent 1200 HPLC system with a Phenomenex Luna column (C18, pore size 10 μm, 25 Semi-preparative chromatography was performed using a particle size of 5 μm (150 × 21.2 mm) and a flow rate of 20 mL / min.
[0561] Record in d6-DMSO, CDCl3, or CD3OD on the Bruker 400 system. 1 H and 13 C10 NMR spectra. Chemical shifts are given in parts per million (ppm), with tetramethylsilane as an internal standard. Abbreviations are used as follows: s = singlet, d = doublet, t = triplet, q = quartet, p = quintet, m = multiplet, dd = doublet, br = broad peak. Coupling constants (J values) are given in Hertz (Hz).
[0562] In a Phemomenex Luna Omega C18 column (C18, aperture) Low-resolution mass spectra were recorded on a Waters Acquity UPLC system with a particle size of 1.6 μm (50 × 2.1 mm) and a flow rate of 0.4 mL / min. Solvents: A-H₂O + 0.1% formic acid, B-MeCN + 0.1% formic acid; gradient: 0–1 min 10–90% B, 1–1.6 min 90% B, 1.6–1.7 min 90–10% B, 1.7–2 min 10% B.
[0563] High-resolution mass spectra (HRMS) were recorded on an Agilent 1200 Series Precision Time-of-Flight (TOF) mass spectrometer equipped with an Aeris Widepore column (XB-C8, 3.6 μm particle size, 150 × 2.1 mm, flow rate: 0.5 mL / min). Solvents: A-H₂O + 0.1% formic acid, B-MeCN + 0.1% formic acid; gradient: 0–2 min 5% B, 2–12 min 5–60% B, 12–13 min 60–80% B, 13–14 min 80–20% B, 14–15 min 20–80% B, 15–16 min 80–20% B, 16–17 min 20–95% B, 17–20 min 95% B, 20–21 min 95–5% B.
[0564] General Scheme A for loading chlorotriphenylmethyl chloro resin
[0565] Fmoc-Lys(ivDde)-OH (60 mg, 100 μmol) was coupled to 2-chlorotriphenylmethyl chloride resin (Novabiochem) (100 mg, 80 μmol) by mixing amino acids, resin, and DIEA (70 μL, 400 μmol) in 5 mL of DMF and stirring for 30 minutes. The resin was then washed with DMF (3×) and DCM (3×) and treated with CH3OH / DCM / DIEA (8:1:1) for 10 minutes to block unreacted triphenylmethyl chloride sites. The resin was then dried under vacuum and stored in a desiccator.
[0566] General Scheme B for Fmoc Protecting Group Deprotection
[0567] Add a 20% DMF solution of piperidine to the resin. Shake the mixture for 5 minutes and drain. Add fresh 20% piperidine, and shake the mixture for 15 minutes. A positive result is observed in the ninhydrin and / or TNBS tests. Then wash the resin with DMF (3×) and DCM (3×).
[0568] General Scheme C for Deprotection of ivDde Protecting Group
[0569] After washing with DMF and DCM, the resin was treated with a 2% hydrazine DMF solution (5 mL, 2 × 15 min). A positive result was observed in the ninhydrin and / or TNBS tests. The resin was then washed with DMF (3 ×) and DCM (3 ×).
[0570] General scheme D for peptide conjugation
[0571] Using a DMF (5 mL) solution of coupling agents HATU (3.3 equivalents) and DIEA (3.3 equivalents), the resin was treated with the specified carboxylic acid derivative (3 equivalents) for 2 h or repeated until ninhydrin and / or TNBS tests were observed to be negative. The resin was then washed with DMF (3×) and DCM (3×).
[0572] General Scheme E for Bromoacetylation on Resins
[0573] The resin was then treated with 200 mL of DCM solution containing bromoacetic anhydride (2.4 equivalents) and DIEA (2.6 equivalents) for 30 minutes.
[0574] General Scheme F for cleaving peptides from chlorotriphenylmethyl chloropolymer resin
[0575] The resin was washed with DCM (3×), and the product was cleaved from the resin for 1 h using 5 mL of DCM solution containing 10% TFA and 10% triisopropylsilane.
[0576] Example 1: Synthesis of fatty acid conjugating agent (FA2).
[0577]
[0578] Intermediate FA2a was prepared by dissolving myristic acid (0.46 g, 2 mmol) in 5 mL of DMF. HATU (0.8 g, 2.1 mmol) and DIEA (0.4 μL, 2.2 mmol) were added, followed by Boc-NH-PEG2-COOH (0.5 g, 2 mmol). The reaction mixture was then stirred for 6 h, and the solvent was removed. The product was extracted with EtOAc (3 × 15 mL). The organic layer was washed successively with saturated NaHCO3, cooled HCl (1 M), and brine, dried over Na2SO4, filtered, and concentrated. Purification by silica gel rapid column chromatography yielded a white solid (2-(2-(2-tetradecanoic acid ethoxy)ethyl)carbamate tert-butyl ester (FA2a) (0.81 g, 90% yield). MS (ES) + )m / z 459.6([M+H] + ), MW calculated value 458.4.
[0579] FA2. A solution of FA2a (0.23 g, 0.5 mmol) in DCM (10 mL) was treated with TFA (2 mL) for 2 h. The mixture was concentrated, and then 10 mL of DCM solution containing bromoacetic anhydride (0.14 g, 0.55 mmol) and DIEA (0.17 mL, 1 mmol) was added at 0 °C. The reaction mixture was then stirred for 2 h, and the solvent was removed. The product was extracted with EtOAc (3 × 15 mL). The organic layer was washed successively with saturated NaHCO3, cooled HCl (1 M), and brine, dried over Na2SO4, filtered, and concentrated. Purification was performed by silica gel rapid column chromatography to give a white solid FA2 (0.2 g, product yield 83%). MS (ES) + )m / z 480.4([M+H] + ), MW calculated value 479.5.
[0580] Example 2: Synthesis of L1
[0581]
[0582] DIEA (276 μL, 1.59 mmol, 2 equivalents) was added to a solution of 1,4-diaminobutane (80 μL, 0.795 mmol, 1 equivalent) in 10 mL of DCM at 0 °C, followed by the addition of bromoacetic anhydride (413 g, 1.59 mmol, 2 equivalents) dissolved in 1 mL of DCM. The reaction mixture was then stirred at 0 °C for 30 min, followed by stirring at room temperature for 1.5 h, and the solvent was removed. Purification was performed by silica gel rapid column chromatography to give a white solid L1 (162 mg, 0.49 mmol, 61%). MS (ES) + )m / z 331.0([M+H] + ). 1 HNMR (400MHz, methanol-d4) δ 3.94 (s, 4H), 3.40-3.30 (m, 4H), 1.68 (p, J = 3.5Hz, 4H).
[0583] Example 3: Synthesis of L1B
[0584]
[0585] DIEA (172 μL, 0.985 mmol, 2.2 equivalents) was added to a 5 mL solution of 1,2-ethylenediamine (30 μL, 0.448 mmol, 1 equivalent) in DCM at 0 °C, followed by the addition of bromoacetic anhydride (233 mg, 0.897 mmol, 2 equivalents) dissolved in 1 mL of DCM. The reaction mixture was then stirred at 0 °C for 30 min, followed by stirring at room temperature for 1.5 h, and the solvent was removed. Purification by silica gel rapid column chromatography yielded a white solid, L1B (43.9 mg, 0.145 mmol, 32%). MS (ES) + )m / z 302.55([M+H] + ),304.54([M+H] + ). 1 ¹H NMR (400 MHz, methanol-d⁴) δ 2.49 (s, 4H), 2.06 (s, 4H).
[0586] Example 4: Synthesis of L1C
[0587]
[0588] DIEA (138 μL, 0.789 mmol, 2.2 equivalents) was added to a 5 mL solution of 1,3-diaminopropane (30 μL, 0.359 mmol, 1 equivalent) in DCM at 0 °C, followed by the addition of bromoacetic anhydride (186 mg, 0.718 mmol, 2 equivalents) dissolved in 1 mL of DCM. The reaction mixture was then stirred at 0 °C for 30 min, followed by stirring at room temperature for 1.5 h, and the solvent was removed. Purification was performed by silica gel rapid column chromatography to give a white solid L1C (60.8 mg, 0.19 mmol, 53%). MS (ES) + )m / z316.32([M+H] + ),318.6([M+H] + ). 1 H NMR (400MHz, methanol-d4) δ3.86 (s, 4H), 3.27 (t, J = 6.8 Hz, 4H), 1.74 (p, J = 6.8 Hz, 2H).
[0589] Example 5: Synthesis of L1D
[0590]
[0591] DIEA (208 μL, 1.197 mmol, 2.4 equivalents) was added to a 15 mL solution of 1,7-diaminohexane (65 mg, 0.499 mmol, 1 equivalent) in DCM at 0 °C, followed by the addition of bromoacetic anhydride (259 mg, 0.998 mmol, 2 equivalents) dissolved in 1 mL of DCM. The reaction mixture was then stirred at 0 °C for 30 min, followed by stirring at room temperature for 1.5 h, and the solvent was removed. Purification by silica gel rapid column chromatography yielded a white solid L1D (120 mg, 0.322 mmol, 64%). MS (ES) + )m / z372.71([M+H] + ),374.70([M+3H] + ). 1 ¹H NMR (400MHz, chloroform-d) δ 6.55 (s, 2H), 3.91 (s, 4H), 3.30 (q, J = 7.1Hz, 4H), 1.56 (p, J = 7.1Hz, 4H), 1.45–1.29 (m, 6H).
[0592] Example 6: Synthesis of L1E
[0593]
[0594] DIEA (108 μL, 0.616 mmol, 2.4 equivalences) was added to a DCM (10 mL) solution of 1,11-diaminoundecane (48 mg, 0.257 mmol, 1 equivalence) at 0 °C, followed by the addition of bromoacetic anhydride (134 mg, 0.515 mmol, 2 equivalences) dissolved in 1 mL of DCM. The reaction mixture was then stirred at 0 °C for 30 min, followed by stirring at room temperature for 1.5 h, and the solvent was removed. Purification by silica gel rapid column chromatography yielded a white solid L1E (62.3 mg, 0.145 mmol, 56%). MS (ES) + )m / z428.33([M+H] + ). 1 H NMR (400MHz, chloroform-d) δ6.53 (s, 2H), 3.91 (s, 4H), 3.30 (q, J = 6.8Hz, 4H), 1.57 (q, J = 7.2Hz, 4H), 1.42-1.20 (m, 14H).
[0595] Example 7: Synthesis of L1F
[0596]
[0597] DIEA (284 μL, 1.63 mmol, 2.4 equivalences) was added to a 20 mL solution of cadaverine (48 mg, 0.257 mmol, 1 equivalence) in DCM at 0 °C, followed by the addition of bromoacetic anhydride (353 mg, 1.36 mmol, 2 equivalences) dissolved in 1 mL of DCM. The reaction mixture was then stirred at 0 °C for 30 min, followed by stirring at room temperature for 1.5 h, and the solvent was removed. Purification was performed by silica gel rapid column chromatography to give a white solid L1F (156 mg, 0.453 mmol, 66%). MS (ES) + )m / z 344.65([M+H] + ),346.64([M+H] + ). 1 ¹H NMR (400MHz, methanol-d⁴) δ 3.83 (s, 4H), 3.23 (q, J = 6.8 Hz, 4H), 1.57 (p, J = 7.2 Hz, 4H), 1.44–1.33 (m, 2H).
[0598] Example 8: Synthesis of L1G
[0599]
[0600] intermediate L1Ga
[0601] DIEA (342 μL, 11.96 mmol, 2.4 equivalences) was added to a 20 mL solution of tert-butyl bis(2-aminoethyl)carbamate (167 mg, 0.82 mmol, 1 equivalent) in DCM at 0 °C, followed by the addition of bromoacetic anhydride (426 mg, 1.64 mmol, 2 equivalents) dissolved in 1 mL of DCM. The reaction mixture was then stirred at 0 °C for 30 min, followed by stirring at room temperature for 1.5 h, and the solvent was removed. Purification was performed by silica gel rapid column chromatography to give a white solid L1Ga (289 mg, 0.65 mmol, 79%). MS (ES) + )m / z 445.71([M+H] + ),447.7([M+H] + ). 1 ¹H NMR (400MHz, methanol-d⁴) δ 3.85 (s, 4H), 3.39 (s, 9H), 1.50 (s, 10H).
[0602] L1G
[0603] Compound L1Ga (20 mg) was dissolved in TFA / DCM (1:1, v / v, 2 mL), stirred at room temperature for 30 minutes, and evaporated (co-evaporated with hexane) to give an oily compound L1G. The product was used directly in other steps. MS (ES) + )m / z 345.2([M+H] + ).
[0604] Example 9: Synthesis of L3
[0605]
[0606] intermediate L3a
[0607] Myristic acid (184 mg, 0.805 mmol, 1 equivalent) was dissolved in 4 mL of DMF. HATU (321 mg, 0.845 mmol, 1.1 equivalent) and DIEA (154 μL, 0.885 mmol, 1.1 equivalent) were added, followed by Boc-NH-PEG2-COOH (200 mg, 0.805 mmol, 1 equivalent). The reaction mixture was then stirred for 1.5 h, and the solvent was removed. The product was dissolved in EtOAc. The organic layer was washed successively with 1 M HCl, saturated NaHCO3, and brine, dried over Na2SO4, filtered, and concentrated. Purification by silica gel rapid column chromatography gave the desired white solid compound L3a (254 mg, 0.55 mmol, 69%). 1¹H NMR (400MHz, chloroform-d) δ 3.66–3.54 (m, 8H), 3.49 (q, J = 5.2 Hz, 2H), 3.35 (d, J = 6.1 Hz, 2H), 2.20 (t, J = 7.7 Hz, 2H), 1.63–1.58 (m, 2H), 1.47 (s, 8H), 1.33–1.24 (m, 2¹H), 0.90 (t, J = 6.9 Hz, 3H). t R =2.21min(Agilent).MS(ES) + )m / z 459.6([M+H] + ).
[0608] intermediate L3b
[0609] A DCM (2 mL) solution of compound L3a (242 mg, 0.527 mmol, 1 equivalent) was treated with TFA (2 mL) for 30 min. The mixture was concentrated and co-evaporated with hexane. HATU (224 mg, 0.59 mmol, 1.1 equivalent) was added to a solution of BocNH-PEG2-CO2H (146 mg, 0.527 mol, 1 equivalent) dissolved in DMF (5 mL). A DMF solution of the deprotected compound L3a and DIEA (183 μL, 1.05 mmol, 2 equivalents) was added to the reaction mixture. The reaction mixture was stirred at room temperature for 2 h. The product was diluted with EtOAc. The organic layer was washed successively with 1 M HCl, saturated NaHCO3, and brine, dried over Na2SO4, filtered, and concentrated. Purification by silica gel rapid column chromatography yielded the desired oily compound L3b (129 mg, 0.209 mmol, 40%). 1 H NMR (400MHz, chloroform-d) δ6.76(s,1H),6.19(s,1H),5.29(s,1H),3.76(t,J=5. 8Hz, 2H), 3.69-3.62 (m, 8H), 3.57 (dt, J = 12.3, 5.0Hz, 6H), 3.48 (dt, J = 10. 4,5.5Hz,4H),3.33(s,2H),2.51(t,J=5.8Hz,2H),2.20(t,J=7.0Hz,2H),1 .90-1.75(m,4H),1.64(p,J=7.3Hz,2H),1.46(s,9H),1.33-1.22(m,17H).
[0610] intermediate L3c
[0611] A DCM (2 mL) solution of compound L3b (129 mg, 0.209 mmol, 1 equivalent) was treated with TFA (2 mL) for 30 min. The mixture was concentrated and co-evaporated with hexane. HATU (88 mg, 0.23 mmol, 1.1 equivalent) was added to a DMF (5 mL) solution of Boc-Orn(Boc)-OH (69 mg, 0.209 mmol, 1 equivalent). A DMF solution of the deprotected compound L3b and DIEA (73 μL, 0.419 mmol, 2 equivalents) was added to the reaction mixture. The reaction mixture was stirred at room temperature for 2 h. The product was diluted with EtOAc. The organic layer was washed successively with 1 M HCl, saturated NaHCO3, and brine, dried over Na2SO4, filtered, and concentrated. Purification by silica gel rapid column chromatography yielded the desired oily compound L3c (137 mg, 0.164 mmol, 78%). R = 4.07 min (Agilent). MS (ES) + )m / z 832.9([M+H] + ). 1 H NMR (400MHz, chloroform-d) δ7.12(s,1H),6.80(s,1H),6.30(s,1H),4.87(s,1H), 3.85-3.73(m,2H),3.68-3.61(m,7H),3.58(p,J=6.1,5.5Hz,7H),3.53-3. 36(m,6H),3.29-3.00(m,2H),2.51(t,J=5.8Hz,2H),2.20(t,J=7.7Hz,2H) ,2.00-1.74(m,6H),1.71-1.51(m,5H),1.45(s,18H),1.35-1.22(m,21H).
[0612] L3
[0613] A 2 mL solution of compound L3c (137 mg, 0.165 mmol, 1 equivalent) in DCM was treated with 2 mL of TFA for 30 min. The mixture was concentrated, co-evaporated with hexane, and dissolved in 10 mL of DCM and cooled at 0 °C. DIEA (115 μL, 0.66 mmol, 4 equivalents) was added, followed by bromoacetic anhydride (85.8 g, 0.33 mmol, 2 equivalents) dissolved in 1 mL of DCM. The reaction mixture was then stirred at 0 °C for 30 min, stirred at room temperature for 1.5 h, and the solvent was removed. Purification by silica gel rapid column chromatography gave a white solid L3 (56 mg, 0.064 mmol, 39%). R = 3.4 min (Agilent). MS (ES) +)m / z 872.4([M+H] + ),874.3([M+H] + ).
[0614] Example 10: Synthesis of L4
[0615]
[0616] intermediate L4a
[0617] To a solution of Boc-Orn(Boc)-OH (595 mg, 1.79 mmol, 1 equivalent) dissolved in DMF (5 mL), HATU (750 mg, 1.79 mmol, 1.1 equivalent), DIEA (343 μL, 1.97 mmol, 1.1 equivalent), and amine-PEG3-N3 (391 mg, 1.79 mmol, 1 equivalent) dissolved in 1 mL of DMF were added. The reaction mixture was stirred at room temperature for 16 h. The product was diluted with EtOAc. The organic layer was washed successively with 1 M HCl, saturated NaHCO3, and brine, dried over Na2SO4, filtered, and concentrated. Purification was performed by silica gel rapid column chromatography to give the desired oily compound L4a (558 mg, 1.05 mmol, 58%). MS (ES) + )m / z 533.13([M+H] + ). 1 ¹H NMR (400MHz, chloroform-d) δ 6.82 (s, 1H), 5.25 (d, J = 8.3 Hz, 1H), 4.75 (s, 1H), 4.19 (s, 1H), 3.76–3.60 (m, 10H), 3.57 (t, J = 5.1 Hz, 2H), 3.43 (t, J = 4.6 Hz, 2H), 3.30–3.19 (m, 1H), 3.18–3.03 (m, 1H), 1.85 (s, 4H), 1.68–1.49 (m, 2H), 1.45 (s, 18H).
[0618] intermediate L4b
[0619] Pd / C (10.9 mg, 0.102 mmol, 0.1 equivalent) was added to an anhydrous MeOH (10 mL) solution of compound L4a (548 mg, 1.02 mmol, 1 equivalent) under argon atmosphere, and the argon atmosphere was replaced with H2. The reaction mixture was stirred at room temperature for 6 h, filtered through diatomaceous earth, and evaporated to give an oily compound L4b (516 mg, 1.02 mmol, quantitative). The product was ready for use without further purification.
[0620] intermediate L4c
[0621] To a solution of tert-butyl octadecanoate (370 mg, 1.02 mmol, 1 equivalent) dissolved in DMF (5 mL), HATU (387 mg, 1.02 mmol, 1.1 equivalent), DIEA (186 μL, 1.07 mmol, 2 equivalent), and compound L4b (516 mg, 1.02 mmol, 1 equivalent) dissolved in 1 mL of DMF were added. The reaction mixture was stirred at room temperature for 3 h. The product was diluted with EtOAc. The organic layer was washed successively with 1 M HCl, saturated NaHCO3, and brine, dried over Na2SO4, filtered, and concentrated. Purification by silica gel rapid column chromatography yielded the desired oily compound L4c (697 mg, 0.81 mmol, 79%). 1 H NMR (400MHz, chloroform-d) δ6.94(s,1H),6.42(s,1H),4.81(s,1H),4.20(s,1H),3.65(d,J=6.7Hz,8H),3.59(dt,J=9.7,5.1Hz,4H),3.51-3. 35(m,4H),3.31-3.18(m,1H),3.17-3.06(m,1H),2.20(q,J=8.0Hz,4H),1.87(s,4H),1.71-1.53(m,6H),1.45(s,26H),1.26(s,24H).
[0622] L4
[0623] A solution of L4c (422 mg, 0.49 mmol, 1 equivalent) in DCM (2 mL) was treated with TFA (2 mL) for 30 min. The mixture was concentrated, co-evaporated with hexane, and dissolved in 20 mL of DCM and cooled at 0 °C. DIEA (327 μL, 1.96 mmol, 4 equivalents) was added, followed by bromoacetic anhydride (254 mg, 0.98 mmol, 2 equivalents) dissolved in 1 mL of DCM. The reaction mixture was then stirred at 0 °C for 30 min, stirred at room temperature for 1.5 h, and the solvent was removed. Purification was performed by silica gel rapid column chromatography to give a white solid L4 (53 mg, 0.063 mmol, 12%). MS (ES) + )m / z 845.08([M+H] + ),847.07([M+H] + ) 1¹H NMR (400MHz, methanol-d⁴) δ 3.68–3.60 (m, 8H), 3.54 (td, J = 5.4, 3.4 Hz, 4H), 3.43–3.35 (m, 4H), 3.30–3.16 (m, 2H), 2.27 (t, J = 7.5 Hz, 2H), 2.17 (t, J = 7.6 Hz, 2H), 1.86–1.73 (m, 1H), 1.72–1.45 (m, 8H), 1.37–1.19 (m, 28H).
[0624] Example 11: Synthesis of L4A
[0625]
[0626] intermediate L4Aa
[0627] Bromoacetic anhydride (1.31 g, 5.04 mmol, 2.05 equivalents, 1 mL DCM solution) was added dropwise to a solution of tert-butyl bis(2-aminoethyl)carbamate (500 mg, 2.45 mmol, 1 equivalent) and DIEA (1.02 mL, 5.88 mmol, 2 equivalents) in 20 mL of DCM at 0 °C. The reaction mixture was stirred at 0 °C for 30 min, stirred at RT for 2 h, and evaporated under vacuum. The product was purified by rapid chromatography to obtain an oily product (883 mg, 81%). 1 ¹H NMR (400 MHz, methanol-d⁴) δ 1.50 (s, 9H), 3.39 (s, 8H), 3.85 (s, 4H). t R = 1.04 min.MS(ES) + )m / z 445.71 / 447.70([M+H] + ).
[0628] intermediate L4Ab
[0629] A DCM / TFA (1:1, v / v) solution of compound L4Aa (1 equivalent) was stirred at room temperature for 30 minutes and then concentrated under vacuum (co-evaporated with heptane). Compound L4Ab was used directly in other steps without purification. R =0.58min.MS(ES) + )m / z345.65 / 347.67([M+H] + ).
[0630] intermediate L4Ac
[0631] HATU (1.05 equivalents) was added to a DMF solution of mono-tert-butyl succinate (1.05 equivalents). The reaction mixture was stirred at room temperature for 5 minutes. Compound L4Ab and DIEA (4 equivalents) were dissolved in DMF (1 mL) and added to the reaction mixture. The reaction mixture was stirred overnight at room temperature and diluted with AcOEt. The organic phase was washed with HCl 1N and saturated NaHCO3 solution, dried over MgSO4, and evaporated. The oily product was purified by rapid chromatography. R = 1.07min.MS(ES) + )m / z501.52 / 503.80([M+H] + ).
[0632] intermediate L4Ad
[0633] A DCM / TFA (1:1, v / v) solution of compound L4Ac (1 equivalent) was stirred at room temperature for 30 minutes and then concentrated under vacuum (co-evaporated with heptane). Compound L4Ad was used directly in other steps without purification. R =0.57min.MS(ES) + )m / z445.71 / 447.73([M+H] + ).
[0634] intermediate L4Ae
[0635] Octadecanedioic acid monotert-butyl ester (200 mg, 0.54 mmol, 1 equivalent) was dissolved in 5 mL of DMF. HATU (225 mg, 0.59 mmol, 1.1 equivalent) and DIEA (103 μL, 0.59 mmol, 1.1 equivalent) were added, followed by Boc-NH-PEG3-NH2 (157.8 g, 0.54 mmol, 1 equivalent). The reaction mixture was then stirred for 3 h, and the solvent was removed. The product was dissolved in EtOAc. The organic layer was washed successively with saturated NaHCO3, 1 M HCl, and brine, dried over Na2SO4, filtered, and concentrated. Purification by silica gel rapid column chromatography yielded the desired white solid product L4Ae (281 mg, 0.43 mmol, 81%). MS (ES) + )m / z645.5([M+H] + ). 1H NMR (400MHz, chloroform-d) δ3.76-3.61(m,8H),3.63-3.54(m,4H),3.48(q,J=5.1Hz,2H),3.34(s,2H),2.2 0(dt,J=9.8,7.6Hz,4H),1.67-1.55(m,4H),1.49-1.44(m,17H),1.30(s,6H),1.30-1.24(m,19H).
[0636] L4A
[0637] The DCM solution of compound L4Ae was treated with TFA for 30 minutes. The mixture was concentrated, co-evaporated with heptane, dissolved in DMF, and added to the DMF solution of compounds L4Ad, HATU, and DIEA. The reaction mixture was stirred for 3 hours and purified by semi-preparative HPLC to obtain the desired product L4A.
[0638] Example 12: Synthesis of L5
[0639]
[0640] General schemes A, B, D (octadecanoic acid monotert-butyl ester); C, D (Fmoc-PEG2-propionic acid); B, D (Fmoc-PEG2-propionic acid); B, D (Fmoc-Orn(Fmoc)-OH); B, E, F.
[0641] The crude product was purified by semi-preparative HPLC with quality control to obtain a white solid product L5 (73 mg, 0.065 mmol, 11%). 1 H NMR (400MHz, methanol-d4) δ4.36 (td, J=8.9, 5.1Hz, 2H), 3.89 (q, J=11.4Hz, 2H), 3.82 (s,2H),3.74(t,J=6.2Hz,2H),3.60(s,4H),3.54(t,J=5.5Hz,2H),3.37(q,J=5. 2Hz,2H),3.29-3.11(m,5H),2.44(t,J=6.2Hz,2H),2.26(dt,J=12.3,7.5Hz,4H) ,1.89-1.77(m,2H),1.76-1.49(m,10H),1.48-1.38(m,2H),1.37-1.25(m,25H).
[0642] Example 13: Synthesis of L5A
[0643]
[0644] intermediate L5Aa
[0645] A solution of Fmoc-OSu (131 g, 388 mmol) in DCM (200 mL) was added dropwise to a solution of diethylenetriamine (20 g, 194 mmol) in DCM (200 mL) at -40 °C under N2, and the mixture was stirred for 2 h. LCMS showed that the reaction was complete. The crude product in the solution was used directly in the next step without purification. 1 H NMR(400MHz,DMSO-d6)δ7.88(d,J=7.6Hz,4H),7.68(d,J=7.6Hz,4H),7.43-7.24(m,10H), 4.30(d,J=6.4Hz,4H), 4.21(d,J=6.4Hz,2H), 3.06(d,J=5.6Hz,4H), 2.57(d,J=7.6Hz,4H). MS(ES + )m / z 548.2([M+H] + ).
[0646] intermediate L5Ab
[0647] DMAP (4.74 g, 38.8 mmol) and tetrahydrofuran-2,5-dione (67.9 g, 678 mmol) were added to a DCM (400 mL) solution of compound L5Aa (106 g, 194 mmol), and the mixture was stirred at 25 °C for 14 h. LCMS showed that the reaction was complete. 1 N HCl was added to the reaction mixture until pH 5–6, and the mixture was stirred for 15 min. The organic phase was separated and washed with water and saturated NaCl (500 mL). The aqueous phase was extracted twice with DCM (500 mL). The combined DCM was dried over anhydrous Na₂SO₄ and concentrated under vacuum. The crude product was purified by silica gel column chromatography using DCM / MeOH (80:0–5:1) as eluent to give compound L5Ab (57.6 g, 45% yield) as a white solid powder. 1 H NMR (400MHz, DMSO-d6) δ12.09(s,1H),7.87(d,J=7.5Hz,4H),7.66(d,J=7.0Hz,4H),7.23-7.48(m ,10H),4.24-4.33(m,4H),4.14-4.22(m,2H),3.27(s,4H),2.95-3.19(m,4H),2.37-2.44(m,4H). MS(ES + )m / z 648.2([M+H] + ).
[0648] L5A
[0649] General schemes A, B, D (octadecanoic acid monotert-butyl ester); C, D (Fmoc-PEG2-propionic acid); B, D (Fmoc-PEG2-propionic acid); B, D (compound L5Ab); B, E, F.
[0650] The crude product was purified by HPLC to give a white solid product L5A (5.2 g, 11% yield). MS (ES) + )m / z1188.5([M+H] + ).
[0651] Example 14: Synthesis of L6
[0652]
[0653] intermediate L6a
[0654] Palmitic acid (235 mg, 0.919 mmol, 1.05 equivalents) was dissolved in 4 mL of DMF. HATU (349 mg, 0.919 mmol, 1.05 equivalents) and DIEA (167 μL, 0.963 mmol, 1.1 equivalents) were added, followed by Boc-NH-PEG2-NH2 (200 mg, 0.875 mmol, 1 equivalent). The reaction mixture was then stirred for 2 h, and the solvent was removed. The product was dissolved in EtOAc. The organic layer was washed successively with 1 M HCl, saturated NaHCO3, HCl, and brine, dried over Na2SO4, filtered, and concentrated to give the desired white solid compound L6a (412 mg, 0.84 mmol, 97%). 1 ¹H NMR (400MHz, chloroform-d) δ 6.17 (s, 1H), 5.07 (s, 1H), 3.58 (s, 4H), 3.53 (t, J = 5.0 Hz, 3H), 3.43 (q, J = 5.3 Hz, 2H), 3.36–3.21 (m, 2H), 2.15 (t, J = 7.5 Hz, 2H), 1.66–1.54 (m, 2H), 1.32–1.15 (m, 26H), 0.84 (t, J = 6.6 Hz, 3H).
[0655] intermediate L6b
[0656] A DCM (2 mL) solution of compound L6a (412 mg, 0.84 mmol, 1 equivalent) was treated with TFA (2 mL) for 30 min. The mixture was concentrated and co-evaporated with hexane. HATU (353 mg, 0.931 mmol, 1.1 equivalent) was added to a solution of BocNH-PEG2-CO2H (258 mg, 0.931 mmol, 1.1 equivalent) dissolved in DMF (5 mL). A DMF solution of the deprotected compound L6a and DIEA (294 μL, 1.69 mmol, 2 equivalents) was added to the reaction mixture. The reaction mixture was stirred at room temperature for 2 h. The product was diluted with EtOAc. The organic layer was washed successively with 1 M HCl, saturated NaHCO3, HCl, and brine, dried over Na2SO4, filtered, and concentrated. Purification by silica gel rapid column chromatography yielded the desired oily compound L6b (329 mg, 0.51 mmol, 60%). 1 H NMR (400MHz, chloroform-d) δ6.79(s,1H),6.28(s,1H),5.28(s,1H),3.68(t,J=5.8Hz,2H),3.61-3.44(m,14H),3.38(p,J=5.6Hz,4H),3.24(q,J= 5.5Hz,2H),2.42(t,J=5.8Hz,2H),2.11(t,J=7.9Hz,2H),1.55(p,J=7.2Hz,2H),1.38(s,9H),1.32-1.10(m,24H),0.81(t,J=6.7Hz,3H).
[0657] intermediate L6c
[0658] A DCM (2 mL) solution of compound L6b (329 mg, 0.51 mmol, 1 equivalent) was treated with TFA (2 mL) for 30 min. The mixture was concentrated and co-evaporated with hexane. HATU (213 mg, 0.56 mmol, 1.1 equivalent) was added to a solution of Boc-Orn(Boc)-OH (186 mg, 0.56 mmol, 1.1 equivalent) dissolved in DMF (5 mL). A DMF solution of the deprotected compound L6b and DIEA (177 μL, 1.02 mmol, 2 equivalents) was added to the reaction mixture. The reaction mixture was stirred at room temperature for 2 h. The product was diluted with EtOAc. The organic layer was washed successively with saturated NaHCO3, 1 M HCl, and brine, dried over Na2SO4, filtered, and concentrated. Purification by silica gel rapid column chromatography yielded the desired oily compound L6c (326 mg, 0.37 mmol, 94%). 1¹H NMR (400 MHz, chloroform-d) δ 7.18 (s, ¹H), 6.92 (s, ¹H), 6.48 (s, ¹H), 5.61 (d, J = 8.4 Hz, ¹H), 5.08 (t, J = 5.9 Hz, ¹H), 4.13 (s, ¹H), 3.73–3.65 (m, 2H), 3.59–3.44 (m, ¹⁴H), 3.42–3.2 9(m,8H),3.19-2.86(m,2H),2.42(t,J=5.9Hz,2H),2.10(d,J=7.3Hz,2H),1.78-1.63 (m,1H),1.60-1.40(m,5H),1.35(s,18H),1.26-1.09(m,22H),0.80(t,J=6.7Hz,3H).
[0659] L6
[0660] A 2 mL solution of compound L6c (100 mg, 0.116 mmol, 1 equivalent) in DCM was treated with 2 mL of TFA for 30 min. The mixture was concentrated, co-evaporated with hexane, and dissolved in 10 mL of DCM and cooled at 0 °C. DIEA (80.8 μL, 0.46 mmol, 4 equivalents) was added, followed by bromoacetic anhydride (61.9 mg, 0.238 mmol, 2.05 equivalents) dissolved in 1 mL of DCM. The reaction mixture was then stirred at 0 °C for 30 min, stirred at room temperature for 1.5 h, and the solvent was removed. Purification by silica gel rapid column chromatography gave a white solid L6 (50.1 mg, 0.055 mmol, 40%). 1 ¹H NMR (400MHz, methanol-d⁴) δ 4.39 (dd, J = 8.4, 5.5Hz, 1H), 3.91 (q, J = 11.4Hz, 2H), 3.84 (s, 2H), 3.76 (t, J = 6.2Hz, 2H), 3.63 (d, J = 7.1Hz, 8H), 3.57 (q, J = 5.5Hz, 6H), 3.43–3.3 6(m,6H),3.25(t,J=13.9,6.8Hz,2H),2.49(t,J=6.2Hz,2H),2.21(t,J=7.5Hz,2H) ,1.91-1.79(m,1H),1.75-1.53(m,5H),1.42-1.25(m,24H),0.92(t,J=6.7Hz,3H).
[0661] Example 15: Synthesis of L7
[0662]
[0663] intermediate L7a
[0664] Stearic acid (261 mg, 0.919 mmol, 1.05 equivalents) was dissolved in 4 mL of DMF. HATU (349 mg, 0.919 mmol, 1.05 equivalents) and DIEA (167 μL, 0.963 mmol, 1.1 equivalents) were added, followed by Boc-NH-PEG2-NH2 (200 mg, 0.875 mmol, 1 equivalent). The reaction mixture was then stirred for 2 h, and the solvent was removed. The product was dissolved in EtOAc. The organic layer was washed successively with 1 M HCl, saturated NaHCO3, and brine, dried over Na2SO4, filtered, and concentrated to give the desired white solid compound L7a (430 mg, 0.83 mmol, 95%). 1 H NMR (400MHz, chloroform-d) δ3.69-3.59(m,4H),3.56(t,J=5.1Hz,4H),3.46(q,J=5.2Hz,2H),3.40-3.23(m,2H) ,2.18(t,J=7.6Hz,2H),1.62(t,J=7.3Hz,2H),1.45(s,9H),1.35-1.19(m,30H),0.88(t,J=6.7Hz,4H).
[0665] intermediate L7b
[0666] A DCM (2 mL) solution of compound L7a (426 mg, 0.87 mmol, 1 equivalent) was treated with TFA (2 mL) for 30 min. The mixture was concentrated and co-evaporated with hexane. HATU (366 mg, 0.96 mmol, 1.1 equivalent) was added to a solution of BocNH-PEG2-CO2H (266 mg, 0.96 mmol, 1.1 equivalent) dissolved in DMF (5 mL). A DMF solution of the deprotected compound L7a and DIEA (304 μL, 1.75 mmol, 2 equivalents) was added to the reaction mixture. The reaction mixture was stirred at room temperature for 2 h. The product was diluted with EtOAc. The organic layer was washed successively with 1 M HCl, saturated NaHCO3, and brine, dried over Na2SO4, filtered, and concentrated. Purification by silica gel rapid column chromatography yielded the desired oily compound L7b (360 mg, 0.53 mmol, 61%). 1HNMR (400MHz, chloroform-d) δ6.75(s,1H),6.18(s,1H),5.26(s,1H),3.75(t,J=5.8Hz,2H),3.69-3.52(m,14H),3.47(p,J=5.4Hz,4H),3.33(q,J=5.5Hz ,2H),2.50(t,J=5.8Hz,2H),2.19(t,J=7.5Hz,2H),2.07(s,1H),1.63(p ,J=7.3Hz,2H),1.46(s,9H),1.37-1.19(m,29H),0.89(t,J=6.7Hz,3H).
[0667] intermediate L7c
[0668] A DCM (2 mL) solution of compound L7b (360 mg, 0.53 mmol, 1 equivalent) was treated with TFA (2 mL) for 30 min. The mixture was concentrated and co-evaporated with hexane. HATU (223 mg, 0.58 mmol, 1.1 equivalent) was added to a solution of Boc-Orn(Boc)-OH (195 mg, 0.58 mmol, 1.1 equivalent) dissolved in DMF (5 mL). A DMF solution of the deprotected compound L7b and DIEA (186 μL, 1.07 mmol, 2 equivalents) was added to the reaction mixture. The reaction mixture was stirred at room temperature for 2 h. The product was diluted with EtOAc. The organic layer was washed successively with 1 M HCl, saturated NaHCO3, and brine, dried over Na2SO4, filtered, and concentrated. Purification by silica gel rapid column chromatography yielded the desired oily compound L7c (373 mg, 0.42 mmol, 78%). 1 HNMR (400MHz, chloroform-d) δ7.14 (s, 1H), 6.84 (s, 1H), 6.35 (s, 1H), 5.53 (d, J = 8.2Hz, 1H),5.05-4.88(m,1H),4.20(s,1H),3.82-3.69(m,2H),3.65-3.31(m,22H),3. 23-3.00(m,2H),2.48(t,J=5.8Hz,2H),2.17(t,J=7.8Hz,2H),1.87-1.72(m,1H ),1.67-1.48(m,5H),1.42(s,18H),1.34-1.14(m,29H),0.87(t,J=6.9Hz,3H).
[0669] L7
[0670] A 2 mL solution of compound L7c (100 mg, 0.112 mmol, 1 equivalent) in DCM was treated with 2 mL TFA for 30 min. The mixture was concentrated, co-evaporated with hexane, and dissolved in 10 mL of DCM and cooled at 0 °C. DIEA (78 μL, 0.44 mmol, 4 equivalents) was added, followed by bromoacetic anhydride (62 mg, 0.24 mmol, 2.05 equivalents) dissolved in 1 mL of DCM. The reaction mixture was then stirred at 0 °C for 30 min, stirred at room temperature for 1.5 h, and the solvent was removed. The product was dissolved in EtOAc. The organic layer was washed successively with 1 M HCl, saturated NaHCO3, and brine, dried over Na2SO4, filtered, and concentrated. Purification by silica gel rapid column chromatography gave a white solid L7 (95 mg, 0.10 mmol, 91%). MS (ES) + )m / z 931.31([M+H] + ),933.25([M+H] + ). 1 H NMR (400MHz, methanol-d4) δ4.39 (dd, J=8.5, 5.4Hz, 1H), 3.91 (q, J=11.3Hz, 2H), 3.84 ( s,2H),3.76(t,J=6.2Hz,2H),3.63(d,J=7.0Hz,8H),3.57(t,J=5.5Hz,6H),3.42 -3.35(m,6H),3.31-3.13(m,4H),2.49(t,J=6.2Hz,2H),2.20(t,J=7.4Hz,2H),1 .91-1.79(m,1H),1.75-1.56(m,6H),1.39-1.26(m,26H),0.92(t,J=6.3Hz,3H).
[0671] Example 16: Synthesis of L8
[0672]
[0673] General schemes A, B, D (mono-tert-butyl hexadecanoate); C, D (Fmoc-PEG2-propionic acid); B, D (Fmoc-PEG2-propionic acid); B, D (Fmoc-Orn(Fmoc)-OH); B, E, F.
[0674] The crude product was purified by semi-preparative HPLC with quality control to obtain a white solid product L8 (42.6 mg, 0.038 mmol, 22%). 1¹H NMR (400MHz, methanol-d⁴) δ 4.38 (td, J = 8.6, 5.1 Hz, 2H), 3.91 (q, J = 11.3 Hz, 2H), 3.84 (s, 2H), 3.76 (q, J = 6.1 Hz, 4H), 3.65–3.59 (m, 8H), 3.56 (td, J = 5.5, 1.7 Hz, 4H), 3.43–3.3 7(m,4H),3.31-3.16(m,4H),2.48(dt,J=15.7,6.2Hz,4H),2.28(dt,J=12.6,7.5Hz, 4H),1.95-1.79(m,1H),1.77-1.51(m,10H),1.49-1.41(m,2H),1.40-1.26(m,31H).
[0675] Example 17: Synthesis of L9
[0676]
[0677] General schemes A, B, D (heptadecanedioic acid monotert-butyl ester); C, D (Fmoc-PEG2-propionic acid); B, D (Fmoc-PEG2-propionic acid); B, D (Fmoc-Orn(Fmoc)-OH); B, E, F.
[0678] The crude product was purified by semi-preparative HPLC with quality control to obtain a white solid product L9 (49 mg, 0.089 mmol, 9%). 1 H NMR (400MHz, methanol-d4) δ4.45-4.33(m,2H),3.92(t,J=10.9Hz,2H),3.85(d,J=1.1Hz,2 H),3.77(q,J=6.0Hz,4H),3.63(s,8H),3.57(t,J=5.6Hz,4H),3.40(t,J=5.5Hz,4H), 3.25(dq,J=22.7,6.7Hz,4H),2.48(dt,J=15.6,6.2Hz,4H),2.29(dt,J=13.2,7.4Hz ,4H),1.95-1.79(m,2H),1.80-1.50(m,10H),1.51-1.41(m,2H),1.40-1.27(m,20H).
[0679] Example 18: Synthesis of L12
[0680]
[0681] General schemes A, B, D (octadecanoic acid); C, D (Fmoc-PEG2-propionic acid); B, D (Fmoc-Orn(Fmoc)-OH); B, E, F.
[0682] The crude product was purified by semi-preparative HPLC with quality control to obtain a white solid product L12 (51.7 mg, 0.054 mmol, 3%). 1 ¹H NMR (400MHz, methanol-d⁴) δ 4.39 (td, J = 9.2, 5.1Hz, 2H), 3.92 (qd, J = 11.4, 1.2Hz, 2H), 3.85 (s, 2H), 3.76 (t, J = 6.2Hz, 2H), 3.63 (s, 4H), 3.57 (t, J = 5.5Hz, 2H), 3.40 (q, J = 11.4, 1.2Hz, 2H), 3.40 (q, J = 11.4, 1.2Hz, 2H). 5.1Hz,2H),3.30-3.12(m,6H),2.47(t,J=6.1Hz,2H),2.29(dt,J=12.1,7.4Hz,4H ),1.95-1.77(m,2H),1.78-1.50(m,10H),1.48-1.40(m,2H),1.39-1.26(m,22H).
[0683] Example 19: Synthesis of L14
[0684]
[0685] Intermediate L14a
[0686] To a solution of tert-butyl hexadecanoate (102 mg, 0.30 mmol, 1 equivalent) dissolved in DMF (5 mL), HATU (125 mg, 0.33 mmol, 1.1 equivalent), DIEA (51 μL, 0.33 mmol, 1.1 equivalent), and compound L4b (151.9 mg, 0.3 mmol, 1 equivalent) dissolved in 1 mL of DMF were added. The reaction mixture was stirred at room temperature for 3 h. The product was diluted with EtOAc. The organic layer was washed successively with 1 M HCl, saturated NaHCO3, and brine, dried over Na2SO4, filtered, and concentrated. Purification by silica gel rapid column chromatography yielded the desired oily compound L14a (147 mg, 0.176 mmol, 59%). 1H NMR (400MHz, chloroform-d) δ6.87(s,1H),6.40(s,1H),5.32(s,2H),4.79(s,1H),4. 20(s,1H),3.66(d,J=7.0Hz,8H),3.60(dt,J=10.0,5.1Hz,4H),3.49-3.45(m ,3H),3.31-3.18(m,1H),3.13-3.06(m,1H),2.21(td,J=7.8,6.0Hz,4H),1. 88-1.78(m,1H),1.66-1.53(m,7H),1.51-1.42(m,27H),1.36-1.19(m,20H).
[0687] L14
[0688] A DCM (2 mL) solution of compound L14a (40 mg, 0.048 mmol, 1 equivalent) was treated with TFA (2 mL) for 30 min. The mixture was concentrated, co-evaporated with hexane, and dissolved in 20 mL of DCM and cooled at 0 °C. DIEA (34 μL, 0.1924 mmol, 4 equivalents) was added, followed by bromoacetic anhydride (23.63 mg, 0.098 mmol, 2.05 equivalents) dissolved in 1 mL of DCM. The reaction mixture was then stirred at 0 °C for 30 min, stirred at room temperature for 1.5 h, and the solvent was removed. Purification by silica gel rapid column chromatography yielded a white solid L14 (18.3 mg, 0.022 mmol, 46%). MS (ES) + )m / z 817.1([M+H] + ),819.09([M+H] + ). 1 H NMR (400MHz, methanol-d4) δ4.38 (dd, J=8.4, 5.5Hz, 1H), 3.92 (q, J=11.2, 10.6Hz, 2H),3.84(s,2H),3.69-3.61(m,8H),3.56(td,J=5.5,2.6Hz,4H),3.44-3.3 6(m,4H),3.30-3.14(m,2H),2.29(t,J=7.4Hz,2H),2.21(t,J=7.5Hz,2H),1 .91-1.78(m,1H),1.76-1.67(m,1H),1.67-1.54(m,6H),1.40-1.29(m,20H).
[0689] Example 20: Synthesis of L15
[0690]
[0691] Intermediate L15a
[0692] To a solution of 20-(tert-butoxy)-20-oxoeicosanoic acid (360 mg, 0.90 mmol, 1.05 equivalents) dissolved in DMF (5 mL), HATU (343 mg, 0.90 mmol, 1.05 equivalents), DIEA (300 μL, 1.71 mmol, 2 equivalents), and compound L4b (435 mg, 0.858 mmol, 1 equivalent) dissolved in 1 mL of DMF were added. The reaction mixture was stirred at room temperature for 3 h. The product was diluted with EtOAc. The organic layer was washed successively with 1 M HCl, saturated NaHCO3, and brine, dried over Na2SO4, filtered, and concentrated. Purification by silica gel rapid column chromatography gave the desired oily compound L15a (555 mg, 0.625 mmol, 72%). 1 ¹H NMR (400MHz, chloroform-d) δ 6.87 (s, 1H), 6.40 (s, 1H), 4.79 (s, 1H), 4.21 (s, 1H), 3.76–3.53 (m, 15H), 3.47 (s, 5H), 3.32–3.05 (m, 3H), 2.29–2.17 (m, 4H), 1.90–1.76 (m, 4H), 1.69–1.53 (m, 2H), 1.52–1.41 (m, 33H), 1.36–1.20 (m, 29H).
[0693] L15
[0694] A DCM (2 mL) solution of compound L15a (100 mg, 0.112 mmol, 1 equivalent) was treated with TFA (2 mL) for 30 min. The mixture was concentrated, co-evaporated with hexane, and dissolved in 20 mL of DCM and cooled at 0 °C. DIEA (79 μL, 0.45 mmol, 4 equivalents) was added, followed by bromoacetic anhydride (60 mg, 0.231 mmol, 2.05 equivalents) dissolved in 1 mL of DCM. The reaction mixture was then stirred at 0 °C for 30 min, stirred at room temperature for 1.5 h, and the solvent was removed. Purification was performed by silica gel rapid column chromatography to give L15 (17.5 mg, 0.02 mmol, 18%) as a white solid. MS (ES) + )m / z 873.21([M+H] + ),875.20([M+H] + ) 1H NMR (400MHz, methanol-d4) δ4.38 (dd, J=8.4, 5.5Hz, 1H), 3.91 (q, J=11.4Hz, 2H), 3.84 (s, 2H), 3.72-3.61 (m, 8H), 3.56 (td, J=5.5, 2.7Hz, 4H), 3.4 4-3.35(m,5H),3.30-3.17(m,2H),2.29(t,J=7.4Hz,2H),2.21(t,J=7.5Hz,2H),1.92-1.77(m,1H),1.75-1.53(m,7H),1.40-1.27(m,27H).
[0695] Example 21: Synthesis of L16
[0696]
[0697] Intermediate L16a
[0698] To a solution of Boc-Orn(Boc)-OH (400 mg, 1.2 mmol, 1 equivalent) dissolved in DMF (10 mL), HATU (504 mg, 1.32 mmol, 1.1 equivalent), DIEA (230 μL, 1.32 mmol, 1.1 equivalent), and amine-PEG2-N3 (210 mg, 1.20 mmol, 1 equivalent) dissolved in 1 mL of DMF were added. The reaction mixture was stirred at room temperature for 4 h. The product was diluted with EtOAc. The organic layer was washed successively with 1 M HCl, saturated NaHCO3, and brine, dried over Na2SO4, filtered, and concentrated. Purification by silica gel rapid column chromatography yielded the desired oily compound L16a (471 mg, 0.96 mmol, 80%). 1 ¹H NMR (400MHz, methanol-d⁴) δ 4.01 (t, J = 6.6 Hz, 1H), 3.71–3.60 (m, 6H), 3.55 (t, J = 5.5 Hz, 2H), 3.41–3.37 (m, 3H), 3.04 (t, J = 6.2 Hz, 2H), 1.78–1.66 (m, 1H), 1.62–1.48 (m, 3H), 1.48–1.39 (m, 18H).
[0699] intermediate L16b
[0700] Pd / C (10.2 mg, 0.09 mmol, 0.1 equivalent) was added to an anhydrous MeOH (10 mL) solution of compound L16a (471 mg, 0.9 mmol, 1 equivalent) under argon atmosphere, and the argon atmosphere was replaced with H2. The reaction mixture was stirred at room temperature for 6 h, filtered through diatomaceous earth, and evaporated to give an oily compound L16b (295.5 mg, 0.64 mmol, 71%). The product was ready for use without further purification. MS (ES) + )m / z 462.51([M+H] + ).
[0701] intermediate L16c
[0702] To a solution of tert-butyl octadecanoate (281 mg, 0.76 mmol, 1 equivalent) dissolved in DMF (5 mL), HATU (288 mg, 0.76 mmol, 1 equivalent), DIEA (132 μL, 0.76 mmol, 1 equivalent), and compound L16b (351 mg, 0.76 mmol, 1 equivalent) dissolved in 1 mL of DMF were added. The reaction mixture was stirred at room temperature for 3 h. The product was diluted with EtOAc. The organic layer was washed successively with 1 M HCl, saturated NaHCO3, and brine, dried over Na2SO4, filtered, and concentrated. Purification by silica gel rapid column chromatography yielded the desired oily compound L16c (351 mg, 0.43 mmol, 57%). 1 H NMR (400MHz, methanol-d4) δ3.61(s,4H),3.54(td,J=5.6,2.3Hz,4H),3.40-3.34(m,4H),3.04(t,J=6.6Hz,2H),2 .20(td,J=7.6,5.9Hz,4H),1.77-1.68(m,2H),1.64-1.48(m,2H),1.48-1.42(m,28H),1.35-1.26(m,26H).
[0703] L16
[0704] A solution of compound L16c (31 mg, 0.038 mmol, 1 equivalent) in DCM (2 mL) was treated with TFA (2 mL) for 30 min. The mixture was concentrated, co-evaporated with hexane, and dissolved in 20 mL of DCM and cooled at 0 °C. DIEA (27 μL, 0.152 mmol, 4 equivalents) was added, followed by bromoacetic anhydride (21 mg, 0.078 mmol, 2.05 equivalents) dissolved in 1 mL of DCM. The reaction mixture was then stirred at 0 °C for 30 min, stirred at room temperature for 1.5 h, and the solvent was removed. Purification was performed by silica gel rapid column chromatography to give L16 as a white solid (12.6 mg, 0.015 mmol, 41%). MS (ES) + )m / z 801.13([M+H] + ),803.12([M+H] + ). 1 H NMR (400MHz, methanol-d4) δ4.37(dd,J=8.5,5.4Hz,1H),3.91(q,J=11.3Hz,2H),3.84(s,2H),3.63(s,4H),3.57(td,J=5.6,2.6Hz,4H),3.43- 3.36(m,4H),3.31-3.17(m,1H),2.29(t,J=7.4Hz,2H),2.21(t,J=7.5Hz,2H),1.90-1.79(m,1H),1.76-1.54(m,7H),1.41-1.30(m,26H).
[0705] Example 22: Synthesis of L17
[0706]
[0707] Intermediate L17a
[0708] To a solution of Boc-Orn(Boc)-OH (400 mg, 1.2 mmol, 1 equivalent) dissolved in DMF (10 mL), HATU (504 mg, 1.32 mmol, 1.1 equivalent), DIEA (230 μL, 1.32 mmol, 1.1 equivalent), and amine-PEG2-N3 (316 mg, 1.20 mmol, 1 equivalent) dissolved in 1 mL of DMF were added. The reaction mixture was stirred at room temperature for 4 h. The product was diluted with EtOAc. The organic layer was washed successively with 1 M HCl, saturated NaHCO3, and brine, dried over Na2SO4, filtered, and concentrated. Purification by silica gel rapid column chromatography yielded the desired oily compound L17a (454 mg, 0.78 mmol, 66%). 1¹H NMR (400MHz, methanol-d⁴) δ 4.04–3.97 (m, 1H), 3.71–3.58 (m, 14H), 3.54 (t, J = 5.4 Hz, 2H), 3.37 (t, J = 5.0 Hz, 4H), 3.04 (t, J = 6.6 Hz, 2H), 1.75–1.67 (m, 1H), 1.62–1.48 (m, 3H), 1.48–1.41 (m, 18H).
[0709] intermediate L17b
[0710] Pd / C (8.3 mg, 0.078 mmol, 0.1 equivalent) was added to an anhydrous MeOH (10 mL) solution of compound L17a (454 mg, 0.9 mmol, 1 equivalent) under argon atmosphere, and the argon atmosphere was replaced with H2. The reaction mixture was stirred at room temperature for 6 h, filtered through diatomaceous earth, and evaporated to give an oily compound L17b (192 mg, 0.35 mmol, 45%). The product was ready for use without further purification.
[0711] intermediate L17c
[0712] To a solution of tert-butyl octadecanoate (225 mg, 0.61 mmol, 1 equivalent) dissolved in DMF (5 mL), HATU (231 mg, 0.61 mmol, 1 equivalent), DIEA (106 μL, 0.61 mmol, 1 equivalent), and compound L17b (335 mg, 0.61 mmol, 1 equivalent) dissolved in 1 mL of DMF were added. The reaction mixture was stirred at room temperature for 2 h. The product was diluted with EtOAc. The organic layer was washed successively with 1 M HCl, saturated NaHCO3, and brine, dried over Na2SO4, filtered, and concentrated. Purification by silica gel rapid column chromatography yielded the desired oily compound L17c (178 mg, 0.20 mmol, 32%). 1 H NMR (400MHz, chloroform-d) δ5.32 (s, 2H), 3.74-3.63 (m, 11H), 3.59 (dt, J = 10.9, 5.0Hz, 4H), 3.52-3.43 (m, 4 H), 3.27-3.08 (m, 2H), 2.22 (d, J = 7.6Hz, 4H), 1.69-1.52 (m, 6H), 1.51-1.42 (m, 27H), 1.27 (s, 26H).
[0713] L17
[0714] A DCM (2 mL) solution of compound L17c (45.6 mg, 0.05 mmol, 1 equivalent) was treated with TFA (2 mL) for 30 min. The mixture was concentrated, co-evaporated with hexane, and dissolved in 20 mL of DCM and cooled at 0 °C. DIEA (36 μL, 0.202 mmol, 4 equivalents) was added, followed by bromoacetic anhydride (27 mg, 0.103 mmol, 2.05 equivalents) dissolved in 1 mL of DCM. The reaction mixture was then stirred at 0 °C for 30 min, stirred at room temperature for 1.5 h, and the solvent was removed. Purification by silica gel rapid column chromatography yielded a white solid L17 (14.9 mg, 0.017 mmol, 33%). MS (ES) + )m / z 889.18([M+H] + ),891.17([M+H] + ) 1 H NMR (400MHz, methanol-d4) δ4.38 (dd, J=8.3, 5.5Hz, 1H), 3.92 (q, J=11.3Hz, 2H), 3.84 (s, 2H), 3.67-3.60 (m, 7H), 3.56 (td, J=5.5, 3.5Hz, 4H), 3.4 5-3.35(m,5H),3.32-3.15(m,3H),2.29(t,J=7.4Hz,2H),2.21(t,J=7.5Hz,2H),1.90-1.76(m,1H),1.74-1.57(m,7H),1.41-1.26(m,25H).
[0715] Example 23: Synthesis of L18
[0716]
[0717] General schemes A, B, D (octadecanoic acid); C, D (Fmoc-PEG2-propionic acid); B (Fmoc-PEG2-propionic acid), B (Fmoc-PEG2-propionic acid); B, D (Fmoc-Orn(Fmoc)-OH); B, E, F.
[0718] The crude product was purified by semi-preparative HPLC with quality control to give a white solid product L18 (47 mg, 0.036 mmol, 10%). MS (ES) + )m / z 1276.39([M+H] + ),1278.37([M+H] + ).
[0719] General solutions for bromoacetyl peptide pinning / conjugation
[0720] The peptide was dissolved at a concentration of 2 mM in 1.5 equivalences of bromoacetyl sterigmazone in a 1:3 (v / v) MeCN / 30 mM NH4HCO3 buffer (pH 8.5). The pH of the reaction mixture was readjusted with ammonium hydroxide to correct for the pH decrease caused by the peptide TFA counterion. For particularly insoluble peptides, more MeCN was added. The reaction mixture was stirred at room temperature for 2–4 h, and then acidified to pH 5 by dropwise addition of acetic acid. The resulting solution was lyophilized and purified by reversed-phase HPLC.
[0721] General solid-phase solutions for lactam stabilization
[0722] The peptide-resin with orthogonally protected amine side chains (Dde / Mmt) at each pinning site was swollen in DMF for 1 h. The Dde protecting group was removed from the first side chain by treatment with a 2% hydrazine solution in DMF (2 × 15 min). A positive TNBS test was observed. The linker building blocks specified below were coupled as described below, and a negative TNBS test was observed. The solvent was exchanged for DCM, and the Mmt group was removed from the second side chain by treatment with a DCM solution containing 5% TIPS and 1% TFA for 5 × 2 min. The resin was washed with DCM, a DMF solution of 10% DIEA, and DMF, and a positive TNBS test was observed. The linker was cyclized as described below, and the PEG-fatty acid moiety of the pinned peptide was extended (if applicable). The intact pinned peptide was cleaved from the resin for 3 h using 95% TFA, 2.5% TIPS, and 2.5% H2O. The peptide cleavage mixture was evaporated into an oil, ground, washed with ether, and purified by reversed-phase HPLC.
[0723] The Dde / Alloc protection scheme can also be used in this method, which requires the addition of allyl alcohol as a scavenger to the Dde deprotection mixture to prevent the simultaneous reduction of the allyl moiety of Alloc.
[0724] Synthesis of K(Fmoc) connectors
[0725]
[0726] intermediate Ka
[0727] Fmoc-β-Ala-OH (1.00 g, 3.21 mmol) and di-tert-butyl iminodiacetic acid (0.461 g, 2.68 mmol) were suspended in 100 mL of DCM. HATU (1.02 g, 2.68 mmol) and DIEA (3.32 mL, 12.8 mmol) were added, and the reaction mixture was stirred at room temperature for 3.5 h. The solvent was evaporated, and the residue was dissolved in methanol and purified by rapid silica gel column chromatography (hexane / EtOAc) to give a white solid product (0.802 g, 56%). 1H NMR (400MHz, chloroform-d) δ7.78(d,J=7.4Hz,2H),7.62(d,J=7.4Hz,2H),7.42(t,J=7.4Hz,2H),7.33(t,J=7.4Hz,2H),5.66(t,J=5.7Hz,1H) ,4.35(d,J=7.3Hz,2H),4.23(t,J=7.3Hz,1H),4.10(s,2H),4.02(s,2H),3.56(q,J=5.7Hz,2H),2.55(t,J=5.7Hz,2H),1.49(s,18H).
[0728] K(Fmoc) connector
[0729] Compound Ka was treated with 20 mL of 1:1 TFA / DCM for 2 h. The solvent was evaporated, the residue was ground, and washed with diethyl ether to give a white solid K(Fmoc) linker (0.371 g, 58%). MS (ES) + )m / z 427.15([M+H] + ).
[0730] Assembling A(Fmoc) connectors
[0731]
[0732] A 10 mL dioxane solution of 5-aminoisophthalic acid (1.00 g, 5.5 mmol) was added to a degassed solution of Na₂CO₃ (1.46 g, 5.5 mmol) in 15 mL of water. The solution was cooled on ice, and then a 10 mL dioxane solution of Fmoc chloride (1.42 g, 5.5 mmol) was added dropwise over 15 minutes with stirring. The reaction mixture was then stirred for 1 h, followed by stirring at room temperature for 24 h. Dioxane was removed under vacuum, and the remaining aqueous solution was acidified with 1 M HCl. The resulting solid precipitate was then washed with diethyl ether (4 × 10 mL), dissolved in EtOAc, filtered, washed with brine, dried over Na₂SO₄, filtered, and concentrated to obtain a white solid A(Fmoc) connector (119 mg, 5%). 1 H NMR (500MHz, DMSO-d6) δ13.24(s,2H),10.12(s,1H),8.33(d,J=1.5Hz,2H),8.12(t,J=1.5Hz,1H),7.91(d,J=7.6Hz,2H),7. 76(dd,J=7.6,1.2Hz,2H), 7.43(t,J=7.6Hz,2H), 7.36(td,J=7.6,1.2Hz,2H), 4.50(d,J=6.8Hz,2H), 4.33(t,J=6.8Hz,1H).
[0733] The general solution G for simple lactam staplers in the “A1” and “K1” series
[0734] For linker coupling, suitable diacid building blocks (2 equivalents) were linked using a DMF solution of HATU (4 equivalents) and DIEA (4 equivalents) for 1×2 h. The cyclization step was performed using a DMF solution of HATU (1 equivalent) and DIEA (2 equivalents) for 1×2 h.
[0735] General Scheme H for 'K'PEG-Fatty Acid Trifunctional Lactam Stapleants
[0736] For linker coupling, an intramolecular symmetric anhydride was pre-formed in dry DCM at room temperature for 10 min using DIC (2 equivalents) and catalytic DMAP to form the building block K(Fmoc) linker (2 equivalents). The peptide-resin solvent was replaced with DCM, and the anhydride was added and stirred overnight. The resin was drained and washed with DCM and DMF. The linker was cyclized overnight by treatment with a DMF solution of DIC (1 equivalent) and HOBt or HOAt (1 equivalent), and TNBS was observed to be negative. The remaining uncyclized linker was capped by treatment with a DMF solution of 10% acetic anhydride (30 min). The Fmoc group of the linker was deprotected by treatment with a DMF solution of 20% piperidine (2 × 10 min). TNBS was observed to be positive. Subsequently, the stapled PEG and fatty acid building blocks were sequentially linked to the linker free amine via standard coupling chemistry: a DMF solution of building blocks (3 equivalents), HATU (3 equivalents), and DIEA (6 equivalents), at room temperature, for 1 h, followed by deprotection cycling (5+10 min, RT) with a DMF solution of 20% piperidine.
[0737] General Solution I for 'A' PEG-Fatty Acid Trifunctional Lactam Stapleants
[0738] For linker coupling, the linker of building block A (Fmoc) (2 equivalents) was coupled using a DMF solution of HATU (4 equivalents) and DIEA (4 equivalents) for 1 × 2 h. Cyclation was performed using a DMF solution of HATU (1 equivalent) and DIEA (2 equivalents) for 1 × 2 h. The remaining uncyclized linker was capped by treatment with a DMF solution of 10% acetic anhydride (30 min). The Fmoc group of the linker was deprotected by treatment with a DMF solution of 20% piperidine (2 × 10 min). A positive TNBS test for aniline nitrogen was not observed. Fmoc-β-Ala-OH (3 equivalents) was coupled using a DMF solution of HATU (3 equivalents) and DIEA (6 equivalents) at room temperature for 4 × 1 h, or as a symmetrical anhydride was coupled using a DCM solution of DIC / DMAP (2 h, RT). Subsequently, the stapled PEG and fatty acid building blocks were sequentially linked to the linker free amine via standard coupling chemistry: a DMF solution of building blocks (3 equivalents), HATU (3 equivalents), and DIEA (6 equivalents), at room temperature, for 1 h, followed by deprotection cycling (5+10 min, RT) with a DMF solution of 20% piperidine.
[0739] In some embodiments, the peptide conjugates described herein comprise the extended half-life portions or pinned compounds listed in Table 6.
[0740] Table 6
[0741]
[0742]
[0743]
[0744]
[0745]
[0746]
[0747] It is part of a cysteine, homocysteine, 2-amino-5-mercaptovalerate, or 2-amino-6-mercaptohexanoate residue, and It is part of lysine, ornithine, diaminobutyric acid, diaminopropionic acid, or high-lysine residues.
[0748] In some implementations, the PYY peptide conjugates described herein are shown in Table 7.
[0749] Table 7: PYY peptide conjugates
[0750]
[0751]
[0752]
[0753]
[0754]
[0755]
[0756]
[0757]
[0758]
[0759]
[0760]
[0761]
[0762]
[0763]
[0764]
[0765]
[0766]
[0767]
[0768] In some implementations, the GLP-1R / GCGR dual agonist peptide conjugates described herein are shown in Table 8.
[0769] Table 8: GLP-1R / GCGR dual agonist peptide conjugates
[0770]
[0771]
[0772]
[0773]
[0774]
[0775]
[0776]
[0777]
[0778] In some implementations, the GLP-1R / GIPR dual agonist peptide conjugates described herein are shown in Table 9.
[0779] Table 9: GLP-1R / GIPR dual peptide conjugates
[0780]
[0781]
[0782]
[0783]
[0784]
[0785]
[0786]
[0787]
[0788]
[0789] In some implementations, the GLP-1R peptide conjugates described herein are shown in Table 10.
[0790] Table 10: GLP-1R peptide conjugates
[0791]
[0792]
[0793] In some embodiments, the peptide conjugates described herein are shown in Tables 11 and 12.
[0794] Table 11 - Pinned PrRP20 peptide sequences a
[0795]
[0796]
[0797]
[0798] a All peptides were confirmed to have a purity >95% by HPLC (LC-MS).
[0799] Table 12 - Pinned PrRP31 peptide sequences a
[0800]
[0801]
[0802]
[0803]
[0804]
[0805]
[0806]
[0807]
[0808] a All peptides were confirmed to have a purity >95% by HPLC (LC-MS).
[0809] Bioassay Protocol
[0810] GPR10-activated β-repressor protein recruitment assay
[0811] The PathHunter CHO-K1 GPR101β-inhibitor orphan GPCR cell line was purchased from DiscoverX. In short, cells (20 μL per well, 5000 cells) were seeded in white solid 384-well plates covered with a metal cap and incubated overnight. On day 2, the medium was replaced with fresh medium (0% FBS group, no FBS). Cells were treated with 5 μL of 12-fold diluted PrRP31 as a positive control and incubated in triplicate with protein dilution buffer (0.1% BSA) at 37°C, 5% CO2. The sample peptides (starting concentration 400 nM and serially diluted 1:3) from the assay kit were processed for 90 minutes. The assay kit was purchased from DiscoverX. The assay kit was used for detection. 12.5 μL of working assay solution was added to each well and incubated at room temperature in the dark for 1 hour. The emission signal was measured using a PerkinElmer spectrometer. EC was obtained using Prism software. 50 value.
[0812] cAMP assay for NPFF2R activation
[0813] CHO cells stably overexpressing human NPFF2R (20 μL, 5000 cells per well; obtained from Christopher McCurdy's laboratory, College of Pharmacy, University of Florida) were seeded in white solid 384-well plates covered with metal caps and incubated overnight. On day 2, the medium was replaced with fresh medium (0% FBS group, FBS-free). Cells were treated with 5 μL of PrRP31 or similar at a 12-point dose-response (starting at 20 μM, followed by 1:3 serial dilutions), with 20 μM tuftrin in the medium as a positive control, and cells were treated with 0.5 mM IBMX (3-isobutyl-1-methylxanthine) to inhibit cAMP degradation. The assay was performed in triplicate for 30 minutes at 37°C and 5% CO2. cAMP levels were detected using the cAMP dynamic 2 kit from Cisbio. In short, add 25 μL of cAMP assay reagent (cAMP-d2: crypt compound conjugate: lysis buffer = 1:1:38) to each well and incubate at room temperature for 1 h. For cell negative control wells, add cAMP assay reagent without d2. Then read the plate at Ex 320 nm, Em-1 665 nm, and Em-2 615 nm. Plot the results using Prism software with ratios or Delta F, and then obtain the EC50 values. 50 Ratio = A 665nm / B 620nm ×10^4. %Delta F = (Ratio of standard or sample - Ratio) neg ) / ratio neg ×100.
[0814] Plasma peptide stability
[0815] Add 12 μL of 1 mM peptide DMSO stock solution to 300 μL of mouse plasma (final concentration 20 μM). Incubate the sample at 37 °C for 48 h. At specific time intervals (0, 0.25, 0.5, 1, 2, 4, 8, 24, and 48 h), collect 25 μL of plasma and add it to 150 μL of cold acetonitrile / H2O (9:1, v / v) + 0.1% TFA to precipitate plasma proteins. Incubate the sample at 0 °C for 30 min and centrifuge at 17 rpm for 10 min (4 °C). Analyze the sample using LC-MS (QTOF).
[0816] In vivo pharmacokinetic studies
[0817] In vivo pharmacokinetics (PK) were performed by WuXi AppTec Co., Ltd. in accordance with the standard animal procedures of the International Association for the Use and Management of Laboratory Animals (IACUC) in Wuxi, as well as the IACUC guidelines in accordance with the Animal Welfare Law, the Guidelines for the Care and Use of Laboratory Animals, and applicable Wuxi standard operating procedures and recognized good laboratory practices. Unfed male C57 mice (7–9 weeks old) from SLAC Laboratory Animal Co., Ltd. or SIPPR / BK Laboratory Animal Co., Ltd. (Shanghai, China) were acclimated for at least 3 days and then administered compound 60 (18-S4) at 0.2 mg / mL (1 mg / kg dose) in physiological saline (0.9% NaCl). Blood samples (70 μL) were collected from the retroorbital or saphenous vein at the following time points: 0.25, 0.5, 1, 3, 7, 24, 48, and 72 h (n = 3 per group, 3 groups). Animals were housed in groups during acclimation and individually during the study period. The animal room environment was controlled (18°C to 26°C, relative humidity 30% to 70%, 12h artificial light and 12h darkness). All animals were allowed free access to a qualified rodent diet (SLAC Laboratory Animal Co., Ltd.) and water. All blood samples were transferred to microcentrifuge tubes containing 2 μL of 0.5M K2EDTA anticoagulant and placed on wet ice until centrifugation, centrifuging at 3000g for 15 minutes (4°C) within 30 minutes of collection. Plasma was stored in polypropylene tubes, rapidly frozen on dry ice and maintained at -70°C until LC-MS / MS analysis.
[0818] LC-MS analysis of plasma samples from pharmacokinetic studies
[0819] PK bioanalysis was performed using WuXi AppTec Co., Ltd. An 8 μL aliquot of plasma sample was added to 8 μL of 4% H3PO4, and plasma proteins were precipitated using 160 μL of methanol containing 100 ng / mL glibenclamide as an internal standard. The mixture was vortexed thoroughly and centrifuged at 3220 g for 15 min (4 °C). 10 μL of the supernatant was injected into the SCIEXTriple Quad. TM 6500 + ACQUITY cascaded in LC-MS / MS architecture (ES+) In an HSS T3 column (1.8 μm, 2.1 × 50 mm). Analysis was performed over 1 minute using a solvent gradient of 10–60% B, where A = 0.1% aqueous formic acid and B = 0.1% acetonitrile solution of formic acid (flow rate 0.6 mL / min, column temperature 60 °C). The retention time for compound 60 (18-S4) was 0.96 min. LC-MS data were analyzed using Analyst 1.6.3 software. Calibration curves were generated using eight non-zero calibration standards consisting of high, medium, and low concentrations, including those with limits of quantitation (LLOQ) of 1–3 ng / mL. Study sample analysis was performed simultaneously with one set of calibration standards and two sets of samples using the calibration curves. Plasma concentration versus time data were analyzed using a non-compartmental method with Phoenix WinNonlin 6.3 software. Due to the volume / sampling limitations of mice, sparse sampling was used. Therefore, a single PK curve was obtained by combining concentrations from different animals, and the PK parameter estimates were averaged.
[0820] Example A: cAMP HTRP assay (PYY)
[0821] To measure the inhibitory effect of peptide-induced NPY2R-mediated cAMP production, cAMP HTRF assays were performed according to the manufacturer's instructions (cAMP-Gs Dynamic Kit, Cisbio). Briefly, cAMP Hunter CHO cells expressing NPY2R (DiscoveRx) were seeded at 5,000 cells per well in 20 μL of F12 medium in white 384-well plates overnight at 37°C and 5% CO2. The next day, the medium was removed and replaced with 20 μL of Opti-MEM (Gibco) with or without 10% FBS. Different concentrations of peptide (prepared as 5× solutions in Opti-MEM) and trichodin (final concentration 10 μM, a direct activator of adenylate cyclase) were added and incubated at 37°C for 30 min. Assay reagents were added and incubated further at room temperature for 60 min, and readings were taken on a compatible HTRF reader (PHERAstar). Concentration-response curves were determined using Prism software (GraphPad Software Inc.) via nonlinear regression analysis.
[0822] Table 13. cAMP HTRP Data (SEQ ID NO)
[0823]
[0824]
[0825] ND = Not determined.
[0826] Table 14. cAMP HTRP data (peptide conjugates)
[0827]
[0828]
[0829]
[0830]
[0831]
[0832] ND = Not determined.
[0833] Example B: In vivo study
[0834] Intravenous infusion
[0835] The compound was dissolved in sterile saline and administered intravenously over 1 hour via femoral vein cannulation to non-fasted male Sprague-Dawley rats (n=3 per group). The formulation was administered at a rate of 1.67 mL / kg / h. Blood samples (approximately 250 μL) were collected via jugular vein cannulation into microcapsules containing a mixture of K2EDTA as an anticoagulant and 25 μL of a protease inhibitor for pharmacokinetic analysis 0.25, 0.5, 0.75, 1, 1.17, 1.33, 1.5, 2, 4, 6, 8, 24, 30, and 48 hours after the start of infusion. Plasma was prepared by centrifugation and stored at -80°C until analysis.
[0836] Plasma sample preparation
[0837] Place aliquots of each plasma sample into a 96-well plate. Add Tween-20 to each well to a final concentration of 0.05%. Vortex the plate, then add 3 volumes of a 0.1% TFA solution in ethanol:acetonitrile (2:1) (containing an appropriate internal standard) to each well. Vortex the plate again and centrifuge at 2844 x g for 10 min. Transfer the supernatant to a clean 96-well plate and evaporate at 45°C under a nitrogen stream. Reconstitute the residue in a 20% acetonitrile (aqueous solution) containing 0.1% formic acid.
[0838] LC / MS quantification of peptides in plasma
[0839] All calibration standards were prepared in control rat plasma containing a mixture of K2EDTA and protease inhibitors.
[0840] The system used consisted of a CTC HTS PAL autosampler (Leap, Carrboro, NC), an Agilent Infinity 1290 system with a column oven (Paloalto, CA), a Valco switching valve (Houston, TX), and an AB Sciex API 5600 Triple TOF. TM Alternatively, a system consisting of a Sciex API 4000QTrap mass spectrometer (Framingham, MA) can be used via TurboIonSpray. TM UPLC-MS / MS analysis of samples and standards. Samples are injected into a 2.1 × 50 mm reversed-phase C18 analytical column, typically Waters ACQUITY UPLC HSS T3, 1.8 μm (Waters Corporation, Milford, MA) or similar. Chromatographic separation is achieved using a gradient method with water (A) containing 0.1% formic acid and acetonitrile (B) containing 0.1% formic acid as the mobile phase. Initial conditions consist of 95% A and 5% B. Organic components are increased to 95% B within 3–4 minutes, depending on the peptide. A typical flow rate is 600 μL / min. The column temperature is maintained constant at 40°C or 45°C. Peptides are quantified by monitoring one or more product ions generated by the multiply charged precursor ion.
[0841] Table 15 Half-life and clearance rate in rats (SEQ ID NO)
[0842]
[0843] Table 16 Half-life and clearance rate in rats (peptide conjugates)
[0844]
[0845]
[0846] Example C: Optimization of staple length and position in PYY analogues
[0847] Pinning sites on PYY were selected by examining the structure of the homologous neuropeptide Y (NPY) that binds to the human G protein-coupled neuropeptide Y receptor Y2 (NPY2R). Residues (Y20, L24, Y27, and I28) on the surface interacting with the receptor were avoided during the selection of covalent modification sites to minimize disruption of key peptide-receptor interactions. Post-secretion, rapid cleavage of the N-terminus of PYY by dipeptidyl peptidase-4 (DPP-4) yielded a truncated peptide PYY. 3-36(PYY1:SEQ ID No:1), this is the dominant form in the cycle. Since PYY1 is more specific to the Y2 receptor subtype than PYY, we decided to use this truncated form for development. A group of PYY1 analogs were synthesized with a di-cysteine mutation incorporated at selected pinning sites representing the entire sequence scan. The choice of Cys substitution enabled the use of previously described liquid-phase chemistry to link the bromoacetyl-functionalized pinns. 40
[0848] First, the i and i+7diCys mutants were screened to find the optimal position in the sequence for L1 pinning with 10-atom U pinning.
[0849] To measure the inhibition of NPY2R-mediated cAMP production induced by peptide, cAMP HTRF (homogeneous time-resolved fluorescence) assays were performed according to the manufacturer's instructions (cAMP-GsDynamic kit, Cisbio). Briefly, cAMP Hunter CHO cells expressing NPY2R (DiscoveRx) were seeded at 5,000 cells per well in 20 μL of F12 medium in white 384-well plates overnight at 37°C and 5% CO2. The next day, the medium was removed and replaced with 20 μL of Opti-MEM (Gibco) with or without 10% FBS. Different concentrations of peptide (prepared as a 5X solution in Opti-MEM) and trichodin (a direct activator of adenylate cyclase, final concentration 10 μM) were added and incubated at 37°C for 30 min. Assay reagents were added and incubated further at room temperature for 60 min, and readings were taken on a compatible HTRF reader (PHERAstar). Concentration-response curves were determined using Prism software (GraphPad Software Inc.) via nonlinear regression analysis.
[0850] Unstapled PYY1 (2-9, 10-17, 20-27, and 23-30) can accommodate numerous diCys substitution sites, and stapled with L1 at positions 23-30 results in sub-nanomolar potency, similar to the potency of the native sequence (Table 17). Longer staples at positions i, i+11 and i, i+15 are also expected to potentially enhance the proteolytic stability of the peptide; however, stapling with length-matched L1D and L1E adversely affects their activity, respectively. Furthermore, mutations introduced into the PYY1 sequence have enhanced the potency of the native peptide (sequence 'PYY2' or SEQ ID NO. 2). PYY2 analogues stapled at positions 10-17 and 23-30 have also been found to be potent NPY2R agonists. Staples L1F and L1G (slightly longer than L1) are also permissible at positions 10-17. Therefore, the PYY1 and PYY2 sequences pinned at positions 10-17 and 23-30 were used for fatty acid conjugation to improve serum binding.
[0851] Table 17: EC of stapled PYY analogues 50
[0852]
[0853]
[0854]
[0855] Example D: Fatty acid conjugation enhances serum protein binding and prolongs half-life
[0856] A conjugate library containing various PEG linkers and fatty acid types was synthesized, facilitating rapid screening of conjugates. To measure the inhibition of NPY2R-mediated cAMP production induced by the peptide, cAMP HTRF (homogeneous time-resolved fluorescence) assays were performed according to the manufacturer's instructions (cAMP-GsDynamic kit, Cisbio). Briefly, cAMP Hunter CHO cells expressing NPY2R (DiscoveRx) were seeded at 5,000 cells per well in 20 μL of F12 medium in white 384-well plates overnight at 37°C and 5% CO2. The next day, the medium was removed and replaced with 20 μL of Opti-MEM (Gibco) with or without 10% FBS. Different concentrations of peptide (prepared as a 5X solution in Opti-MEM) and trichodin (a direct activator of adenylate cyclase, final concentration 10 μM) were added and incubated at 37°C for 30 min. Add the detection reagent and incubate at room temperature for another 60 minutes, then read the values on a compatible HTRF microplate reader (PHERAstar). Determine the concentration-response curve using Prism software (GraphPad Software Inc.) via nonlinear regression analysis.
[0857] The results are shown in Table 18. Typically, a large shift is observed between the activities of the pinned L4 and L5 as measured in the presence and absence of serum. For example, when comparing PYY1 conjugates tested in the presence of 10% FBS, the conjugates with pinned L4 and L5 showed a higher EC50 at positions 10-17 compared to the 0.97 nM EC50 of unpinned PYY1 tested under the same conditions. 50 250 nM and 310 nM respectively, at EC positions 23-30 50 The values were 150 nM and 340 nM, respectively. Similarly, when comparing the PYY2 conjugate at 10% FBS, the EC50 of the unconjugated PYY2 at 0.45 nM tested under the same conditions was... 50 In contrast, conjugates with pinned bodies L4 and L5 are located at EC positions 10-17. 50 21 and 15 respectively, and EC at positions 23-30. 50 The values are 9.2 and 170 respectively.
[0858] Table 18: NYPYR2 activation of fatty acid-paired PYY conjugates
[0859]
[0860] Example E: Symmetrically pinned conjugates are effective against NPY2R
[0861] A “symmetric” stapler, L5A, was introduced to avoid the formation of regioisomers, which can occur when stapled with an “asymmetric” L5. To measure the inhibition of NPY2R-mediated cAMP production induced by the peptide, cAMP HTRF (homogeneous time-resolved fluorescence) assays were performed according to the manufacturer’s instructions (cAMP-GsDynamic kit, Cisbio). Briefly, cAMP Hunter CHO cells expressing NPY2R (DiscoveRx) were seeded at 5,000 cells per well in 20 μL of F12 medium in white 384-well plates overnight at 37°C and 5% CO2. The next day, the medium was removed and replaced with 20 μL of Opti-MEM (Gibco) with or without 10% FBS. Different concentrations of peptide (prepared as a 5X solution in Opti-MEM) and trichodin (a direct activator of adenylate cyclase, final concentration 10 μM) were added and incubated at 37°C for 30 min. Add the detection reagent and incubate at room temperature for another 60 minutes, then read the values on a compatible HTRF microplate reader (PHERAstar). Determine the concentration-response curve using Prism software (GraphPad Software Inc.) via nonlinear regression analysis.
[0862] The activity of L5A-linked conjugates is shown in Table 19. For the conjugates at positions 23 and 30 in PYY1, the EC50 of the symmetrically linked conjugates at 10% FBS is shown. 50 The value is 160 nM. For PYY2, the EC values of the symmetrically linked conjugates at positions 10–17 and 23–30 are [value missing] under 10% FBS. 50 The values are 14 nM and 36 nM, respectively.
[0863] Table 19: Activity of Symmetrically Pinned Conjugates
[0864]
[0865] Furthermore, simple esterification of the FA2 conjugate (without pinning) yielded an NPY2R agonist with impressive potency. Significant serum shifts were observed at a single Cys conjugate site (62) in both pinned (diCys mutant 40) and esterified fatty acid conjugates, as shown in dose-response curves with and without serum, implying enhanced serum binding and a longer in vivo half-life.
[0866] Example F: The PYY conjugate has an extended half-life.
[0867] The pharmacokinetic properties of the conjugate were assessed in vivo to determine its half-life prolongation effect. The conjugate was dissolved in sterile saline and administered intravenously over 1 h via femoral vein cannulation to non-fasted male Sprague-Dawley rats (n=3 per group). The formulation was administered at a rate of 1.67 mL / kg / h. Blood samples (approximately 250 μL) were collected via jugular vein cannulation into microcapsules containing a mixture of K2EDTA as an anticoagulant and 25 μL of a protease inhibitor for pharmacokinetic analysis at 0.25, 0.5, 0.75, 1, 1.17, 1.33, 1.5, 2, 4, 6, 8, 24, 30, and 48 h after the start of infusion. Plasma was prepared by centrifugation and stored at -80°C until analysis.
[0868] Place aliquots of each plasma sample into a 96-well plate. Add Tween-20 to each well to a final concentration of 0.05%. Vortex the plate, then add 3 volumes of a 0.1% TFA solution in ethanol:acetonitrile (2:1) (containing an appropriate internal standard) to each well. Vortex the plate again and centrifuge at 2844 × g for 10 min. Transfer the supernatant to a clean 96-well plate and evaporate at 45°C under a nitrogen stream. Reconstitute the residue in a 20% acetonitrile (aqueous solution) containing 0.1% formic acid.
[0869] All calibration standards were prepared in control rat plasma containing a mixture of K2EDTA and protease inhibitors. A CTC HTS PAL autosampler (Leap, Carrboro, NC), an Agilent Infinity 1290 system with column oven (Paloalto, CA), a Valco switching valve (Houston, TX), and an AB Sciex API 5600 TripleTOF were used. TM Alternatively, a system consisting of a Sciex API 4000Q Trap mass spectrometer (Framingham, MA) can be used via Turbo Ion Spray. TMUPLC-MS / MS analysis of samples and standards. Samples are injected into a 2.1 × 50 mm reversed-phase C18 analytical column, typically Waters ACQUITY UPLCHSS T3, 1.8 μm (Waters Corporation, Milford, MA) or similar. Chromatographic separation is achieved using a gradient method with water (A) containing 0.1% formic acid and acetonitrile (B) containing 0.1% formic acid as the mobile phase. Initial conditions consist of 95% A and 5% B. Organic components are increased to 95% B within 3–4 minutes, depending on the conjugate. A typical flow rate is 600 μL / min. The column temperature is maintained constant at 40°C or 45°C. Conjugates are quantified by monitoring one or more product ions generated by the multiply charged precursor ion.
[0870] As shown in Table 20, PYY1 analogs stapled at positions 10-17 with L4 and L5 showed half-lives of 0.45 h and 5.4 h, respectively, in rats. PYY1 analogs stapled with L4 and L5 at positions 23 and 30 showed half-lives of 2.4 h and 3.9 h, respectively, in rats. PYY2 analogs with staples at positions 10-17 retained activity, with half-lives of 1.9 h and 2.0 h, respectively. Figure 2 As shown in Table 21, PYY2 pinned at positions 23–30 exhibited excellent long-lasting action, with a rat half-life of up to 15 h. Lipidification at position 10 also resulted in a prolonged half-life of up to 12 h. This effect corresponds to a large in vitro serum shift and is presumably due to a favorable interaction between the conjugate and serum albumin, as observed with other commercially available lipid-conjugated therapeutic agents such as semaglutide. Pinned conjugates L4, L5, and L5A, with the fatty acid moiety fully incorporated with a carboxylic acid group, and lipid FA2 (unpinned conjugate) were found to provide the most favorable pharmacokinetic properties, with L5, FA2, and L5A modified with an “internal” carboxylic acid ester at the lysine linker being the most favorable. Although serum shift is considered an indicator of enhanced albumin binding, the predicted prolonged in vivo half-life was not observed for analogs pinned at positions 10–17, possibly because pinning at this position is not protective against protein degradation.
[0871] Table 20: In vivo pharmacokinetic data of PYY analogues
[0872]
[0873]
[0874] Detailed pharmacokinetic profiles for long-acting analogs 40 and 62 are shown in Table 21. Compared to SEQ ID No:2, both conjugates exhibited a 10-fold or greater increase in half-life and a significantly reduced clearance rate. This is similar to the fatty acid-conjugated GLP-1R agonist semaglutide, which is administered once weekly in humans.
[0875] Table 21: Rat Pharmacokinetic Data
[0876]
[0877]
[0878] Example G: The pinned PYY conjugate has a long predicted human plasma half-life.
[0879] The serum albumin binding affinity of the conjugates was directly measured using Biacore surface plasmon resonance (SPR) assay, which was then used to calculate the unbound fraction (f) of each conjugate. u Using steady-state distributed volume (V) ss The half-life is calculated using the following equation: (The equation is incomplete and requires further context to be fully translated.)
[0880]
[0881] For metabolically stable conjugates, in terms of renal clearance (CLR) and glomerular filtration rate (GFR):
[0882]
[0883] therefore:
[0884]
[0885] Table 19 shows the predicted human half-life based on a scale corrected for albumin binding, as well as experimentally determined rat (RSA) and human serum albumin (HSA) parameters. All compounds were found to have relatively high affinity for both RSA and HSA, comparable to that of semaglutide. Furthermore, no significant species differences were observed.
[0886] Table 22: Predicted Human Half-Life
[0887]
[0888]
[0889] Specifically, conjugate 40 exhibited a significantly prolonged 14-hour half-life in rats, compared to a predicted human half-life of approximately 4.5 days. Further in vivo studies revealed highly favorable food intake control and significant weight loss in combination with our previously identified long-acting GLP-1R agonist conjugate 187 in long-term potency studies. Comparison with the approved peptide therapeutic semaglutide suggests that the observed rodent half-life may translate into predicted pharmacokinetic profiles suitable for once-weekly human dosing.
[0890] Example H: PYY analogues showed high specificity for NPY2R.
[0891] The specificity of PYY analogs for NPY2R was assessed using a luciferase assay. HEK293 cells were infected with a lentivirus encoding the firefly luciferase gene under the control of the cAMP response element (CRE) promoter (Qiagen, Netherlands), followed by selection for one week with 1 μg / mL puromycin (Life Technologies, Carlsbad). Surviving cells (designated CRE-HEK293) were expanded and transfected with G418 selective mammalian expression plasmids encoding human NPY1R, NPY2R, NPY4R, and NPY5R. The plasmids were transfected into CRE-HEK293 cells using Lipofectamine 2000 and selected with 400 μg / mL genimycin (Life Technologies, Carlsbad, CA). Single-colony stable cell lines overexpressing CRE-luciferase and NPY receptors were then established for in vitro activity assays of each NPY receptor. Cells were seeded at a density of 5000 cells per well in 384-well plates and cultured for 18 h in DMEM containing 10% FBS at 37°C and 5% CO2. Cells were treated with conjugates for 24 h and activated via a luminescence intensity reporter receptor using One-Glo (Promega, WI) luciferase reagent according to the manufacturer's instructions. The EC50 of each conjugate was determined using GraphPad Prism 6 software (GraphPad, San Diego, CA). 50 .
[0892] As shown in Table 23, SEQ ID No:1, SEQ ID No:2, and conjugate 21 exhibited high specificity for NPY2R compared to other NPY receptors. For the unconjugated PYY1 analogue, the EC50 concentration was 0.49 against NPY2R. 50 In comparison, EC for NPY1R, NPY4R, and NPY5R 50The EC values were 1900 nM, 6700 nM, and 410 nM, respectively. For unstuck PYY2 analogues, the EC values for NPY1R and NPY4R were 1.2 nM compared to 2.2 nM for NPY2R. 50 >10000nM, EC for NPY5R 50 >1200 nM. For conjugate 21, the PYY2 analogue with conjugate L5 at positions 10-17, for NPY2R EC 50 The EC50 value for the NPY receptor was 0.39 for all other tested values. 50 >10000nM.
[0893] Table 23: Specificity of PYY analogues for NPY receptors
[0894]
[0895] Example 1: PYY analogues reduce food intake in mice
[0896] Given the well-established appetite-suppressing effects of PYY administration, food intake studies were conducted in C57BL / 6 wild-type mice using conjugate 40 administered subcutaneously (SC) at doses of 0.04 and 0.2 mg / kg. Combinations of conjugate 40 with the previously disclosed long-acting GLP-1R agonist conjugate 187 were also tested.
[0897] C57BL / 6 wild-type male mice (15 weeks old, from the Jackson Laboratory in Barthon, Maine) were acclimatized to a reversed photocycle and administered a single dose of the conjugate (5 mL / kg) subcutaneously (n=6, 2 mice / cage per group). Food intake was monitored at 0 (at the start of the dark cycle), 3, 6, 12, and 24 h, and body weight was monitored at 0 and 48 h after administration.
[0898] like Figure 3A As shown, all groups exhibited a significant reduction in food intake, with conjugate 40 alone showing a dose-dependent reduction in food consumption in the wild-type model. While conjugate 187 at 0.01 mg / kg showed a similar reduction in food intake as conjugate 40 at 0.04 mg / kg, the strongest reduction in food intake was observed when conjugate 187 was used in combination with conjugate 40 at 0.04 and 0.2 mg / kg, resulting in a 64% and 90% reduction in cumulative food intake over 24 hours, respectively. The single-dose combination of conjugates 187 and 40 produced a significant weight loss (-5%) observed at 48 hours post-administration, as shown in the figure. Figure 3B As shown, this demonstrates the lasting effect.
[0899] Example J: Administration of PYY analogues resulted in weight loss in mice.
[0900] A two-week chronic study was conducted in a diet-induced obese (DIO) mouse model to investigate the effects of daily administration of conjugate 40, alone or in combination with conjugate 187, on body weight and glucose homeostasis.
[0901] Male mice (18 weeks old, from Taconic Biosciences) were used to establish a diet-induced obesity (DIO) model by maintaining a high-fat diet (D12492, 60% fat diet) for 12 weeks. The mice were administered the conjugate via daily subcutaneous injection for up to 13 days (n=6, grouped, 2 mice / cage, regular photoperiod). The mean body weight at the start of the experiment was 50 g. Mouse body weight was measured on days 0, 2, 4, 6, 8, 10, 12, and 13. Mice were fasted overnight before the oral glucose tolerance test (OGTT) on day 14, followed by administration of the conjugate. Six hours later, 1 g of glucose solution per kilogram of body weight was administered orally. Tail blood glucose levels were measured 2 hours before (0 min) and after the glucose challenge. Data were compared using an unpaired Student's t-test. Repeated measures or one-way ANOVA was used for comparison where appropriate, followed by a Student-Newman-Keuls (SNK) post-hoc test.
[0902] Two separate doses of the PYY analogue (40) showed a dose-dependent decrease in food intake on day 1. Figure 4A Although the effect appears to diminish over time (day 5), Figure 4B ).like Figure 4C As shown, high doses of conjugate 40 alone also showed significant weight loss compared to the mediator control. As observed in acute food intake studies, conjugate 187 alone showed some potency, but superior weight loss was observed in both combination groups. Administration of 0.01 mg / kg conjugate 187 in combination with a high dose (0.2 mg / kg) of conjugate 40 resulted in a weight loss of nearly 25% after 13 days. Furthermore, the weight loss in the combination groups significantly exceeded the predicted curve based on the additive effect of the individual components (expected additivity, as plotted in the figure), indicating a synergistic enhancement of potency with combination administration. Similarly, as... Figure 4B As shown, on day 5 of administration, the combination therapy exhibited a greater inhibitory effect on food consumption compared to GLP-1R agonist conjugate 187 alone.
[0903] Glucose homeostasis on day 14 was evaluated using an oral glucose tolerance test (OGTT). Figure 4D-4FTreatment with PYY analogue 40 alone had no significant effect on OGTT results or fasting blood glucose. While significant improvements were observed in the GLP-1R agonist (conjugate 187) group, as expected, the combination group produced slightly better glucose control. The relatively modest glucose control demonstrated was not unexpected and is likely due to the slightly mild hyperglycemia observed in the prediabetic DIO model. The significant difference between those groups treated with conjugate 187 and those not treated with conjugate 187 suggests that the effect of the GLP-1R agonist was driving the glucose control in this study. However, as... Figure 4F As shown, the combination group exhibited excellent effects on fasting glucose levels, indicating that the combination therapy can exert some sustained cumulative effects on glucose management.
[0904] Example K: Generation of stable CRE-Luc cell lines overexpressing GLP-1R or GCGR. HEK293 cells were infected with a lentivirus encoding a firefly luciferase gene under the control of the cAMP response element (CRE) promoter (Qiagen, Netherlands), followed by selection for 1 week with 1 μg / mL puromycin (Life Technologies, Carlsbad). The surviving cells (designated CRE-HEK293) were expanded and then transfected with the G418 selective mammalian expression plasmid encoding human GLP-1R or GCGR. In short, GLP-1R or GCGR plasmids were transfected into CRE-HEK293 cells using Lipofectamine 2000 and selected with 400 μg / mL puromycin (Life Technologies, Carlsbad, CA). Then, single-colony stable cell lines overexpressing CRE-luciferase and GLP1R or GCGR (HEK293-GLP-1R-CRE or HEK293-GCGR-CRE) were established for in vitro activity assays.
[0905] Example L: In vitro receptor activation reporter molecule assay (receptor-mediated cAMP synthesis)
[0906] HEK293-GLP-1R-CRE or HEK293-GCGR-CRE cells were seeded at a density of 5000 cells per well in 384-well plates and cultured for 18 h in DMEM containing 10% FBS at 37°C and 5% CO2. Cells were then treated with peptides in a dose-dependent manner for 24 h and activated via a luminescence intensity reporter receptor using One-Glo (Promega, WI) luciferase reagent according to the manufacturer's instructions. The EC50 of each peptide was determined using GraphPad Prism 6 software (GraphPad, San Diego, CA). 50 .
[0907] Table 24. cAMP data (peptide conjugates)
[0908]
[0909]
[0910] Example M: cAMP assay
[0911] CHOK1 cells stably overexpressing human GLP-1R or GCGR (20 μL per well, 5000 cells) were seeded in white solid 384-well plates covered with a metal cap and incubated overnight. On day 2, the medium was replaced with fresh FBS-free medium (for the 0% FBS group). Cells were treated with 5 μL of peptide at a 12-point dose for 30 minutes at 37°C and 5% CO2 in medium containing 0.5 mM IBMX, in triplicate. cAMP levels were detected using the Cisbio cAMP dynamic 2 kit. Briefly, 25 μL of cAMP assay reagent (cAMP-d2: cAMP conjugate: lysis buffer = 1:1:38) was added to each well and incubated at room temperature for 1 h. For cell negative control wells, cAMP assay reagent without d2 was added. The plates were then read at Ex 320 nm, Em 1665 nm, and EM 2615 nm. Use Prism software to plot the ratio or Delta F, and then obtain the EC. 50 Ratio = A 665nm / B 620nm ×10^4. %Delta F = (Ratio of standard or sample - Ratio) neg ) / ratio neg ×100. See results below. Figures 5A-5C .
[0912] Example N: PK Study
[0913] In short, female CD-1 mice (n=3 or 4 per group) from the Charles River Laboratories were fasted overnight and administered 100 μL of phosphate-buffered saline (pH=8.2) for each peptide via intravenous (iv) or subcutaneous (sc) route. Mice were fed after blood collection at 3 h. Blood was collected into heparin tubes and centrifuged at 3,000 x g for 15 min. The resulting plasma was then stored at -80 °C for peptide concentration assays. The concentration of peptides in plasma at each time point was determined by in vitro cell-based activity assays. In short, HEK293-GLP-1R-CRE cells were treated with plasma samples at different time points (5-point dose-response, starting from 1:10 to 1:100 dilutions of each plasma sample) and incubated for 16 h at 37 °C and 5% CO2 in DMEM containing 10% FBS, followed by measurement of firefly luciferase activity. Bottom (input data), Top (output data), and EC50 data were obtained using the same peptides. 50 The standard curve and parameters for the Hill slope were obtained. Using the parameters derived from the standard curve, the peptide concentration in plasma (nmol / L) was calculated using the relative luciferase units (RLU) for each plasma sample (RLU = Bottom + (Top - Bottom) / (1 + 10^(LogEC)). 50 -Conc.)*Hill slope)). The concentration of peptides in plasma was obtained, and the in vivo half-life of each peptide was obtained by plotting it relative to time points using WinNonLinPhoenix software (Pharsight Corp, St. Louis, MO).
[0914] See the results for peptides 122 and 135. Figures 6A-6B See Tables 25a and 25b.
[0915] Table 25a: Pharmacokinetic parameters of analytes administered intravenously
[0916]
[0917]
[0918] Table 25b: Pharmacokinetic parameters of analytes administered subcutaneously
[0919]
[0920] Figure 6C The plasma concentrations of peptide 142 over time are described. Pharmacokinetic parameters are listed in Tables 26a and 26b. The mean half-life of peptide 142 administered intravenously is 10.71 h, and the mean half-life of administered subcutaneously is 11.56 h.
[0921] Table 26a: Pharmacokinetics of intravenously administered peptide 142
[0922]
[0923]
[0924] Table 26b: Pharmacokinetics of subcutaneously administered peptide 142
[0925]
[0926] Figure 6D The plasma concentrations of peptide 183 over time are described. Pharmacokinetic parameters are listed in Tables 26c and 26d. The mean half-life of peptide 142 administered intravenously is 6.335 h, and the mean half-life of administered subcutaneously is 7.87 h.
[0927] Table 26c: Pharmacokinetics of intravenously administered peptide 183
[0928]
[0929] Table 26d: Pharmacokinetics of subcutaneously administered peptide 183
[0930]
[0931] Example O: In vivo efficacy
[0932] Ten- to twelve-week-old C57BL / 6J mice (n=6 / group) were fasted overnight and then administered 5 mL / kg of each peptide in PBS solution (pH=8.2) subcutaneously. Six hours later, the mice were orally or intraperitoneally administered 2 g glucose solution / kg body weight, and their tail blood glucose levels were measured 2 hours before (0 min) and after the glucose challenge. In the same mice after overnight fasting, an oral glucose tolerance test (OGTT) was also performed at 48 h and 96 h after the original dose.
[0933] The potency of the dual GLP-1R / GCGR agonist 135 was then evaluated in an oral glucose tolerance test (OGTT) in wilted type mice. As a positive control, we used a single GLP-1R agonist, semaglutide, administered once weekly, and a dual GLP-1R / GCGR agonist, cotautide, a peptide currently administered once daily by AstraZeneca in a Phase II trial.
[0934] Compared with the mediator control (PBS pH 8.2), the compound's effects in the oral glucose tolerance test (OGTT) at 6 h, 48 h, and 96 h post-dose were shown to be... Figures 7A-7C middle. Figures 7A-7C The effect of the compound on blood glucose over time was shown. Figure 7D-7F The effect of the compound on glucose levels is shown by measuring the area under the curve. Figure 7G-7I The effects of the compounds on fasting blood glucose are shown. For all figures, A: 1224, B: 135, C: 138, D: Cotadutide, E: Semaglutide. Compared to the mediator, all peptides significantly reduced blood glucose to similar levels 6 h after administration. Similar results were observed for fasting blood glucose for all peptides. However, a significant difference in glucose levels was observed 48 h after peptide administration. After 48 h, Cotadutide did not show any improvement over the mediator, consistent with its suitability for once-daily injection in human subjects. On the other hand, mice treated with conjugate 135 showed a more significant improvement in glucose levels 48 h after glucose treatment compared to semaglutide. Furthermore, conjugate 135 was able to significantly reduce fasting blood glucose levels, while the other peptides did not lead to an improvement in potency. The increased in vivo potency of conjugate 135 observed here is likely due to higher dual agonist activity and a prolonged in vivo half-life. Assuming a direct relationship between pharmacokinetics and pharmacokinetics, the results of this experiment indicate that peptide conjugate 135 exhibits a longer half-life than semaglutide and therefore has the potential to be developed with appropriate formulations once a week or every two weeks.
[0935] Example P: Generation of stable CRE-Luc cell lines overexpressing GLP-1R or GCGR.
[0936] HEK293 cells were infected with a lentivirus encoding the firefly luciferase gene under the control of the cAMP response element (CRE) promoter (Qiagen, Netherlands), and then selected for 1 week with 1 μg / mL puromycin (Life Technologies, Carlsbad). Surviving cells (designated CRE-HEK293) were expanded and then transfected with the G418 selective mammalian expression plasmid encoding human GLP-1R or GCGR. In short, GLP-1R or GCGR plasmids were transfected into CRE-HEK293 cells using Lipofectamine 2000 and selected with 400 μg / mL genimycin (Life Technologies, Carlsbad, CA). Single-colony stable cell lines overexpressing CRE-luciferase and GLP1R or GIPR (HEK293-GLP-1R-CRE or HEK293-GIPR-CRE) were then established for in vitro activity assays.
[0937] Example Q: In vitro receptor activation reporter assay (receptor-mediated cAMP synthesis) HEK293
[0938] GLP-1R-CRE or HEK293-GIPR-CRE cells were seeded at a density of 5000 cells per well in 384-well plates and cultured for 18 h in DMEM containing 10% FBS at 37°C and 5% CO2. Cells were then treated with peptides in a dose-dependent manner for 24 h and activated via a luminescence intensity reporter receptor using One-Glo (Promega, WI) luciferase reagent according to the manufacturer's instructions. The EC50 of each peptide was determined using GraphPad Prism 6 software (GraphPad, San Diego, CA). 50 The result is as follows Figures 8A-8B As shown.
[0939] Table 27 Creluc Data (Peptide Conjugates)
[0940]
[0941] Example R: cAMP determination
[0942] CHOK1 cells stably overexpressing human GLP-1R or GIPR (20 μL per well, 5000 cells) were seeded in white solid 384-well plates covered with a metal cap and incubated overnight. On day 2, the medium was replaced with fresh FBS-free medium (for the 0% FBS group). Cells were treated with 5 μL of peptide at a 12-point dose for 30 minutes at 37°C and 5% CO2 in medium containing 0.5 mM IBMX, in triplicate. cAMP levels were detected using the Cisbio cAMP dynamic 2 kit. Briefly, 25 μL of cAMP assay reagent (cAMP-d2: cAMP compound conjugate: lysis buffer = 1:1:38) was added to each well and incubated at room temperature for 1 h. For cell negative control wells, cAMP assay reagent without d2 was added. The plates were then read at Ex 320 nm, Em 1665 nm, and EM 2615 nm. Use Prism software to plot the ratio or Delta F, and then obtain the EC. 50 Ratio = A 665nm / B 620nm ×10^4. %Delta F = (Ratio of standard or sample - Ratio) neg ) / ratio neg ×100. See results below. Figures 5A-5C .
[0943] Table 28. cAMP data (peptide conjugates)
[0944]
[0945]
[0946] Example S: Oral Glucose Tolerance Test (OGTT)
[0947] C57BL / 6J mice (n=6 / group) aged 10-12 weeks were fasted overnight and then administered 5 mL / kg of each peptide in PBS solution (pH=8.2) subcutaneously. Six hours later, the mice were orally or intraperitoneally administered 2 g glucose solution / kg body weight, and tail blood glucose levels were measured 2 hours before (0 min) and after the glucose challenge. In the same mice after overnight fasting, an oral glucose tolerance test (OGTT) was also performed at 72 h, 96 h, and 144 h after the original dose.
[0948] For all figures, A: 141, 4, B: 171, C: tesipatide, D: 142, E: semaglutide.
[0949] like Figures 9A-9D As shown, oral glucose tolerance tests (OGTT) were performed at 2 h, 72 h, 96 h, and 144 h after drug administration. Figure 9E As shown, at 2 h, compared with mice treated with the mediator alone, mice treated with compounds 141, 171, 142, semaglutide, and tesipatide exhibited significantly lower blood glucose levels, as measured by AUC. Figure 9F As shown, in an OGTT performed 72 hours after drug administration, mice treated with compounds 141, 171, 142, and semaglutide exhibited significantly lower blood glucose levels, as measured by AUC, compared to mice treated with the mediator alone. Figure 9G As shown, in an OGTT performed 96 hours after drug administration, mice treated with compounds 141, 142, and semaglutide exhibited significantly lower blood glucose levels, as measured by AUC, compared to mice treated with the mediator alone. Figure 9F As shown, in an OGTT performed 144 h after administration, mice treated with compounds 141, 142, and semaglutide, as measured by AUC, showed a significant reduction in blood glucose levels compared to mice treated with the mediator alone.
[0950] like Figure 9I As shown, treatment with compounds 141, 171, 142, semaglutide, and tesipatide resulted in a significant reduction in fasting blood glucose levels 2 hours post-treatment compared to treatment with the mediator alone. Figure 9J As shown, treatment with compounds 141, 171, and semaglutide resulted in a significant reduction in fasting blood glucose levels 72 hours post-treatment compared to treatment with the mediator alone. Figure 9K-9LAs shown, treatment with compounds 141, 142, and semaglutide resulted in a significant reduction in fasting blood glucose levels at 96 h and 144 h post-treatment, compared to treatment with the mediator alone.
[0951] Example T: DIO Mouse Study
[0952] Results are expressed as mean ± SE, and data were compared using an unpaired Student's t-test. Repeated measures or one-way ANOVA was used for comparison where appropriate, followed by a Student-Newman-Keuls (SNK) post-hoc test. Incremental analysis of the area under the curve (AUC) for plasma glucose was calculated using GraphPad Prism 6. Data groups were considered significantly different if p < 0.01.
[0953] Measurement of body weight, food intake, and visceral fat mass
[0954] DIO mice (C57BL / 6, male, 37 weeks old) were randomly assigned to groups based on their body weight and treated with subcutaneous injections of peptides or a carrier twice daily or weekly (n = 6 / group). Body weight and food intake were monitored daily throughout the study.
[0955] like Figures 10A-10B As shown, mice treated with compound 142 or tesipatide showed a decrease in total weight and body weight percentage over time compared to mice treated with the medium alone. Furthermore, as... Figure 10C As shown, mice treated with compound 142 or tesipatide exhibited reduced cumulative food intake compared to mice treated with the medium alone. Figure 10D As shown, in the oral glucose tolerance test (OGTT), mice treated with compound 142 or tesipatide showed decreased blood glucose levels over time compared to mice treated with the medium alone. Furthermore, compared to mice treated with the medium alone, mice treated with compound 142 or tesipatide exhibited a significant reduction in total glucose levels, as measured by the area under the curve (AUC). Mice treated with these compounds also showed reduced glucose levels after an overnight fast on day 8 compared to mice treated with the medium alone. Mice treated with compound 142 seven times a week showed a 53% reduction in glucose levels, mice treated with compound 142 twice a week showed a 42% reduction, and mice treated with tesipatide showed a 30% reduction.
[0956] Animal and statistical analysis
[0957] All animal care and experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of the California Institute of Biomedical Research (Calibr) and strictly followed the National Institutes of Health (NIH) guidelines for the humane handling of animals. Results are expressed as mean ± SE, and data were compared using unpaired Student's t-tests. Repeated measures or one-way ANOVA was used for comparisons where appropriate, followed by a Student-Newman-Keuls (SNK) post-hoc test. Incremental analysis of the area under the curve (AUC) for plasma glucose was calculated using GraphPadPrism 6. Data groups were considered significantly different if p < 0.01.
[0958] Measurement of body weight, food intake, and visceral fat mass
[0959] DIO mice (C57BL / 6, male, 28 weeks old) were randomly assigned to groups based on their body weight and treated daily with subcutaneous injections of peptides or a mediator (n = 7 / group). Body weight and food intake were monitored daily throughout the study. At the end of the experiment, mice were sacrificed and visceral fat mass was weighed. Collected plasma was used for cholesterol level determination according to the manufacturer's instructions (cholesterol assay kit, Abcam, Cambridge, England), and triglyceride levels were determined using a triglyceride colorimetric assay kit (Cayman Chemicals, Ann Arbor, Michigan).
[0960] Cholesterol level measurement
[0961] The collected plasma was used to determine cholesterol levels according to the manufacturer's instructions (Cholesterol Assay Kit, Abcam, Cambridge, England). In short, the plasma was diluted with cholesterol assay buffer and then reacted with an equal volume of a reaction mixture containing cholesterol assay buffer, cholesterol probe, enzyme mixture, and cholesterol esterase. After incubation at 37°C for 1 hour, the absorbance at 560 nm was measured using an Envision multi-plate reader (PerkinElmer, Waltham, MA). The concentration of cholesterol in the plasma was then calculated based on a standard curve.
[0962] Triglyceride measurement
[0963] Collected plasma was used for triglyceride level determination using a triglyceride colorimetric assay kit (Cayman Chemicals, Ann Arbor, Michigan). 5 μL of plasma sample or standard was plated into a 384-well plate, and 75 μL of diluted enzyme buffer was added to each well. The mixture was incubated at room temperature for 15 minutes, and the absorbance was read at 560 nm using an Envision microplate reader (PerkinElmer, Waltham, MA). The concentration of triglycerides in the plasma was calculated using a standard curve.
[0964] Biochemical and histological analysis
[0965] Using Alfa Wassermann Vet Clinical analyzers measured serum terminal analytes including total cholesterol, triglycerides, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP). Liver triglycerides were measured in liver homogenates produced using a colorimetric triglyceride kit (Cayman Chemical). Paraformaldehyde-fixed livers were paraffin-embedded, sectioned, and stained with hematoxylin-eosin and Sirius Red by HistoTox Laboratories (Boulder, CO). All histological assessments (steatodegenesis, fibrosis scores) were performed by certified, treatment-unaware histopathologists (HistoTox Labs) according to the classification outlined by Kleiner et al. 3
[0966] result
[0967] The results are as follows Figure 11A-11Q As shown in the figures. For all figures, A: 122, B: 142, C: semaglutide, D: cotadutide. The medium control is PBS at pH 8.2. Figure 11A As shown, mice treated with compound 122, compound 142, or semaglutide exhibited reduced food consumption over 20 days compared to mice treated with the medium alone. Furthermore, as... Figure 11B-11C As shown, compared with mice treated with the mediator alone, mice treated with compounds 122, 142, or semaglutide showed a reduced percentage change in total weight and initial body weight over 21 days. Treatment with these compounds also affected glucose levels. Figure 11D-11EAs shown, mice treated with compounds 122, 142, or semaglutide exhibited significantly reduced plasma glucose excursions on day 20 (feeding state) and day 21 (fasting state). In the fasting state, mice treated with cotadutide showed only a significant reduction in plasma glucose excursion. Figure 11F-11G As shown, in the oral glucose tolerance test (OGTT) conducted on day 21, mice treated with compound 122, compound 142, or semaglutide showed significantly lower glucose levels over time compared to mice treated with the medium alone, as measured by the area under the curve.
[0968] These compounds were used to treat plasma levels that affect liver function markers. For example... Figure 11J-11L As shown, treatment with compound 122 or semaglutide significantly reduced the levels of ALT, ALP, cholesterol, and triglycerides compared to treatment with the mediator alone, while treatment with compound 142 significantly reduced the levels of AST, ALT, ALP, cholesterol, and triglycerides compared to treatment with the mediator alone. Figure 11M , 11O As shown in 11P, compared with mice treated with the mediator alone, mice treated with compounds 122, 142, semaglutide, or cotadutide had significantly reduced liver-to-body weight ratio, liver weight, and liver triglyceride levels. Figure 11N As shown, treatment with compounds 122, 142, or semaglutide significantly reduced fat weight compared to mice treated with the mediator alone. The grade of fatty degeneration was also reduced in mice treated with compounds 122, 142, or semaglutide compared to mice treated with the mediator alone.
[0969] Example U: cAMP assay (GLP-1R single agonist)
[0970] HEK293 cells were infected with a lentivirus encoding the firefly luciferase gene under the control of the cAMP response element (CRE) promoter (Qiagen, Netherlands), and then selected for 1 week with 1 μg / mL puromycin (Life Technologies, Carlsbad). The surviving cells (designated CRE-HEK293) were expanded and then transfected with the G418 selective mammalian expression plasmid encoding human GLP-1R. In short, GLP-1R particles were transfected into CRE-HEK293 cells using Lipofectamine 2000 and selected with 400 μg / mL puromycin (Life Technologies, Carlsbad, CA). A single-colony stable cell line overexpressing CRE-luciferase and GLP-1R (HEK293-GLP-1R-CRE) was then established for in vitro activity assays.
[0971] HEK293-GLP-1R-CRE cells were seeded at a density of 5000 cells per well in 384-well plates and cultured for 18 h in DMEM containing 10% FBS at 37°C and 5% CO2. Cells were treated with peptides in a dose-dependent manner for 24 h and activated via a luminescence intensity reporter receptor using One-Glo (Promega, WI) luciferase reagent according to the manufacturer's instructions. The EC50 of each peptide was determined using GraphPad Prism 6 software (GraphPad, San Diego, CA). 50 .
[0972] Table 29. cAMP Data (Peptide Conjugates)
[0973]
[0974] Example A: β-Repressor Protein Recruitment Assay
[0975] The results are shown in Tables 30-32.
[0976] Table 30. The potency of PrRP20 and PrRP31 derivatives against the GPR10 receptor.
[0977]
[0978]
[0979] a EC2 cells overexpressing GPR10 were used in the β-inhibitor protein recruitment assay. 50 Cells were treated with triplicate of peptides at 37°C and 5% CO2 for 90 minutes. Efficacy was measured and plotted against log agonist concentration. The slope was fitted in Prism to generate ECs.50 The report is the mean ± SEM (n=3).
[0980] Table 31. Sequence of C(6-13)PrRP31 and optimization of the stapled MEG-FA.
[0981]
[0982]
[0983] a EC2 cells overexpressing GPR10 were used in the β-inhibitor protein recruitment assay. 50 Mean ± SEM (n=3).
[0984] Table 32 Optimization of MEG-FA for Nle8, hArg23, and C(6-13)PrRP31 stapling
[0985]
[0986]
[0987] a EC50 in CHO-K1 cells overexpressing GPR10, as measured in a β-inhibitor recruitment assay, was observed in the presence (10%) or absence (0%) of FBS. 50 . b EC2 levels in cAMP reporter assays were measured using NPFF2R-overexpressing CHO cells in the presence (10%) or absence (0%) of FBS. 50 Mean ± SEM (n = 3). CHO cells overexpressing NPFF2R were treated with a 12-point dose-response peptide and 0.5 mM IBMX (3-isobutyl-1-methylxanthine) in culture medium to inhibit cAMP degradation, with 20 μM trichodin as a positive control. The assay was performed in triplicate for 30 minutes at 37°C and 5% CO2, and cAMP accumulation was quantified using a cAMP assay kit from Cisbio. c EC obtained under 0% FBS 50 Calculate the ratio.
[0988] Example B: Plasma Stability
[0989] To investigate the stability of the conjugates in plasma, PrRP31, conjugate 255 (97-L3), and conjugate 263 (97-L5) were incubated in mouse plasma for up to 24 hours. Figure 12After serum protein precipitation, the remaining intact peptide levels were quantified by LC-MS (QTOF). PrRP31 in mouse plasma degrades rapidly, with a half-life of approximately 11 minutes, and disappears completely after 1 hour. Pinning to L3 at positions 6-13 enhances stability and prolongs the half-life to 30-60 minutes. When pinned to L5, the half-life further increases to approximately 3 hours.
[0990] Plasma stability was performed in a single replicate, with peptides incubated in mouse plasma at different time points, followed by precipitation of plasma proteins in methanol and quantification by LC-MS.
[0991] Example C: Pharmacokinetic Study
[0992] The pharmacokinetic profile of conjugate 263(97-L5) was evaluated in male C57 mice after subcutaneous injection at 1 mg / kg. Figure 13 The plasma concentrations of peptides at different time points (0.25, 0.5, 1, 3, 7, 24, 48, and 72 h) were determined using LC-MS. max It reaches approximately 1.67 μg / mL about 3 hours after administration, with an elimination half-life of 8 hours, which is similar to the elimination half-life of semaglutide in rodents.
[0993] Mouse pharmacokinetic (PK) studies were conducted using a single subcutaneous injection of 1 mg / kg conjugate 263 (97-L5) into mice, and plasma samples were collected at different time points and quantified using LC-MS. PK parameters were calculated using WinNonlin fitting of the data. Due to mouse volume / sampling limitations, sparse sampling was used. Therefore, a single PK curve was obtained by combining concentrations from different animals, and the estimated PK parameters were averaged. Therefore, SEM was not reported.
[0994] Further pharmacokinetic studies were conducted at a dose of 5 mg / kg, and similar pharmacokinetic curves were observed, in which plasma concentrations were determined using cell-based functional assays. Figure 14 ).
[0995]
[0996] Example D: In vivo efficacy assay
[0997] To demonstrate that the extended half-life of conjugate 263(97-L5) translates into in vivo potency, a 12-day weight study was conducted in a diet-induced obese (DIO) mouse model (n=8 per group), with daily subcutaneous administration. Figure 15 Significant weight loss was observed with conjugate 263 (97-L5) at a dose of 0.5 mg / kg. Higher doses of compound 263 (97-L5) administered daily produced similar potency to the 0.5 mg / kg dose. Figure 16 This indicates that the ED of conjugate 263(97-L5) 50 Below 0.5 mg / kg. Although this selectivity appears to result in a reduced appetite-suppressing effect, conjugate 263 (97-L5) is expected to exhibit a more favorable safety profile regarding undesirable cardiovascular side effects associated with NPFF2R agonism. The 24-hour plasma exposure in the 5 mg / kg and 1 mg / kg PK studies was significantly higher than the EC50 of conjugate 263 (97-L5). 50 This may indicate that lower doses are needed to demonstrate a dose-response effect. Detailed dose-response and efficacy studies are currently underway in more models of chronic obesity and metabolic diseases.
[0998] The efficacy was determined in diet-induced obese (DIO) mice by subcutaneous administration of conjugate 263 (97-L5) or the carrier (n=8) at 0.5 mg / kg daily for 12 days. Significant weight loss was observed compared to the carrier treatment; ****=p≤0.0001, ***=p≤0.001, **=p≤0.01.
[0999] Example E: In vivo body weight study and oral glucose tolerance test (OGTT)
[1000] All animal care and experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of the California Institute of Biomedical Research (Calibr) and strictly followed the National Institutes of Health (NIH) guidelines for the humane handling of animals. Charles River diet-induced obesity (DIO) model male mice (24 weeks old, from Jackson Labs, Bar Harbor, ME) maintained on a high-fat diet (D12492, 60% fat diet) for 18 weeks were administered peptides via daily subcutaneous injection at doses of 0.5 or 5 mg / kg for up to 12 days (grouped, 2 mice / cage). The average body weight at the start of the experiment was 50 g. Mouse body weight was monitored daily throughout the study, and food intake was monitored on days 1, 2, 6, and 9. Mice were fasted overnight before the oral glucose tolerance test (OGTT) on day 14, followed by peptide administration. Six hours later, 1 g of glucose solution per kilogram of body weight was administered orally, and tail blood glucose levels were measured 2 hours before (0 min) and after the glucose challenge. Data were compared using an unpaired Student's t-test. When appropriate, repeated measures or one-way ANOVA was used to compare data, followed by a Student-Newman-Keuls (SNK) post-hoc test. Glucose levels and AUC following oral administration of PrRP31 and conjugate 263 (97-L5) are shown in [data missing]. Figure 17 and Figure 18 middle.
Claims
1. A peptide conjugate comprising a peptide and a stapler, wherein: a) The peptide is PKPEAPGKDASPEEWNRYYACLRHYLNCLTRQRY (SEQ ID NO: 6); and b) The stapled peptide is linked to the first cysteine residue of SEQ ID NO: 6 and the second cysteine residue of SEQ ID NO: 6, and has the following structure: ; Each "S" is a sulfur atom of the first or second cysteine.
2. A peptide conjugate comprising a peptide and a stapler, wherein: a) The peptide is H[D-Ser]QGTFTSDYSKYLDECAAKEFICWLLNGGPSSGAPPPS (SEQ ID NO: 60); and b) The stapled peptide is linked to the first cysteine residue of SEQ ID NO: 60 and the second cysteine residue of SEQ ID NO: 60, and has the following structure: ; Each "S" is a sulfur atom of the first or second cysteine.
3. A peptide conjugate comprising a peptide and a stapler, wherein: a) The peptide is HGEGTFTSDLSKQLEECAVRLFICWLKNGGPSSGAPPPS (SEQ ID NO: 76); and b) The stapled peptide is linked to the first cysteine residue of SEQ ID NO: 76 and the second cysteine residue of SEQ ID NO: 76, having the following structure: ; Each "S" is a sulfur atom of the first or second cysteine.
4. A peptide conjugate comprising a peptide and a stapler, wherein: a) The peptide is Y[Aib]EGTFTSDYSIYKDKQAA[Aib]KFVNWLLAGGPSSGAPPPS (SEQ ID NO:63); and b) The stapled peptide is linked to the peptide at the first lysine and the third lysine of SEQ ID NO: 63, and has the following structure: ; Each "NH" is a portion of the first lysine or the third lysine.
5. A pharmaceutical composition comprising a peptide conjugate according to any one of claims 1-4 and a pharmaceutically acceptable excipient.
6. Use of the peptide conjugate according to any one of claims 1-4 in the preparation of a medicament for treating diabetes or obesity.
Citation Information
Patent Citations
Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors
CN110036022A
Stabilized insulinotropic peptides and methods of use
US20170260248A1
